


ISSN: 2613-5817; E-ISSN:2613-5825; DOI: 10.36962/PIRETC



© THE BALTIC SCIENTIFIC JOURNALS

PROCEEDINGS

OF THE INTERNATIONAL RESEARCH, EDUCATION & TRAINING CENTER

JOURNAL OF SOCIAL RESEARCH & BEHAVIORAL SCIENCES
REFERRED & REVIEWED JOURNAL

VOLUME 32 (07) ISSUE 03 2024

<http://bsj.esif.net/index.php/piretc>



AGRICULTURAL, ENVIRONMENTAL & NATURAL SCIENCES

SOCIAL, PEDAGOGY SCIENCES & HUMANITIES

MEDICINE AND BIOLOGY SCIENCES

COMPUTING AND APPLIED SCIENCES

ECONOMIC, MANAGEMENT & MARKETING SCIENCES

LEGAL, LEGISLATION AND POLITICAL SCIENCE



Platform &
workflow by
OJS/PKP

The beautiful thing about learning is nobody can take it away from you—B. B. King

ISSN: 2613-5817; E-ISSN:2613-5825, DOI PREFIX: 10.36962/PIRETC

VOLUME 32 (07) ISSUE 03 2024

© THE BALTIC SCIENTIFIC JOURNALS

PROCEEDINGS

OF THE INTERNATIONAL RESEARCH, EDUCATION & TRAINING CENTER

**JOURNAL OF SOCIAL RESEARCH & BEHAVIORAL SCIENCES
REFERRED & REVIEWED JOURNAL**

JOURNAL INDEXING

CROSSREF

FREESIA ISDSJ

DISSEMINATION SCORES 2023 – 8.28

QUALITY FACTOR 2023 – 1.3

OAJIF-1.25 (2023)

TALLINN, EESTI 2024



ISSN: 2613-5817; E-ISSN: 2613-5825

PIRETC

JOURNAL OF SOCIAL RESEARCH & BEHAVIORAL SCIENCES

VOLUME 32 (07) ISSUE 03 2024

Editors-in-chief:

Historical and Natural Sciences

Lienara Adzhyieva

Social, Pedagogy Sciences & Humanities

Heyder Guliyev

Economic, Management & Marketing Sciences

Badri Gechbaia

Medicine

Gulnara Kiliptari

**ISSN: 2613-5817; E-ISSN: 2613 – 5825; UDC: 0 (0.034); DOI: 10.36962/PIRETC
PROCEEDINGS OF THE INTERNATIONAL RESEARCH, EDUCATION & TRAINING CENTER**

©**Publisher:** NGO International Center for Research, Education and Training. R/C: 80550594
MTÜ Rahvusvaheline Teadus-, Haridus- ja Koolituskeskus.

©**Publisher:** NGO Azerbaijan International Diaspora Center in Georgia.
Management Board Member and founder of organization: Seyfulla Isayev.

©**Editorial office:** Harju county, Tallinn, Lasnamäe district, Väike-Paala tn 2, 11415
Narva mnt 5, 10117 Tallinn, Estonia.

©**Typography:** NGO International Research, Education & Training Center. The Baltic Scientific Journals.

Registered address: Narva mnt 5, 10117 Tallinn, Estonia.

Tel: +994 552 80 70 12; +994 552 41 70 12 (Whatsapp)

E-mail: sc.mediagroup2017@gmail.com

Website: <https://bsj.fisdd.org/>, <https://bsj.esif.net/>

Accepted for publication in this edition 20.06.2024

© MTÜ IRETC. The Baltic Scientific Journals. All rights reserved. Reproduction, storage in a retrieval system, or transmitted in any form, electronic, mechanic photocopying of any publishing of The Baltic Scientific Journals permitted only with the agreement of the publisher. The editorial board does not bear any responsibility for the contents of advertisements and papers. The editorial board's views can differ from the author's opinion. The journal was published and issued by MTÜ IRETC. International Center for Research, Education & Training. R/C 80550594. Non-profit Associations and Foundations Register as of 21.05.2018



TABLE OF CONTENTS

Mirza Dadash-zade, Inglab Aliyev SOME FEATURES OF THE MOVEMENT OF NON-NEWTONIAN OILS INTO THE WELL, TAKING INTO ACCOUNT THE SPHERICAL-RADIAL FLOW CHARACTER ACCORDING TO THE LINEAR LAW OF FILTRATION	04
Leara Alili Ademi, Blerim Ademi ELECTRO-CLINICAL PATTERN OF EPILEPSY IN A CHILD WITH SCN8A EPILEPTIC ENCEPHALOPATHY (CUTE SYNDROME): CASE REPORT OF DRUG-RESISTENT EPILEPSY	10
Lali Patsia, Ketevan Lartsuliani, Nodar Sulashvili, Luiza Gabunia, Nana Gorgaslidze, Nino Intskirveli POSTPARTUM PREECLAMPSIA AND BENIGN POSTPARTUM PLEURAL EFFUSION- TIMELY RECOGNITION AND MANAGEMENT OF THE CONDITION WITH CLINICAL CASE	21
Nodar Sulashvili, Vira Kravchenko, Nana Gorgaslidze, Luiza Gabunia, Shafiga Topchiyeva, Nato Alavidze, Nino Abuladze, Natia Kvizhinadze, Ketevani Gabunia, Igor Seniuk, Marika Sulashvili, Tamar Okropiridze, Giorgi Pkhakadze, Marina Giorgobiani¹⁴, Irine Zarnadze, Shalva (Davit) Zarnadze THE MANIFESTATION OF KEY ISSUE ASPECTS OF PHARMACISTS' OCCUPATIONAL FEATURES AND STUDY OF SOME DRIVING FORCES IMPACT ON PHARMACISTS' PROFESSION AND ROLE EXPANSION	35
Omar Sultanov, Aynur Jabiyeva ADVANTAGES OF DIGITAL RADIOGRAPHY (DR) OVER COMPUTED RADIOGRAPHY (CR) IN MEDICAL IMAGING	53
Aygul Mammadova, Dinara Aliyeva, Sadi Rustamov, Namig Gasimov, Zahid Khalilov, Tarana Aliyeva ENVIRONMENTAL PROTECTION AGAINST THE EFFECTS OF CLIMATE CHANGE THE ROLE OF GIS IN ITS FORMATION	66
Nodar Sulashvili, Gocha Chankseliani, Avtandil Girdaladze, Omar Gibradze, Paata Meshveliani, Kakha Chelidze, Mirian Cheishvili, Ana Kvernadze THE MANIFESTATION OF KEY ISSUE ASPECTS OF SOME CHARACTERISTICS OF ENDOVASCULAR SURGERY AND TREATMENT STRATEGIES FOR GASTROINTESTINAL AND DUODENAL ULCER BLEEDING WITH BRIEF CASE REPORT	69
Mahira, Ismayilova, Aytakin Hasanova PRE-IMPLANTATION GENETIC DIAGNOSIS IN THE PROGRAM OF ASSISTED REPRODUCTIVE TECHNOLOGY	87

SOME FEATURES OF THE MOVEMENT OF NON-NEWTONIAN OILS INTO THE WELL, TAKING INTO ACCOUNT THE SPHERICAL-RADIAL FLOW CHARACTER ACCORDING TO THE LINEAR LAW OF FILTRATION

Mirza Dadash-zade¹, Inqilab Aliyev²

^{1,2} Azerbaijan State Oil and Industry University, ^{1,2} Department of Petroleum Engineering,

^{1,2} PhD, Associate Professor

² <https://orcid.org/0000-0003-3098-7208>

E-mail: ¹mirza.dadashzade@asoiu.edu.az; ²nqilab.aliyev@asoiu.edu.az.

ABSTRACT

When studying the behavior of a fluid in a reservoir, taking into account anomalous properties, a necessary condition is to determine the lower limit of applicability of Darcy's law for very small values of the Reynolds number. At the same time, it should be noted that these properties arise upon contact with a porous medium and explained by the fact that at very low filtration rates, along with viscous resistance forces, there are these characteristics that do not depend on the filtration rate and are associated with the physical and chemical dependencies of filtering liquids with the porous medium material. Accounting for these forces leads to the non-linear character of the filtration law.

It is known that the filtration process is described using models. Basically, three types of oil flow models have been defined in the reservoir. If we assume that all fluid particles move in a porous medium in such a way that their filtration velocities are not parallel to the same plane, then such a movement is called spherical-radial. One can give such an example of a spherical radial flow in various cases of filtration. Let us assume that a hydrodynamically imperfect well barely penetrates the impermeable horizontal top of a homogeneous formation of a very large thickness; corresponds to the spherical-radial model.

Keywords: spherical-radial model, contour and bottom hole pressure, volume flow, cross-sectional area, non-Newtonian fluids, oils, anomalous fluids.

Introduction

The analysis shows that during the development of many fields in Azerbaijan, Russia (Tatarstan, Bashkiria), Romania, Kazakhstan, facts that can be explained by the appearance of non-Newtonian anomalous properties of liquids in a porous medium are known. The features of the movement of such anomalous oils are mainly associated with the content of high-molecular components in them: resins, asphaltenes, paraffin, an increase in the proportion of clay particles in the reservoir, etc.

In the world, the price of hydrocarbons is constantly growing. In this regard, interest in such deposits is increasing.

In recent years, various stimulation methods have been used to increase oil recovery in reservoirs. Methods of influencing natural deposits in order to increase oil and gas condensate recovery have led to a significant expansion of the range of substances injected into productive horizons and reservoirs. Note that many of these substances do not have the properties of Newtonian fluids, and

therefore the study of the features of the filtration of non-Newtonian fluids is of particular importance and is relevant.

The aim of the study is to study the issue of non-Newtonian fluid filtration in a spherical-radial model.

The scientific novelty lies in the study of the influence of a non-Newtonian fluid on the main indicators of filtration.

In this paper, non-linear laws of filtration are considered, provided that the filtering liquid has non-Newtonian properties.

It is known that for a non-Newtonian fluid, the main parameter characterizing its motion is the dynamic coefficient of viscosity. This coefficient is proportional in Newton's law. The relationship between the shear stresses, and the velocity gradient is in this case a straight line passing through the origin.

Fluids that do not obey the law of friction are called anomalous or non-Newtonian. Basically, according to literature analysis, non-Newtonian fluids can be divided into three groups:

1. non-Newtonian fluids, for which shear stress depends only on the velocity gradient (stationary rheological oils)

$$\tau = f\left(\frac{dv}{dy}\right) \quad (1)$$

2. non-Newtonian fluids, for which the relationship between shear stress and velocity gradient depends on the time of stress action (non-stationary rheological oils)

$$\tau = f\left(\frac{dv}{dy}; t\right) \quad (2)$$

Where t - time of stress, sec.

3. viscoelastic oils, i.e. a medium that has the properties of both a solid and a liquid, as well as the tendency of its physical properties and shape to partially recover after stress relief.

Among non-Newtonian fluids of the first class, three classes can be distinguished:

a) viscoplastic fluids, for which the equation has the form

$$\tau = \mu \frac{dv}{dy} + \tau_0 \quad (3)$$

b) pseudoplastic fluids, for which the equation takes the form

$$\tau = k \left(\frac{dv}{dy}\right)^n \quad (4)$$


c) dilatant fluids are described by a power equation, but with $n > 1$.

Models of dilatant liquids describe well the properties of suspensions with a high solids content.

Problem statement

The main studies are based on the laws of hydro-mechanics and are solved by mathematical methods.

Where k and n are constant coefficients for a given fluid. This model is used, in particular, to describe the motion of solutions and polymer compositions.



In porous media, consisting of many micro-capillaries of various diameters, as the pressure drop decreases, the capillaries gradually “plug”; at first, the flow stops in the smallest pores, and as the pressure decreases, this process is observed in large capillaries.

Note that in this case, anomalous properties of reservoir systems arise. The literature [1–5] provides numerous properties of a liquid, such as viscosity, porosity, ultimate shear stress, pressure etc. at low flow rates and low permeability of a porous medium. This is also typical for heterogeneous layers. Note that in the area of low permeability, the appearance of anomalous properties of oil is most likely.

It is known, that the determination of the filtration of liquids and gases is not only of theoretical interest, but also of wide practical importance, because without knowledge of the law of filtration in the rock, especially near the bottom of the well, it is impossible to calculate the possible flow rates of oil and gas, their change over time under various operating conditions wells, and it is also impossible to determine the parameters of the horizon, reservoir, such as permeability, porosity, etc. These parameters, in particular, are determined according to the data of studies of production wells producing hydrocarbons.

Basically, three types of reservoir models are considered. One of these models is spherical-radial. If all fluid particles move in a porous medium so that their filtration rates are not parallel to the same plane, then such movement is called spatial or three-dimensional, since three coordinates are required to determine the position of a hydrocarbon particle in space. Note that if during spatial motion all trajectories are rectilinear and converge radially at one point, then this motion is called three-dimensional radial or spherical-radial.

In this case, due to the spatial symmetry relative to the center of the well, the value of the filtration rate and pressure at an arbitrary point in the flow will be a function of the distance between this point and the center, the well.

Since the magnitude of the filtration rate and pressure are functions of only one variable, a complete study of spherical radial flow can be performed mathematically. Note that an example of a spherical radial flow is a hydrodynamically imperfect well that has barely penetrated an impermeable horizontal top of the layer. In this case, the inflow of hydrocarbons in the immediate vicinity to the bottom of the well will comply with the laws of three-dimensional radial motion.

The problem of fluid inflow to a well that is imperfect in terms of the degree of opening of the reservoir in a reservoir of finite thickness was studied by M. Masket [6]. I.A. Charniy proposed a method for determining the flow rate of a well that is imperfect in terms of the degree of opening. In this case, the well area is conditionally divided into two zones. The first zone is located between the feed loop and a radius equal to or greater than the formation thickness. In this zone, the motion can be considered plane-radial. The second zone is located between the borehole wall and the cylindrical surface, where the movement is spatial, that is, spherical-radial, taken as radial-spherical.

This paper proposes a method for studying the movement of a fluid in a given zone, taking into account the anomalous properties of the fluid (oil).

It is known that in a spherical-radial flow for non-Newtonian, viscous-plastic fluids, the velocity can be written

$$v = \frac{k}{\mu} \left(\frac{dP}{dr} - G \right) \quad (5)$$

where v - is the filtration rate of the anomalous, viscous-plastic liquid, m/sec; k - permeability coefficient, m^2 ; μ - dynamic viscosity, Pa*sec; $\frac{dP}{dr}$ - pressure gradient, Pa/m; G - limit value of the pressure gradient, Pa/m.

Let's take the cross-sectional area $S = 2\pi r^2$. Multiplying the right and left parts of this expression by the cross-sectional area:

$$Sv = \frac{k}{\mu} 2\pi r^2 \left(\frac{dP}{dr} - G \right) \quad (6)$$

We have

$$Q = \frac{k}{\mu} 2\pi r^2 \left(\frac{dP}{dr} - G \right) \quad (7)$$

Let's solve the equation in the given range

$$\frac{Q\mu}{2\pi k} \frac{1}{r^2} + G = \frac{dP}{dr} \quad (8)$$

We accept the boundary conditions

$$\begin{aligned} r = R_w & \quad P = P_w \\ r = R_c & \quad P = P_c \end{aligned}$$

Then we obtain,

$$\frac{Q\mu}{2\pi k} \left(\frac{1}{R_w} - \frac{1}{R_c} \right) + G(P_c - P_w) = P_c - P_w \quad (9)$$

As a first approximation $P_c = P_w$. Then, with respect to the volumetric flow, we have

$$Q = \frac{2\pi k (P_c - P_w) - G(R_c - R_w)}{\mu \left(\frac{1}{R_w} - \frac{1}{R_c} \right)} \quad (10)$$

where P_c - pressure on the well contour; P_w - bottom hole pressure; R_c - pressure on the well contour; R_w - well radius.

If we accept that $G=0$, then we have an equation for the inflow in a spherically radial flow [3, 4]. If we assume that $P_c - P_w = G(R_c - R_w)$, then in this case the volume flow is equal to zero. In [7-14], it is proposed $R_w = 1,5h$, where h is the thickness or height of the reservoir.

This equation makes it possible to determine the volumetric flow rate of a liquid, taking into account the spherical-radial model for viscous-plastic liquids.

The solution of the problem

The experiments were carried out in laboratory conditions. As can be seen from the figure, the applied model in a particular case affects the filtering process. Figure 1 shows the dependence of the flow rate on the value of the limiting pressure gradient. Obviously, with an increase in the latter, the volumetric flow rate decreases significantly, while it should be noted that this graph is a dependence for small volumes, in well conditions, which is of great importance.




Figure 1. Dependence of liquid consumption Q on G .

Results discussion

The study shows that, taking into account the imperfection of the well, a three-dimensional spherical-radial flow movement is more realistic in practice. Many researchers have pointed to this process. This issue is considered in more detail in [4, 5, 6, 7] for conventional oils.

This paper discusses the issue of non-Newtonian fluid filtration in a spherical-radial model, which is closer to the fields of Russia (Tatarstan, Bashkiria), Romania, Azerbaijan, etc. Given the above, in the development and operation process, it is necessary to take into account these issues.

Conclusion

1. A technique that considers changes in the model at the bottom of the well is proposed.
2. A procedure for determining the volumetric flow rate, taking into account the use of a spherical-radial model for a viscous-plastic fluid has been obtained.

Declarations

The manuscript has not been submitted to any other journal or conference.

Study Limitations

There are no limitations that could affect the results of the study.

Acknowledgment

The author would like to express gratitude to the care support workers and elderly individuals who participated in this study, sharing their invaluable insights and experiences. Their cooperation and openness have significantly contributed to the depth and richness of the research findings.

REFERENCES

1. Mirzajanzadeh A.Kh., Kovalyov A.G., Zaytsev Yu.V. Peculiarities of exploitation of anomalous oil fields. – M.: Nedra, 1972.
2. Pykhachev G.B., Isayev R.G. Underground hydraulics. – M.: Nedra, 1973.
3. Charniy I.A. Underground fluid dynamics. – M.: Gostoptekhizdat, 1963.
4. Shchelkachev V.N., Lapuk B.B. Underground hydraulics. – M.: Gostoptekhizdat, 1949. – 358 p.
5. Shchelkachev V.N. Development of oil reservoirs under elastic conditions. – M.: Gostoptekhizdat, 1959. – 467 p.
6. Masket M. Movement of homogeneous fluids in a porous medium. – M.: Russian State University of Oil and Gas, 2006, 308 p.
7. Basniyev K.S., Vlasov A.M., Kochina I.N., Maksimov I.M. "Underground hydraulics", M.: Nedra, 1986, 303 p.
8. Punanova S.A., Shuster V.L. A new look at the prospects for oil and gas potential of deep-seated pre-Jurassic deposits in Western Siberia. // *Georesources*. – 2018, 20(2). – Pp.67-80. <https://doi.org/10.18599/grs.2018.2.67-80>
9. Yashchenko I.G., Polishchuk Yu.M. Features of the physical and chemical properties of hard-to-recover types of oil. // *Technologies of oil and gas*. – 2014, 91(2). – Pp.3-10.
10. Yashchenko I.G., Polishchuk Y.M. Classification of Poorly Recoverable Oils and Analysis of Quality Characteristics (Reviews) // *Chemistry and Technology of Fuels and Oils*. – 2016, 52(4). – Pp.434-444. <https://doi.org/10.1007/S.10553-016-727-9>.
11. Entov V.M., Glivenko E.V. Continuum mechanics and its application in gas and oil production. – M.: Nedra, 2008. – 204 p.
12. Prachkin V.G., Mullakaev M.S., Asylbaev D.F. Improving well productivity by acoustic impact on high-viscosity oils in the channels of the bottomhole zone of wells // *Chemical and oil and gas engineering*. – 2014, No.9. – Pp.15-19.
13. Shipulin A.V. Using the inertia of the well fluid mass when acting on the reservoir. // *Oil. Gas. Innovations*. – 2009, No.2. – Pp.34-35.
14. Kryakov D.Yu., Zhdanov S.A. Application of methods for enhanced oil recovery in Russia and abroad. – M.: Burenie i Neft, 2011, No.2. – Pp.22-26.

Publication history

Article received: 22.04.2024

Article accepted: 13.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-01

ELECTRO-CLINICAL PATTERN OF EPILEPSY IN A CHILD WITH SCN8A EPILEPTIC ENCEPHALOPATHY (CUTE SYNDROME): CASE REPORT OF DRUG-RESISTENT EPILEPSY

Leartha Alili Ademi¹, Blerim Ademi²

¹University Clinic for pediatric diseases, department of neurology, Skopje, North Macedonia

Dr.leartha.alili@gmail.com

²University Clinic of neurology, Skopje, North Macedonia

Dr.blerim.ademi@gmail.com

ABSTRACT

Having into consideration the expansion research of the epilepsy in children, this study tries to investigate the electro – clinical pattern of the epilepsy in children with SCN8A Epileptic Encephalopathy (Cute syndrome). It is known that there exists a different epilepticus etiology due to the genetic, structural, metabolic, infectious and immune reasons, yet although plenty of research has been made in this regard, in most cases the cause of the epilepsy is unknown, thus leading to a lack of consensus regarding the cause of the epilepsy among the scholars and researches.

Thus, this paper will give a contribution to the existing research, by elaborating a case report of a drug – resistant epilepsy in a 7-year-old child for recurrent afebrile unprovoked seizures, since the age of 16 months. In addition, genetic and clinical features, as well as effectiveness of sodium channel blockers were assessed in the patient confirmed with SCN8A mutation, while to identify the pathogenic epileptic gene next generation sequencing (NGS) was performed. Further, to analyze the electroencephalographic characteristics, electroencephalogram (EEG) was performed initially and during follow-ups.

Finally, the findings suggest that she suffered from focal, febrile to tonic-clonic seizures, treated with various AEDs, making a drug-resistant epilepsy diagnosis. Even though the result cannot be conclusive, we hypothesize that the represented EEG pattern together with the epilepsy and seizure type, ID, and behavioral disorders, may help to characterize the phenotype of Cute syndrome.

Keywords: epilepsy; drug-resistant epilepsy; SCN8A.

Introduction

Epilepsy is known as one of the most common neurological disorder in pediatric population, affecting 1% to 3% of children, defined as any disorder in which spontaneous recurrence of unprovoked seizures is the main symptom. It has also been informed about the etiology of epilepsy which can be different, including structural, genetic, infectious, metabolic and immune causes, yet in most of the cases the cause of epilepsy is unknown. Although there has been made a recent introduction of new antiepileptic drugs (AEDs), about one-third of epilepsy patients have drug resistant (refractory) epilepsy, affecting about 30% of children with epilepsy. In addition, refractory epilepsy, which is the most severe form of epilepsy, according to International league against epilepsy (ILAE), is defined as failure to control seizures when using two or more appropriately chosen and tolerated antiepileptic drugs (as monotherapy or in combination) during an appropriate period of time. Severe and refractory epilepsies in children affect their cognitive

function, leading to worsening of the prognosis, serious psychosocial consequences, difficulties in care and quality of life, anxiety in the family, as well as an increase in the risk of death, including unexpected death in epilepsy (SUDEP).

Recently, extensive genetic research and technology development and the advance development in next-generation sequencing (NGS) has shown that a large proportion of unexplained epilepsies have a genetic basis. The published mutations are all missense except for one splice site mutation resulting in an in-frame deletion. Most mutations arise de novo.

Having into consideration such facts, SCN8A-related epilepsy and/or neurodevelopmental disorders are autosomal dominant epileptic encephalopathies caused by de novo missense mutations in the gene that is part of the voltage gated sodium channels (VGSCs) gene family. VGSC, encoded by the gene SCN8A, plays important role in controlling neuronal excitability and, initiation and propagation of action potentials. SCN8A mutations cause dramatic increase in persistent sodium current and incomplete channel inactivation. De novo SCN8A mutation, was firstly reported in a patient with an infantile epileptic encephalopathy who died of SUDEP. Studies suggest that clinical presentation of SCN8A-related epilepsy and/or neurodevelopmental disorders include variable phenotypes. Thus, indicating that genetic testing of SCN8A should be considered in children with unclassified severe epilepsy.

Epilepsy phenotypes of SCN8A mutations include developmental and epileptic encephalopathy (DEE) associated with severe developmental delays and usually drug resistant epilepsy with multiple seizure types; mild-to-moderate DEE, or intermediate epilepsy with partially treatable epilepsy; self-limited familial infantile epilepsy (SeLFIE, also known as benign familial infantile epilepsy or BFIE) with normal cognition and medically treatable seizures; neurodevelopmental delays with generalized epilepsy (NDDwGE); and neurodevelopmental disorder without epilepsy (NDDwoE) with mild-to-moderate intellectual disability (though it can be severe in ~10% of affected individuals).

SCN8A encephalopathy is characterized by onset of drug-resistant seizures at a mean age of 5 months (range 1 day–18 months). Patients develop multiple seizure types, including generalized tonic–clonic seizures that are present in most patients; tonic, atonic, myoclonic, focal, and absence seizures, febrile seizures and epileptic spasms have also been described. Electroencephalography at the time of seizure onset is normal in approximately 50 % of cases. However, in the following months, most individuals develop electroencephalographic abnormalities, often comprising moderate-to-severe background slowing with focal or multifocal epileptiform discharges. Prior to seizure onset, development is normal for approximately half of patients, and after seizure onset developmental stagnation or regression often results in mild-to-severe intellectual disability. Movement disorders such as ataxia and choreoathetosis are common, and hypotonia, hypertonia, and/or dystonia are present in 50 % of cases. Sudden unexpected death in epilepsy has been reported in approximately 10 % of cases.

Seizures in patients with SCN8A mutations are often refractory to conventional antiepileptic treatment. However, in approximately half of patients, good responses to sodium channel blockers have been described, either as a reduction in seizures or even seizure-free periods, including OXC, CBZ, lamotrigine (LTG), Phenobarbital (PB), topiramate (TPM) and PHT, etc. Reported is worsening of seizures with levetiracetam. Study of 22 patients with SCN8A mutations in who drug-resistant epilepsy started at a median age of 4 months, the most effective antiepileptic drugs reported were OXC, CBZ, PHT, and benzodiazepines. It was reported that EEG findings showed epileptiform abnormalities with a temporo-occipital predominance.

An already conducted study has reported from 36 patients with SCN8A-related epilepsy and normal intellect (33%) or mild (61%) to moderate ID (6%), having neurological disturbances including ataxia (28%) and hypotonia (19%) as the most prominent features. Interictal electroencephalogram was reported to be normal in 41%. Wang et al. identified seven SCN8A mutations in a Chinese family and six sporadic patients, half of which showed good responses to sodium channel blockers, either as a reduction in seizures frequency or even seizure-free.

In their study, authors Anand et al. reported a family with SCN8A mutation, who had early onset focal epileptic seizures without cognitive or neurological impairment. The seizures were controlled well by mono-therapy, with CBZ and phenytoin (PHT). Additionally, in the report of Parrini et al., patients with the same mutation presented with drug resistant focal epilepsy and mild intellectual disability. This study and previous reports suggest that same mutation in SCN8A can lead to a different phenotype. In addition, it was the authors Trudeau et al. who first reported a frame-shift mutation of SCN8A in a family with mental retardation and ataxia, but without epilepsy. Gardella et al. discovered a SCN8A mutation in 16 affected members of three families with BFIS/ICCA.

Meanwhile, research reported brain magnetic resonance imaging (MRI) to show cerebellar and cerebral atrophy in one and six patients, respectively. In addition, Lyu et al. collected genetic and electro-clinical data from unrelated families carrying novel SCN8A variants associated with chronic progressive or episodic ataxia, and reported variants in SCN8A to be associated with a spectrum of epilepsies and neurodevelopmental disorders including ataxia as a predominant symptom. Moreover, authors Larsen et al. studying seventeen patients with de novo heterozygous mutations of SCN8A, reported multiple refractory seizures including focal, tonic, clonic, myoclonic and absence seizures, and epileptic spasms, as well as motor manifestations including hypotonia, dystonia, hyperreflexia, and ataxia. Furthermore, EEG findings were reported to be moderate to severe background slowing with focal or multifocal epileptiform discharges.

Boerma et al. report patients with SCN8A encephalopathy successfully treated with high doses of PHT, and describe the first study suggesting PHT as a treatment option in patients with SCN8A encephalopathy. CBZ is thought to have a similar working mechanism but with 3 times lower affinity for inactivated sodium channels. Boerma et al. report that high levels of PHT were required before optimal treatment effect was achieved. High serum levels of PHT increase the risk of irreversible adverse effects such as cerebellar atrophy and ataxia, therefore, high doses of PHT could be considered in patients who do not respond adequately to other sodium channel blockers.

Research methodology

Aim: To delineate the onset, electroencephalographic and clinical features of SCN8A-related drug resistant epilepsy (SCN8A developmental and epileptic encephalopathy – Cute syndrome) in order to facilitate early recognition, and eventually early and effective treatment with sodium channel blockers.

Methods: Genetic and electroclinical features, as well as effectiveness of sodium channel blockers were assessed in the patient confirmed with SCN8A mutation. To identify the pathogenic epileptic gene NGS was performed. A detailed clinical history was obtained. To analyze the electroencephalographic characteristics, EEG was performed initially and during follow-ups.

Case report

We report on a now 7-year-old girl, referred to our department for recurrent afebrile unprovoked seizures, since the age of 18 months. First seizures were noted by the parents since the age of 16 months old. She was born at term by spontaneous vaginal delivery, with average birth weight, of healthy non-consanguineous parents, and with uneventful perinatal and postnatal period. She did not experience traumatic brain injury, or central nervous system infections. There was no medical history of excessive vomiting, abnormal urine or body odor, unconsciousness, feeding abnormality, skin manifestation, trauma, altered sensorium etc. Meanwhile, there was noted history of frequent fever and respiratory tract infections as well as recurrent febrile convulsions. Before the onset of seizures, development was normal for her age. Over time she was found to have progressive regression of achieved milestones, was least responsive to surroundings, leading to intermediate global learning and speech difficulty that improved over time with occupational and speech therapy. In addition, she had difficulty with fine and gross motor skills, and ataxia that improved with physical therapy. During clinical assessment, there was a normal systemic examination and no craniofacial dysmorphic features were noted. Regarding the neurologic and behavioral aspects, the patient had moderate intellectual disability, learning difficulties, and neurobehavioral problems such as attention deficit hyperactivity disorder (ADHD) since toddler age. However, she was able to participate in normal school life with assistance.

Targeted exome sequencing in human genome (WES) with Illumina technology of next generation sequencing (NGS) of clinically significant genes was performed and a pathogenic heterozygous variant, NM_001330260.2(SCN8A): c.2890G>A, missense, was identified at exon 16 of SCN8A gene, c.2890G>A, p. (Gly964Ser). This variant causes exchange of glycine amino acid with serine in position 964. As the parental genetic tests revealed that the parents did not have this missense, the variation was identified as a de novo variant. This variant was categorized as pathogenic by the American College of Medical Genetics and Genomics (ACMG) guideline (PS2, PM2, PM5, PP3) and has not been reported earlier. The variant is absent from control sequences (Genome Aggregation Database (gnomAD) and no alternative plausible variants or known mutations were identified as competing possibilities in this patient. Disease as per OMIM was EIEE type 13, inheritance-autosomal dominant, classification-likely pathogenic.

Table 1. Electroclinical characteristics of epilepsy.


Seizure type	EEG abnormalities	Age	AEDs	Seizure frequency
FCS, MS, FeS	Multifocal discharges	16-18 mo		First seizures/10 times a day
FCS, GTCS	Multifocal bursts	2 yo	VPA	1-2 /day
FCS, MS	Multifocal discharges	3 yo	VPA	1/week
GTCS	Generalized paroxysmal discharges	4 yo	VPA	2-3 /week
FS, EMS	Multifocal bursts with generalized discharges	4 yo	VPA + OXC	Every day in sleep
FS, MS	Multifocal paroxysmal discharges	4 yo	VPA + OXC (ex, dwz)+ LEV	1/week



GTCS	Generalised bursts	4.5 yo	VPA + LEV	1/week
FS, MS, FeS	Multifocal bursts	5 yo	VPA + LEV (ex) + CBZ	2-3/day
FS, FeS	Multifocal bursts with generalized discharges	5 yo	VPA + CBZ (ex, dwz) + CLB	1-2/month
FS, MS	Generalised discharges	5.5 yo	VPA + CLB	1/month
FS, EMS	Generalised discharges	5.5 yo	VPA + CLB + TPM	Every day in sleep
FS, MS	Multifocal bursts	6 yo	VPA + CLB + TPM (ex) + LCM	Stabilization
EMS	Multifocal bursts	7 yo	VPA + CLB + LCM	4-5/day in sleep


Abbreviations: Generalized tonic-clonic seizures= GTCS, focal clonic seizures= FCS, FeS= febrile seizures, EMS= eyelid myoclonic seizure, MS= myoclonic seizure, Sodium valproate/valproic acid=VPA, Lacosamide= LCM, Topiramate=TPM, Levetiracetam=LEV, Oxcarbazepine= OXC, Clobazam= CLB, Carbamazepine= CBZ, Drowsiness=dwz, mo= months old, years old=yo, excluded=ex.

Her first seizures were focal clonic seizure by description and myoclonic jerks that occurred at the age of 16 months, with a frequency of around 4-10 seizures a day. The seizure frequency was noted to increase during febrile state. The first sleep interictal EEG showed regular alpha activity, associated with mainly frontal and temporal intermittent multifocal bihemispheric discharges of high voltage spike-and-wave complexes. (*see picture 1*). These seizures were misdiagnosed for extrapyramidal tremor. Therefore, treatment with sodium valproate was started at the age of 2 years old. With AED Initially, there were 1-2 generalized tonic-clonic seizures or focal seizures in a day on average, followed by a partial stabilization in the following year leading to one seizure in a week. Sleep EEG revealed multifocal bursts of spike-and-wave complex discharges. Epilepsy protocol magnetic resonance imaging of the brain was normal.




Picture 1. First interictal sleep EEG showing multifocal bihemispheric discharges of high voltage spike-and-wave complexes.

Stabilization of seizures was not achieved, despite GTCS and FCS there were also noted febrile seizures. In addition, the seizures were more frequent, 2-3 times a week. Therefore, a second AED, oxcarbazepine, was added to the treatment. Regarding the adverse effects due to oxcarbazepine, such as dizziness, it was discontinued, and in the treatment was included levetiracetam. During this period the EEG findings in sleep, showed multifocal frontal and temporal bursts of spike-and-waves complexes with generalized discharges (*see pictures 2*). Partial stabilization was achieved with valproic acid in combination with levetiracetam. Sleep EEG showed multifocal, mainly frontal spike-and-wave discharges (*see picture 3*).




Picture 2. Sleep EEG: multifocal bursts of spike-and-waves complexes with generalized discharges




Picture 3. Sleep EEG in stabilization showing multifocal, mainly frontal spike-and-wave discharges.

Thereafter followed a period of worsening with GTCS, as well as febrile seizures. The sleep EEG findings showed generalized paroxysmal spike-and-wave discharges (*see picture 4*).




Picture 4. The sleep EEG findings during worsening with generalized paroxysmal spike-and-wave discharges.

Eyelid myoclonic seizures in sleep were also noted. The follow-up sleep EEG findings showed regular brain activity of alpha rhythm with generalized bursts of paroxysmal discharges of spike-and-wave complexes (*see picture 5*). There followed a period of partial stabilization after commencing clobazam and excluded levetiracetam. The EEG findings showed bifrontal focal spike wave discharges, in stabilization (*see picture 6*).




Picture 5. EEG findings generalized bursts of paroxysmal discharges of spike-and-wave complexes.



Picture 6. The EEG findings in stabilization showing bifrontal focal spike wave discharges.

Thereafter, followed a period of frequent everyday focal seizures and eyelid myoclonic seizures in sleep. Topiramate was included in the antiepileptic treatment. There was no improvement on the clinical and EEG findings. The follow-up wakefulness and sleep EEG showed continuous multifocal high voltage discharges of spike-and-wave complexes (*see picture 7*).



Picture 7. Wakefulness and sleep EEG showing continuous multifocal high voltage discharges of spike-and-wave complexes.

A period of seizure freedom occurred at age 6 to 7, when lacosamide was included in the treatment. During a period of less than a year, the girl had rarely focal seizure, and no generalized tonic-clonic seizures were noted. The sleep EEG findings revealed basic brain activity of regular alpha rhythm with multifocal mainly frontal and temporal bursts of spike-and-waves discharges (see picture 8).



Picture 8. The sleep EEG findings: multifocal mainly frontal and temporal bursts of spike-and-waves discharges.

Nowadays, she has mostly short-lasting eyelid myoclonic seizures daily on sleep. Sleep EEG findings showed regular alpha activity with multifocal bilateral paroxysmal discharges of spike-and-waves.

Her seizures proved difficult to control, despite trials of valproic acid in combination with levetiracetam, oxcarbazepine, carbamazepine and topiramate. A trial of lacosamide in combination with valproic acid and clobazam led to a marked reduction in seizure frequency and partial stabilization.

Conclusions and discussion

In many of the studies done in this area it is noted that Cute syndrome is a severe form of epilepsy caused by mutations in *SCN8A* gene, which is encoding VGSCs that have a crucial role in neuronal excitability.

In addition, it was also discussed that the phenotypic spectrum *SCN8A* mutations varies largely. Most patients can have intractable epilepsy beginning at the first year of life, accompanied by severe developmental delay and intellectual disability (ID), while others have milder phenotype, such as BFIS and ICCA. Furthermore, a few patients with ID or movement disorders without epilepsy have been reported. The epileptic discharges are most prominent in temporal regions, comprised of spike or spike-and-waves.

Literature has suggested that patients with *SCN8A* encephalopathy respond to the sodium channel blockers such as PHT, valproate, CBZ, lacosamide, LTG, rufinamide and OXC.

Cranial MRI is not specific in SCN8A encephalopathy; usually it is normal. However, there may be cortical atrophy or corpus callosum abnormality in some cases or progressive cerebral or cerebellar atrophy in follow up imaging. According to several groups of authors the amino acid substitution is severely damaging to the structure of the sodium channel.

Our case had similarities with the previously reported cases. The report illustrated a girl presenting with a drug-resistant, monogenic epilepsy syndrome, epileptic encephalopathy due to SCN8A pathogenic de novo variant found by NGS associated with the Cute syndrome. This variant has never been reported so far in the literature. Clinical features of our patient responded to severe developmental delays and usually drug resistant epilepsy with multiple seizure types. Seizure-free was not achieved by multi-antiepileptic drugs usage. Seizure recurrence increased with age. Seizure type included focal motor seizures, febrile seizures, myoclonic and generalized tonic-clonic seizures. In our patient, movement disorder was present in the form of ataxia. Early EEG features showed focal or multifocal epileptic discharges, that changed over time and the background showed progressive slowing. In our case cortical atrophy was not found in MRI. Partial response has been noted with valproic acid, clobazam and lacosamide. We did not use phenytoin for our case due to its side effects.

The detailed discussion of our case would contribute to early detection and targeted treatment of SCN8A encephalopathy. Even though our result cannot be conclusive, we hypothesize that the represented EEG pattern together with the epilepsy and seizure type, ID, and behavioral disorders, may help to characterize the phenotype of Cute syndrome. Future studies regarding these issues may outline the electroclinical pattern in a larger series of patients with Cute syndrome. This also gives special emphasis on a genetic test in infants with intractable epilepsy, movement disorder and developmental delay.

Authors contributions

All authors had main contribution in literature search, writing and drafting the manuscript. LAA contributed in the diagnosing, treatment, and follow-up of the patient. BA edited the manuscript. All authors approved the final version.

Acknowledgements

The authors are grateful to the patient and his family for generously permitting usage of clinical information.

Conflict of interest

None of the authors have any conflict of interest to disclose.

Funding

No funding was obtained for this case report.

Availability of data

The data of the current case report are available from the corresponding author on reasonable request.

Consent

The case report protocol was performed in accordance with the Declaration of Helsinki.

Informed consent

Written informed consent was obtained from the patient's parent to publish this report in accordance with patient consent policy.

REFERENCES

1. Kim HJ, et al. Genetic and clinical features of SCN8A developmental and epileptic encephalopathy. *Epilepsy Res.* 2019 Dec; 158:106222.
2. Denis J, et al. Clinical study of 19 patients with SCN8A-related epilepsy: Two modes of onset regarding EEG and seizures. *Epilepsia.* 2019 May;60(5):845-856
3. Takahashi S, Yamamoto S, Okayama A, Araki A, Saitsu H, Matsumoto N, Azuma H. Electroclinical features of epileptic encephalopathy caused by SCN8A mutation. *Pediatr Int.* 2015 Aug;57(4):758-62.
4. Ohba C, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. *Epilepsia.* 2014 Jul;55(7):994-1000.
5. Larsen J, Carvill GL, Gardella E, et al; EuroEPINOMICS RES Consortium CRP. The phenotypic spectrum of SCN8A encephalopathy. *Neurology.* 2015 Feb 3;84(5):480-9
6. Hammer MF, Xia M, Schreiber JM. SCN8A-Related Epilepsy and/or Neurodevelopmental Disorders. 2016 Aug 25 [updated 2023 Apr 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews*[®] [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023.
7. Gardella E, et al. The phenotype of SCN8A developmental and epileptic encephalopathy. *Neurology.* 2018 Sep 18;91(12):e1112-e1124.
8. Johannesen KM, Gardella E, et al. The spectrum of intermediate SCN8A-related epilepsy. *Epilepsia.* 2019 May;60(5):830-844.
9. Lyu H, et al. Clinical and electrophysiological features of SCN8A variants causing episodic or chronic ataxia. *EBioMedicine.* 2023 Dec; 98:104855.
10. Fatema K, Rahman MM, Faruk O. SCN8A Mutation in Infantile Epileptic Encephalopathy: Report of Two Cases. *J Epilepsy Res.* 2019 Dec 31;9(2):147-151.
11. Wang, J., Gao, H., Bao, X. et al. SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures. *BMC Med Genet* **18**, 104 (2017).
12. Larsen J, et al; EuroEPINOMICS RES Consortium CRP. The phenotypic spectrum of SCN8A encephalopathy. *Neurology.* 2015 Feb 3;84(5):480-9.
13. Møller RS, Johannesen KM. Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers. *Neurotherapeutics.* 2016 Jan;13(1):190-1.

Publication history

Article received: 22.04.2024

Article accepted: 13.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-02

POSTPARTUM PREECLAMPSIA AND BENIGN POSTPARTUM PLEURAL EFFUSION- TIMELY RECOGNITION AND MANAGEMENT OF THE CONDITION WITH CLINICAL CASE

Lali Patsia¹, Ketevan Lartsuliani², Nodar Sulashvili³, Luiza Gabunia⁴, Nana Gorgaslidze⁵, Nino Intskirveli⁶

¹MD, PhD, Doctor of Medical Sciences, Invited Professor of Tbilisi State Medical University, Professor of Faculty of Medicine at Sul Khan-Saba Orbeliani University, Professor of International School of Medicine at Alte University; Professor of Ken Walker International University; Doctor Cardiologist at Central University Clinic After Acad. N. Kipshidze; Doctor Cardiologist at Tbilisi State Medical University First University Clinic, Tbilisi, Georgia; lpatsia@yahoo.com, <https://orcid.org/0009-0007-7125-6862>

²MD, PhD, Doctor of Medical Sciences, Professor, Doctor Cardiologist, Echocardiologist at Aversi Clinic, Tbilisi, Georgia; k.lartsuliani@aversi.ge

³MD, PhD, Doctor of Theoretical Medicine In Pharmaceutical and Pharmacological Sciences, Invited Lecturer of Scientific Research-Skills Center at Tbilisi State Medical University, Professor of Pharmacology of Faculty of Medicine at National University SEU, Associate Professor of Medical Pharmacology of Faculty of Medicine at Sul Khan-Saba Orbeliani University, Associate Professor of Division of Pharmacology of International School of Medicine at Alte University; Associate Professor of Pharmacy Program at Shota Meskhia Zugdidi State University; Associate Professor of Medical Pharmacology at School of Medicine at David Aghmashenebeli University of Georgia, Associate Professor of Biochemistry and Pharmacology Direction at the University of Georgia, School of Health Sciences. Associate Professor of Pharmacology of Faculty of Medicine at East European University, Associate Professor of Pharmacology of Faculty of Dentistry and Pharmacy at Tbilisi Humanitarian Teaching University; Tbilisi, Georgia; n.sulashvili@ug.edu.ge, <https://orcid.org/0000-0002-9005-8577>

⁴MD, PhD, Doctor of Medical Sciences, Professor, Director of the Scientific Research-Skills Center at Tbilisi State Medical University, Professor of the Department of Medical Pharmacology at Tbilisi State Medical University, Clinical Pharmacologist of The First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia. <https://orcid.org/0000-0003-0856-2684>

⁵MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Tbilisi State Medical University, Head of The Department of Social and Clinical Pharmacy, Tbilisi, Georgia. <https://orcid.org/0000-0002-4563-5224>

⁶PhD, Associate Professor of Department of Physics, Biophysics, Biomechanics and Information Technology at Tbilisi State Medical University, Tbilisi, Georgia.

ABSTRACT

New-onset postpartum preeclampsia (NOPP) is defined as the diagnosis of new-onset postpartum preeclampsia, which develops from ≥ 48 hours to ≤ 6 weeks after delivery (these patients did not have hypertension before). This is a little-studied pathology, its exact spread, risk factors and pathophysiologic mechanisms are still not fully known. In this article, the authors present a clinical case, where a 38-year-old woman visited the cardiologist 3 days after the cesarean section with complaints: post-cesarean section headache, slight deterioration of vision, mild respiratory insufficiency, mild peripheral swellings, chest discomfort, arterial hypertension within 140-160/90-95mm/Hg. The patient did not have hypertension in the past. Blood pressure started to rise 48 hours after surgery. Echocardiography revealed bilateral pleural effusion. The patient's condition was evaluated as NOPP, postpartum cardiomyopathy was ruled out, and clinical management was performed in coordination with the doctor gynecologist. Within 3 weeks, the pleural effusion decreased and resolved, it was evaluated as benign postpartum pleural effusion. Hypertension was regulated in 2.5-3 months with labetalol. There is a need to raise awareness about postpartum hypertension, as NOPP can lead to serious complications if symptoms are not properly assessed and left untreated. Thus, postpartum preeclampsia requires timely recognition

and proper treatment. Future studies should focus on pathophysiology and specific risk factors. A better understanding of pathomechanisms is essential for better postpartum patient care and guideline development, as well as, for reducing maternal morbidity and mortality in the postpartum period. Hypertensive disorders of pregnancy complicate 10 to 20% of pregnancies in the United States. They are responsible for a significant proportion of maternal morbidity and mortality and are a leading cause of readmission to hospital after delivery.¹⁻³ Although most cases are diagnosed in the antenatal period, postpartum preeclampsia de novo or new at birth is increasingly recognized as a major contributor. maternal morbidity and mortality in the postpartum period. Hypertension in the puerperium is most often observed in women with prenatal hypertensive disorders, but can develop de novo in the postpartum period.

Introduction

Postpartum hypertension most commonly occurs in women with antenatal hypertension, but it can develop de novo in the postpartum period. It is unclear whether postpartum preeclampsia is antepartum preeclampsia or a pathology independent of eclampsia. Although definitions vary, the diagnosis of postpartum preeclampsia should be considered between 48 hours and 6 weeks postpartum in women with new-onset hypertension. Postpartum preeclampsia is an understudied disease and guidelines for its diagnosis and management are based on insufficient evidence.

Nevertheless, it is currently recommended, that new-onset postpartum hypertension (including markedly elevated blood pressure in women without a history of hypertension) be termed postpartum preeclampsia after exclusion of other etiologies to facilitate timely recognition and management of the condition. Older maternal age, black race, maternal obesity and cesarean delivery are associated with a higher risk of postpartum preeclampsia.

In most women, late postpartum preeclampsia presents within the first 7-10 days after delivery, most often with neurological symptoms such as headache.

Treatment: use of antihypertensive drugs, magnesium and diuretics. Postpartum preeclampsia may be associated with a higher risk of maternal morbidity than prenatal preeclampsia, although it remains underreported disease.

Future studies should focus on pathophysiology and specific risk factors. A better understanding of pathomechanisms is essential for better postpartum patient care and guideline development, as well as, for reducing maternal morbidity and mortality in the postpartum period [1-7].

Hypertensive disorders of pregnancy complicate 10 to 20% of pregnancies in the United States. They are responsible for a significant proportion of maternal morbidity and mortality and are a leading cause of readmission to hospital after delivery.¹⁻³ Although most cases are diagnosed in the antenatal period, postpartum preeclampsia de novo or new at birth is increasingly recognized as a major contributor. maternal morbidity and mortality in the postpartum period. Hypertension in the puerperium is most often observed in women with prenatal hypertensive disorders, but can develop de novo in the postpartum period. Although definitions vary, the diagnosis of postpartum preeclampsia should be considered in women with new-onset hypertension during the postpartum period. There is a need to improve terminology regarding immediate postpartum preeclampsia (within 48 hours of delivery) and late postpartum preeclampsia, which has traditionally been defined as new-onset preeclampsia between 48 hours and 6 weeks after delivery. Most reports of postpartum preeclampsia are limited to smaller case series, so the overall incidence has not been reliably determined prospectively [8-15].

Few national and international guidelines address the occurrence of postpartum hypertension, and existing guidelines lack clear definitions. The American College of Obstetricians and Gynecologists (ACOG), the Royal College of Obstetricians and Gynecologists (RCOG)/National Institute of Excellence in Health and Care (NICE), and the Society of Obstetricians and Gynecologists of Canada (SOGC) do not specifically define preeclampsia. They do not differentiate between new-onset puerperal preeclampsia and new-onset puerperal hypertension. In our experience, this is a diagnostic issue that frequently arises in the clinical care of this group of women.

Regarding timing, we suggest considering the diagnosis of postpartum preeclampsia in women with new-onset preeclampsia 48 hours postpartum and within 6 weeks postpartum. Although this timing is not clearly defined, this is the terminology used by experts and in existing literature on the subject.^{8–10} We recognize that the postpartum period is a continuum and may need to be modified as we better understand the pathophysiology of this state. Traditionally, 48 hours is used as it usually covers immediate postpartum changes and routine hospital management. It is important to note that other causes of postpartum hypertension and seizures at 4 weeks postpartum should be considered. We believe that more research is needed to determine whether new-onset postpartum preeclampsia/eclampsia is distinct from prepartum preeclampsia; However, we recommend highlighting this condition here and in national/international guidelines as it is not sufficiently recognized by service providers [16-21].

Definitions of hypertension and preeclampsia are extrapolated from guidelines on hypertensive disorders in pregnancy with antepartum onset, i.e. 140/90 mmHg possible subtypes of postpartum hypertension. In our clinical experience, women without proteinuria are as likely to have adverse clinical outcomes as women with significant proteinuria. However, given the limited clinical outcome data, we suggest that proteinuria continue to be assessed according to current guidelines until additional studies evaluating outcomes in this population become available. Extrapolating from ACOG guidelines for prenatal diagnosis of preeclampsia and gestational hypertension, we suggest that less attention be paid to the presence of proteinuria in women with new-onset postpartum hypertension.

Preeclampsia is a pregnancy-associated hypertensive disorder and a leading cause of maternal and perinatal morbidity and mortality. Despite its prevalence, clearly classified risk factors and clinical features, the exact pathophysiology of this disease remains unknown. This knowledge gap has hampered the development of targeted therapies and limited treatment options for healthcare providers.

Clinically, preeclampsia is associated with a number of complications for both mother and fetus. It is considered to belong to the spectrum of disorders of hypertension during pregnancy, with gestational hypertension being on the milder end of the spectrum, followed by preeclampsia, chronic hypertension with superimposed preeclampsia, hemolysis, elevated liver enzymes, low platelet counts, and eclampsia on the milder end of the spectrum. form. forms. End of the spectrum. the most extreme [1]. Because preeclampsia is a true systemic disease, it can present in a variety of ways. It is classically defined as maternal hypertension and renal dysfunction, especially characterized by proteinuria [1]. However, recent guidelines mention thrombocytopenia, liver failure, pulmonary edema, and cerebral/visual symptoms as diagnostic features. Other maternal complications include seizures (eclampsia), cerebral hemorrhage, disseminated intravascular coagulation, and liver rupture. Obstetric complications associated with preeclampsia include uteroplacental insufficiency, placental abruption, preterm birth, and

increased risk of cesarean section [2]. Other fetal complications include fetal distress during labor, intrauterine growth restriction, oligohydramnios, and, in severe cases, fetal death [3]. In addition to obstetric and neonatal consequences, preeclampsia carries a long-term risk of complications, including stroke and hypertension.

As doctors try to better manage this rising tide, a number of risk factors have been identified that reflect the complex nature of preeclampsia. These include diseases such as chronic high blood pressure and other classic cardiovascular risk factors, as well as chronic kidney disease, antiphospholipid syndrome, collagen-related vascular diseases (eg, lupus), and pre-existing diabetes. In addition, factors such as nulliparity, previous diagnosis of preeclampsia, abnormal placentation, multiple pregnancies, and maternal age at both ends of the spectrum (<20 years or >35 years) increase susceptibility. The incidence and severity of preeclampsia is higher in African Americans, likely due to health care disparities as well as higher rates of determinants such as chronic hypertension, obesity, and type 2 diabetes, which are underdiagnosed in the African American community. Finally, there appears to be a genetic component to preeclampsia, as a family history of preeclampsia, hypertension, and type II diabetes (maternal or paternal) also suggests an increased risk [22-25].

Despite the health disparities and significant clinical impact of preeclampsia, childbirth is the only “cure” and even after birth, these mothers and their babies remain at high risk for future cardiovascular and metabolic diseases.

Thus, efforts to promote early detection, better understanding of pregnancy mechanisms, and improved treatment options are essential to improve the treatment outcomes and health of patients with this complex disease. As the field advances, there is growing recognition that there are many subtypes of preeclampsia, and these subtypes may differ in underlying cause, placental transcriptomic landscape, and disease severity. Suggested classifications include early and late onset, with early onset more commonly associated with uterine malposition, impaired uterine perfusion, and fetal growth restriction. On the other hand, late-onset preeclampsia may be associated with excessive growth of the placenta (leading to chorionic villus compression), stress, or aging toward the end of pregnancy. Redman et al. The idea that the placental syncytiotrophoblast layer is sensitive to cellular stress (i.e., oxidative, mitochondrial, and endoplasmic reticulum) during pregnancy, independent of triggering factors, and ultimately the maternal response to These syncytial stress signals determines whether a pregnant woman will develop preeclampsia. Although vascular dysfunction can lead to trophoblastic stress or trophoblastic stress can disrupt the vasculature, many of the risk factors, putative mechanisms, and long-term consequences of preeclampsia are directly related to the maternal and placental vasculature. Therefore, we would like to summarize the main research priorities in the field of preeclampsia and highlight the role of the vascular system in these areas [26-29].

It is generally accepted that placental development is impaired in some pregnancies caused by preeclampsia, resulting in cellular, molecular, immunological and vascular changes, and the role of inappropriate decidualization has also received increasing attention. It is traditionally believed that early preeclampsia is caused by abnormal placentation and superficial invasion of trophoblasts into the uterus, leading to incomplete remodeling of the spiral artery. This can lead to placental hypoxia, an aberrant angiogenic state, endothelial dysfunction, further reduction in placental formation, trophoblastic stress and ultimately the onset of maternal preeclampsia. Although much of the etiology remains unknown, research suggests that impaired decidual


differentiation before pregnancy may contribute to impaired trophoblast invasion and its consequences [31-35].

However, it is a complex syndrome and the exact sequence of pathogenesis is unclear. The prognosis of preeclampsia is imprecise, and it is difficult to determine whether physiological changes are the cause of preeclampsia or whether it is a secondary outcome.

During normal placentation, trophoblasts, divided into cytotrophoblasts and syncytiotrophoblasts, descend from the blastocyst to form extraembryonic cells necessary for the formation of the placenta. Cytotrophoblasts form the inner villous layer of the placenta, closest to the fetal circulation, and syncytiotrophoblasts arise from the fusion of cytotrophoblasts and form the outer villous part in contact with the maternal environment. Together, this arrangement of cells creates a branching structure called chorionic villi. Although chorionic villi are essential for maternal-fetal exchange, the release of syncytiotrophoblastic placental-derived microvilli (STBM) into the maternal circulation is increased in women with preeclampsia and impairs endothelial cell proliferation. In addition, endothelium-dependent vasodilation is also impaired following infusion of placental STBM vesicles into fatty arterioles collected during cesarean section. Electron micrographs after this perfusion confirm severe destruction of the endothelial layer and intracellular organelles, but the underlying smooth muscle remains intact. Therefore, the spread of CTBM in the bloodstream is a mechanism of vascular dysfunction in preeclampsia [36].

These inflammatory, hypotensive, and fetal growth effects were mitigated by nitric oxide (NO) analogue treatment, supporting the theory that vascular dysfunction is a likely etiological factor in preeclampsia. Both TLR4 and TLR9 have suppressive effects on trophoblast migration, suggesting that these receptors are due to placental aberrations. Placental TLR3 is also upregulated in preeclampsia. Viral mimetic treatment in pregnant rats confirmed a more causal relationship and resulted in increased placental TLR3 expression, increased systolic blood pressure, decreased aortic vasodilation, and increased urinary protein excretion, with these effects being limited to pregnant animals. Natural killer cells in the uterus secrete the anti-inflammatory cytokine interleukin 10 (IL-10), which plays an important role in pregnancy. Specific functions of IL-10 include preventing fetal allograft rejection by the maternal immune system, reducing placental endoplasmic reticulum stress, and compensating for antiangiogenic factors. In preeclampsia, there is a decrease in IL-10 immunostaining and an increase in TNF α . In mice, activation of TLR3 and deletion of IL10 alone resulted in preeclampsia phenotypes, and together these manipulations resulted in more severe disease. Exogenous administration of recombinant IL-10 restored impaired endothelium-dependent vasodilatory responses in these mice and may have useful therapeutic potential given the limited treatment options available.

Maternal T cells have many subtypes and a wide range of immunological functions during pregnancy. Group differentiation (CD) 4+ promotes fetal acceptance and consists of regulatory and helper subsets, whereas CD8+ T cells control trophoblast invasion. Adequate levels of T-cell subtypes prevent overactive immune system and fetal-damaging or autoimmune attacks. Regulatory T cells (Tregs) control the defense of T helper cells (Th cells) and are thought to be unbalanced in preeclampsia. In particular, patients with preeclampsia exhibit suppressed Treg cell numbers with increased circulating and decidual activity of the proinflammatory Th1 and Th17 subgroups. Treg cell depletion in mice results in increased uterine artery vasoconstriction and endothelin-1 production, suggesting that altered vasoreactivity in preeclampsia may be related to Treg cell depletion.



Preeclampsia is characterized by an imbalance of pro- and antiangiogenic factors, which directly affects endothelial function. VEGFA stimulates angiogenesis, vascular permeability and cell migration by binding to its tyrosine kinase receptors VEGFR1 and VEGFR2. Binding of VEGFA to VEGFR2 results in stronger signaling than VEGFR1 through activation of the phospholipase C gamma (PLC γ)/protein kinase C (PKC)/MAPK pathway, which is involved in endothelial cell proliferation. During placental villous development, VEGFA is present in trophoblasts and perivascular cells to support vascular development (i.e., vasculogenesis) as well as vascular dilation by endothelial sprouting (i.e., vasculogenesis). During pregnancy, VEGF induces greater activation of endothelial nitric oxide synthase (eNOS), and NO production occurs primarily through VEGFR2-mediated PI3K/AKT signaling (105,106). PlGF, its proangiogenic counterpart, binds to VEGFR1, increasing the likelihood of VEGF binding to VEGFR-2. The interaction of PlGF with VEGFR1 also promotes other critical events such as: B. Transphosphorylation of VEGFR2, thereby increasing the downstream signaling cascade. Like VEGF, the action of PlGF facilitates the growth and migration of endothelial and trophoblast cells. In a healthy pregnancy, PlGF levels increase until week 32 and then decrease. However, with preeclampsia, there is a significant decrease in venous levels already at 13–16 weeks, which occurs before the appearance of other clinical symptoms. Not only does this have adverse cardiovascular consequences during pregnancy, but these vascular diseases and adverse cardiac remodeling may persist for many years after pregnancy. This suggests that mothers' obvious symptoms often disappear after childbirth.

Platelet activation, aggregation and blood clotting (coagulation) are interrelated processes. In short, platelets have adhesive properties and, when bound to damaged endothelium, release substances such as thromboxane that promote aggregation. Platelet aggregation stimulates platelet plug formation and thrombin-mediated fibrin clot formation. A recent systemic review and meta-analysis suggests that patients with preeclampsia have a higher mean platelet volume (indicating platelet activation) and a higher likelihood of adhesion and aggregation. In this article, Jacobsen et al reported conflicting results regarding aggregation, and additional studies showed no difference or decreased aggregation, but these specific studies did not assess adherence. A study examining platelet adhesion showed decreased immunohistochemical expression of platelet endothelial cell adhesion molecule 1 and increased intercellular adhesion molecule 1 in the human placenta of individuals with preeclampsia, which is believed to play a role in trophoblastic invasion and vascular dysfunction. Consistent with the idea that syncytiotrophoblast stress is the final common factor leading to the maternal elements of preeclampsia and the importance of platelet function in this syndrome, syncytiotrophoblast-derived extracellular vesicles (SDEVs) have been shown to activate platelets *ex vivo*. SDEVs derived from preeclamptic placentas cause greater platelet activation than in normal pregnancies, but aspirin treatment prevents platelet aggregation.

During pregnancy, there is a natural decrease in platelet counts, partly due to sequestration of blood cells in the interstitial space [37], an increase in plasma volume, and increased aggregation of thromboxane A₂. Thrombocytopenia, beyond the normal decrease in platelet count caused by pregnancy, is common in preeclampsia and may be particularly associated with a decrease in platelet count and activation of blood clotting. Together, these hemostatic effects increase the risk of bleeding and microthrombi in mothers with preeclampsia.

The generation of reactive oxygen species as a result of placental hypoxia, immune activation, and other cellular damage has numerous consequences, including damage to mitochondrial DNA (mtDNA). The DNA repair capabilities of mitochondria are less extensive than those of nuclear DNA, which increases the likelihood of cell death with mtDNA mutations as a result of apoptosis

or necrosis. This results in the release of DNA into the maternal bloodstream, which is considered a damage-associated molecular pattern (DAMP) and is recognized by pattern recognition receptors such as TLR9. TLR9 is a proinflammatory component of the innate immune system activated by hypomethylated CpG dinucleotides widely expressed in mtDNA and bacteria. Although surface receptors are also present, DNA recognition by TLR9 occurs preferentially on endolysosomes because the acidic environment allows TLR9 to bind negative DNA more easily. Thus, DNA enters the cell via endocytosis and, upon TLR9 binding, triggers a cascade of subsequent proinflammatory events, including IFN, NF κ B, and AP-1 signaling.

This hypothesis is supported by the fact that preeclamptic plasma contains higher amounts of serum mtDNA and that TLR9 activity increases with the onset of preeclamptic symptoms. Linking the TLR9 inflammatory response to other aspects of preeclampsia, including angiogenesis and trophoblast function. In this study, VEGFA levels were reduced in human placenta, but TLR9 and sFLT-1 were increased in preeclamptic samples (83). Applying these results to a mouse model, the TLR9 agonist induced traditional features of preeclampsia and also recapitulated the downregulation of VEGFA and upregulation of sFLT-1 observed in human tissues. siRNA knockdown of TLR9 in human trophoblast cells facilitates migration and invasion, highlighting the importance of TLR9 also in the early stages of placentation. Dendritic cells from women with preeclampsia appear to be hypersensitive to immune stimulating agents, suggesting a possible cause of over-recruitment of TLR9.

Despite the profound impact of preeclampsia on maternal and fetal health, its pathogenesis is not yet fully understood and is likely variable, limiting the development of treatment options. In conclusion, treatment of preeclampsia has been predominantly symptomatic and aimed at maintaining an acceptable blood pressure range, neuroprotection and seizure prevention, with immediate delivery at term or after 34 weeks for severe manifestations. However, cases of vascular insufficiency have been found to occur at all stages of preeclampsia, from placentation to the puerperium, and are likely due to a combination of inadequate trophoblast invasion, poor oxygen extraction by the placenta, and a proinflammatory immune environment. antiangiogenic factors, endothelial dysfunction and oxidative stress.

Due to the lack of robust studies assessing vascular parameters before pregnancy and before the onset of preeclampsia, it is unclear whether women who develop this syndrome have underlying vascular pathology or whether the possible vascular effects are simply a byproduct of increased trophoblast stress signaling. Both aspects are likely to play a role, and physiological abnormalities in preeclampsia begin long before clinical diagnosis. Therefore, it is important to improve early detection methods and screening tools. Although routine measurement of vasopressin levels during pregnancy is not yet used in clinical practice, it represents a promising opportunity to predict the future development of preeclampsia and provide more proactive care for these patients. In terms of molecular targets, less explored areas include the modulation of RGS proteins to mitigate the negative consequences of excessive GPCR induction by hormones such as angiotensin II, endothelin-1 and vasopressin, or the uptake of cellular stress leading to mitochondrial dysfunction leading to cellular dysfunction. Death, circulating DNA and subsequent TLR9 activation. Although much remains to be discovered, translational research, basic animal models, and mechanistic cell studies have already had a profound impact on the field, and new technologies such as trophoblast organoid cultures offer great potential for new ideas. Thus, collaboration across the spectrum, from the laboratory to the bedside, will accelerate



our understanding of preeclampsia as quickly as possible and potentially facilitate the development of new targeted treatments.

Birth conditions are favorable for the development of pleural effusion. Normal pregnancy may promote transudation of fluid into the pleural cavity due to increased hydrostatic pressure in the systemic circulation, increased blood volume, and decreased colloid osmotic pressure. Repeated Valsalva maneuvers may further contribute to pleural effusion.

Increased intrathoracic pressure and impaired lymphatic drainage of the pleural cavity due to increased systemic venous pressure. Atelectasis of the gravid uterus can also contribute to the formation of pleural fluid. The value of ultrasound in detecting pleural fluid is well known.

Treatment of hypertension during pregnancy depends primarily on expert opinion and observational studies because few randomized controlled trials have been conducted in this population, traditionally considered a vulnerable group by institutional review boards. An important factor is weighing the risks and benefits of treating high blood pressure in pregnant women for both the mother and the fetus. This, in turn, determines the exact blood pressure at which drug treatment in pregnant women begins.

After birth, the primary treatment of hypertensive disorders of pregnancy in most cases continues to be carried out by an obstetrician. Immediately after birth, the focus is on stabilizing the mother and normalizing her blood pressure with medication, if necessary. The American College of Obstetricians and Gynecologists (ACOG) recommends maintaining blood pressure below 150/100 during the postpartum period, although initiation of treatment, drug titration, and choice of antihypertensive drug are based on clinical judgment as there are no standardized treatments. Recommendations for specific antihypertensive medications or titration parameters for postpartum medications. Currently, women in the United States are typically discharged from the hospital 2 to 4 days after delivery, and ACOG recommends a single blood pressure measurement 3 to 10 days after delivery for women with hypertension during pregnancy. Women with persistent hypertension or those who need to take antihypertensive medications are generally more likely to be monitored for medications after delivery. However, this depends on the institution. The woman is then seen for a comprehensive postpartum visit, usually 4 to 6 weeks after birth, and referred to her primary care physician if additional need for antihypertensive medications arises.

Increasing evidence suggests a high rate of progression of chronic hypertension or persistent hypertension in the first year after hypertension during pregnancy. A recent study using ambulatory and inpatient blood pressure monitoring found that women with severe preeclampsia had persistent hypertension one year after delivery. These cases were detected only by APBM, suggesting that masked hypertension may significantly contribute to the increased risk of cardiovascular disease in this population. Factors appear to increase this risk including overweight and obesity, black race, and severity of hypertension during pregnancy.

The lifestyle interventions to improve cardiometabolic risk factors after complicated pregnancy were feasible and effective in the first year postpartum. The recently published SNAP-HT study demonstrated that regular titration of antihypertensive medications in the postpartum period not only shortens the duration of antihypertensive treatment, but can also lead to long-term improvements in blood pressure lasting up to 6 months postpartum. The authors suggested that this beneficial effect was secondary to more favorable cardiovascular remodeling. These results suggest that the first year postpartum may be critical for risk classification and easier

identification of women with persistent or unresolved hypertension after hypertension during pregnancy.

Few health care providers offer postpartum counseling or cardiovascular disease risk screening, although the postpartum period may be a time when women become motivated to make lifestyle changes [26]. Although some health care providers are well aware of the risk of future cardiovascular disease and try to promptly educate patients, they face many barriers to reducing this risk. It is difficult to determine the appropriate time and place for counseling and implementation of recommended risk reduction measures. Much of this counseling occurs immediately after birth, which is often a stressful and emotional time for women. Given the birth of a newborn, numerous physical changes, pain and lack of sleep, it is not surprising that women do not retain all the information doctors give them during labor [27]. Although remote blood pressure monitoring may be a promising method for improving medication adherence in the postpartum period, blood pressure monitoring is often not reimbursed by health insurance, potentially harming women of lower socioeconomic status. Postpartum care following hypertension during pregnancy is often fragmented, and there is no clear transition from obstetrician to primary care physician or cardiologist [26]. This poor monitoring of care is compounded by underlying socioeconomic issues affecting care delivery during this period. The United States is one of the few developed countries without paid parental leave, which disproportionately affects the most disadvantaged women. Access to health care must also be considered, as many publicly insured women who were only covered during pregnancy lose coverage within 60 days of giving birth, significantly limiting their care following pregnancy complications, with conditions varying from state to state. States are different. The state is different. Significantly higher rates of posttraumatic stress disorder in women with hypertensive disorders during pregnancy. These women are less likely to return to the health care system for follow-up care after a traumatic birth. Postpartum screening as part of a trauma-informed model of care may be useful, but is untested to date.

Prenatal care focuses on caring for women between pregnancies with the overall goal of improving pregnancy outcomes for the woman and fetus. The Society of Maternal-Fetal Medicine (SMFM) and ACOG recommend prenatal care for women with hypertension disorders during pregnancy. They especially emphasize the importance of care during pregnancy to maximize a woman's health, not only between pregnancies and during subsequent pregnancies, but throughout her life. This prenatal care should actually begin during prenatal care during the first pregnancy, with SMFM recommending that during prenatal care providers discuss who will provide primary care immediately after birth, discuss contraceptive options, and provide proactive breastfeeding and maternal health counseling, and also discussed the context of prenatal care between pregnancy complications and maternal long-term health. At a full postpartum visit between 4 and 6 weeks, health care providers should assess pregnancy complications and their impact on the mother's future health, and ensure that the patient remains in primary care for additional care. In particular, for women whose pregnancy is complicated by preeclampsia or gestational hypertension, the SMFM recommends measuring blood pressure to rule out hypertension and maintaining blood pressure <120/80 mm Hg. Art. Consider starting treatment or contacting your primary care provider if blood pressure goals are not being achieved. They also recommend that women achieve a normal BMI and discuss taking aspirin in future pregnancies. In women with chronic hypertension, testing for ventricular hypertrophy, retinopathy, and renal disease should be

considered in addition to the above recommendations in women with long-standing or uncontrolled hypertension.

Goal

Aim of the research was to study clinical case of postpartum preeclampsia and benign postpartum pleural effusion- timely recognition and management of the condition.

Case

A 38-year-old woman came to us with complaints: headache developed after caesarean section, slight deterioration of vision, episodes of mild respiratory insufficiency, small peripheral edema, chest discomfort, arterial hypertension within 140-160/90-95mm/Hg. Pregnancy and caesarean section went without complications. The increase of blood pressure started 48 hours after the operation, no significant changes were observed in the laboratory during the hospital stay. she had been discharged on prescribed methyldopa at home.

Hypertension continued, the above-mentioned complaints were added, which became the reason for an outpatient visit to a cardiologist.

No arterial hypertension or any cardio pathology in the past history. One pregnancy and caesarean section 6 years ago without complications. The patient was a smoker, she refused any family history.

On Electrocardiography: normal sinus rhythm.

Echocardiography revealed: the dimensions of the heart chambers within the normal range, the function of the global contractility of left ventricle was normal, the ejection fraction 56%, no hemodynamically significant regurgitation was observed, the pericardium - free of fluid. 3-3 cm pleural effusion bilaterally has been revealed.

With laboratory control: complete blood analysis, electrolytes, complete urine analysis, creatinine, type B natriuretic peptide-proBNP, liver function tests - normal. The patient's condition was evaluated as postpartum preeclampsia and clinical management was done with the attending gynecologist.

Methyldopa was replaced by labetalol and blood pressure stabilized. Postpartum cardiomyopathy was ruled out, echocardiographic control was performed one and three weeks later, left ventricular contractility remained within normal limits, pleural effusion decreased and resolved, it was assessed as benign postpartum pleural effusion. Arterial blood pressure normalization occurred after 2.5-3 months on labetalol.

Discussion

Most often, the symptoms of preeclampsia appear during pregnancy [2], although some women develop preeclampsia after childbirth, including those who had a normal pregnancy, as it happened in our case. Postpartum preeclampsia mostly occurs within a few days of delivery, but can develop up to 6 weeks. Untreated preeclampsia can lead to stroke, seizures, and other serious complications [3].

A doctor should be consulted immediately if the systolic blood pressure reading is 140 mm Hg or higher and/or the diastolic blood pressure reading is 90 mm Hg or higher [4]. Preeclampsia should also be recognized immediately if the patient notices: changes in vision (blurring, sensitivity to light, spots in the field of vision), headache that does not resolve with medication, shortness of

breath, swelling of the face or hands, pain in the shoulder or abdomen, mostly in the right upper quadrant, nausea or vomiting, sudden weight gain (1.5 to 2 kg or more per week), decreased urination.

In our case, the patient did not have hypertension before delivery, nor did during first pregnancy, have not any complications during delivery. The blood pressure started increase 48 hours after cesarean section, blurred vision, progressive respiratory insufficiency, peripheral edema, chest discomfort developed in 72-96 hours, 3-3 cm pleural effusion bilaterally has been revealed and it should be considered as a benign postpartum pleural effusion [5,6,7].

Early recognition of postpartum preeclampsia and initiation of appropriate treatment is important. Postpartum preeclampsia can be treated with hypotensive tablet medications, sometimes intravenously (IV), to prevent seizures.

Preeclampsia is a progressive multisystem disorder characterized by the development of new-onset hypertension, proteinuria, or other important target organ dysfunction during the last half of pregnancy or the postpartum period. The progression of the disease from mild to severe can occur gradually or rapidly.

A major focus of routine prenatal care is monitoring patients for signs and symptoms of preeclampsia. If diagnosed during pregnancy, the only definitive treatment is delivery to avoid maternal or fetal complications from disease progression. The problem will eventually resolve with delivery, although target organ function may deteriorate in the first three days after delivery. The timing of delivery is based on a combination of factors, including the severity of the disease, maternal and fetal condition and gestational age.

Postpartum maternal monitoring is important to identify the minority of patients whose blood pressure does not return to normal levels after delivery. Long-term follow-up of the mother is also important, as patients with a history of preeclampsia have a later risk of cardiovascular disease and mental disorders .

Most NOPP develops within 48 hours of delivery. But it sometimes develops up to six weeks after child birth or later. This is known as late postpartum preeclampsia.

NOPP detection is sometimes difficult. Most of women with NOPP have no signs or symptoms during pregnancy, as was in our case, and may not suspect a problem when they are focused on postpartum recovery and caring for their newborn.

Studies in this direction are rare. Possible risk factors: high blood pressure during the last pregnancy, arterial hypertension (gestational hypertension) developed after 20 weeks of pregnancy, obesity, multiple pregnancy - having twins, triplets or more increases the risk of preeclampsia. Chronic high blood pressure – uncontrolled high blood pressure before pregnancy increases the risk of gestational preeclampsia and postpartum preeclampsia.

Diabetes – type 1 or type 2 diabetes or gestational diabetes increases the risk of preeclampsia and postpartum preeclampsia.

In our case, the patient did not have any of the above risk factors. Symptoms of preeclampsia developed shortly after delivery and progressed rapidly. Early recognition and management of preeclampsia is important, as NOPP can be complicated by conditions such as postpartum eclampsia.

This is essentially postpartum preeclampsia with seizures. NOPP can permanently damage vital organs, including the brain (stroke), vision, liver and kidneys. Possible complications are: thromboembolism, HELLP syndrome, which involves hemolysis, increased liver enzymes, and thrombocytopenia. It can quickly turn into a life-threatening condition. Manifestations of this

syndrome are: nausea, vomiting, headache and pain in the upper right quadrant of the abdomen. Sometimes it can develop suddenly, even before high blood pressure is detected, or it can develop without any symptoms [8,9,10].

Conclusion

There is a need to raise awareness about postpartum hypertension, as NOPP can lead to serious complications if symptoms are not promptly assessed and treated. Thus, postpartum preeclampsia requires timely recognition and proper treatment.

Declaration of Interest Statement: No potential conflict of interest was reported by the authors.

Declarations

The manuscript has not been submitted to any other journal or conference.

Study Limitations

There are no limitations that could affect the results of the study.

Acknowledgment

The author would like to express gratitude to the care support workers and elderly individuals who participated in this study, sharing their invaluable insights and experiences. Their cooperation and openness have significantly contributed to the depth and richness of the research findings.

REFERENCES

1. Review Am J Obstet Gynecol 2022 Feb;226(2S): S1211-S1221. Epub 2021 Jul 7. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy Alisse Hauspurg, arun jeyabalan
2. Observational Study, BMC Pregnancy Childbirth 2020 Oct 15;20(1):625. Preeclampsia knowledge among postpartum women treated for preeclampsia and eclampsia at Korle Bu Teaching Hospital in Accra, Ghana Avina Joshi , Titus Beyuo , Samuel A Oppong ; Cheryl A Moyer , Emma R Lawrence
3. Review J Matern Fetal Neonatal Med 2022 Dec;35(25): 8443-8449. doi: 10.1080/14767058.2021.1978067. Epub 2021 Sep 19. Preeclampsia and postpartum mental health: mechanisms and clinical implications Amelia Srajer , Jo-Ann Johnson , Kamran Yusuf
4. Review Curr Hypertens Rep 2020 Aug 6;22(8):58. doi: 10.1007/s11906-020-01058-w. Postpartum Hypertension, V Katsi , G Skalis , G Vamvakou , D Tousoulis , T Makris
5. Ann Intern Med 1982 Dec;97(6): 856-8. doi: 10.7326/0003-4819-97-6-856. Postpartum pleural effusion: a common radiologic finding W G Hughson, P J Friedman, D S Feigin, R Resnik, K M Moser
6. Review Semin Respir Crit Care Med 2019 Jun;40(3): 402-409. Epub 2019 Sep 16. Pleural Disease in Women Angela Christine Argento , Colin T Gillespie
7. Eur Respir J 1995 Oct;8(10): 1748-50. Benign postpartum pleural effusion K I Gourgoulianis 1, A H Karantanas, G Diminikou, P A Molyvdas

8. Review Obstet Gynecol Clin North Am 1995 Jun;22(2):337-56. Complicated postpartum preeclampsia-eclampsia E F Magann 1, J N Martin Jr
9. Adv Emerg Nurs J 2023 Apr-Jun;45(2): 154-163. Postpartum Preeclampsia: What Can Stories Posted on the Internet Tell Us? Cheryl Tatano Beck 1
10. ANetwOpen2020Dec1;3(12):e2030815.doi:10.1001/jamanetworkopen.2020.30815.Racial Differences in Postpartum Blood Pressure Trajectories Among Women After a Hypertensive Disorder of Pregnancy Alisse Hauspurg , Lara Lemon , Camila Cabrera , Amal Javaid , Anna Binstock Beth Quinn , Jacob Larkin, Andrew R Watson , Richard H Beigi , Hyagriv Simhan
11. Data on Pregnancy Complications | Pregnancy | Maternal and Infant Health | CDC. [https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pregnancy-co....](https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pregnancy-co...) Published 2019. Accessed February 10, 2020.
12. Hoyert DL, Miniño AM. National Vital Statistics Reports Maternal Mortality in the United States : Changes in Coding, Publication and Data Release, 2018. Natl Vital Stat Reports. 2020;69(2).
13. Clapp MA, Little SE, Zheng J, Robinson JN. A multi-state analysis of postpartum readmissions in the United States. Am J Obstet Gynecol. 2016;215(1):113.e1–113.e10.
14. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019;133(1):e1–e25.
15. Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol. 2012;206(6):470–475.
16. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive
17. Overview | Hypertension in pregnancy: diagnosis and management | Guidance | NICE. <https://www.nice.org.uk/guidance/ng133>. Accessed June 1, 2020.
18. Redman EK, Hauspurg A, Hubel CA, Roberts JM, Jeyabalan A. Clinical Course, Associated Factors, and Blood Pressure Profile of Delayed-Onset Postpartum Preeclampsia. Obstet Gynecol. 2019;134(5):995–1001.
19. Matthys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum preeclampsia: An experience of 151 cases Postpartum period Hypertension Preeclampsia Eclampsia. Am J Obstet Gynecol. 2004;190:1464–1470.
20. Al-Safi Z, Imudia AN, Filetti LC, Hobson DT, Bahado-Singh RO, Awonuga AO. Delayed postpartum preeclampsia and eclampsia: Demographics, clinical course, and complications. Obstet Gynecol. 2011;118(5):1102–1107.
21. ACOG. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–1131.
22. Larsen WI, Strong JE, Farley JH. Risk factors for late postpartum preeclampsia. J Reprod Med. 2012;57(1–2):35–38.
23. Takaoka S, Ishii K, Taguchi T, et al. Clinical features and antenatal risk factors for postpartum-
24. Skurnik G, Hurwitz S, Mcelrath TF, et al. Labor therapeutics and BMI as risk factors for postpartum preeclampsia: a case-control study. Pregnancy Hypertens. 2018;10:177–181.



25. Bigelow CA, Pereira GA, Warmsley A, et al. Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia. *Am J Obstet Gynecol.* 2014;210(4):338.e1–338.e8.
26. Al-Safi Z, Imudia AN, Filetti LC, Hobson DT, Bahado-Singh RO, Awonuga AO. Delayed postpartum preeclampsia and eclampsia. *Obstet Gynecol.* 2011;118(5):1102–1107.
27. Giwa A, Nguyen M. Late Onset Postpartum Preeclampsia 3 Months After Delivery. *Am J Emerg Med.* 2017;35(10).
28. Atterbury JL, Groome LJ, Hoff C, Yarnell JA. Clinical Presentation of Women Readmitted With Postpartum Severe Preeclampsia or Eclampsia. *J Obstet Gynecol Neonatal Nurs.* 1998;27(2):134–141.
29. Sperling JD, Dahlke JD, Huber WJ, Sibai BM. The Role of Headache in the Classification and Management of Hypertensive Disorders in Pregnancy. *Obstet Gynecol.* 2015;126(2):297–302.
30. Stella CL, Jodicke CD, How HY, Harkness UF, Sibai BM. Postpartum headache: is your work-up complete? *Am J Obstet Gynecol.* 2007;196(4):318.e1–7.
31. Berhan Y, Endeshaw G. Clinical and Biomarkers Difference in Prepartum and Postpartum Eclampsia. *Ethiop J Health Sci.* 2015;25(3):257–266.
32. Vilchez G, Hoyos LR, Leon-Peters J, Lagos M, Argoti P. Differences in clinical presentation and pregnancy outcomes in antepartum preeclampsia and new-onset postpartum preeclampsia: Are these the same disorder? *Obstet Gynecol Sci.* 2016;59(6):434.
33. Health Division A THE CALIFORNIA PREGNANCY-ASSOCIATED MORTALITY REVIEW Report from 2002 to 2007 Maternal Death Reviews.; 2018. <https://www.cmqcc.org/sites/default/files/CA-PAMR-Report-1%283%29.pdf>. Accessed September 28, 2020.
34. Oremus M, McKelvie R, Don-Wauchope A, et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. *Heart Fail Rev.* 2014;19(4):413–419.
35. Tsai S-H, Lin Y-Y, Chu S-J, Hsu C-W, Cheng S-M. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. *Yonsei Med J.* 2010;51(2):151–163.
36. Shekhar S, Gupta N, Kirubakaran R, Pareek P. Oral Nifedipine Versus Intravenous Labetalol for Severe Hypertension During Pregnancy: A Systematic Review and Meta-Analysis. *BJOG.* 2016;123(1).
37. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane database Syst Rev.* 2018;10(10):CD002252.

Publication history

Article received: 23.04.2024

Article accepted: 14.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-03

THE MANIFESTATION OF KEY ISSUE ASPECTS OF PHARMACISTS' OCCUPATIONAL FEATURES AND STUDY OF SOME DRIVING FORCES IMPACT ON PHARMACISTS' PROFESSION AND ROLE EXPANSION

Nodar Sulashvili¹, Vira Kravchenko², Nana Gorgaslidze³, Luiza Gabunia⁴, Shafiga Topchiyeva⁵, Nato Alavidze⁶, Nino Abuladze⁷, Natia Kvizhinadze⁸, Ketevani Gabunia⁹, Igor Seniuk¹⁰, Marika Sulashvili¹¹, Tamar Okropiridze¹², Giorgi Pkhakadze¹³, Marina Giorgobiani¹⁴, Irine Zarnadze¹⁵, Shalva (Davit) Zarnadze¹⁶

¹MD, PhD, Doctor of Pharmaceutical Sciences, Doctor of Theoretical Medicine In Pharmaceutical and Pharmacological Sciences, Invited Lecturer (Professor) of Scientific Research-Skills Center at Tbilisi State Medical University, Professor of Pharmacology of Faculty of Medicine at Georgian National University SEU, Associate Affiliated Professor of Medical Pharmacology of Faculty of Medicine at Sulxan-Saba Orbeliani University, Associate Professor of Division of Pharmacology of International School of Medicine at Alte University; Associate Professor of Pharmacy Program at Shota Meskhia Zugdidi State University; Associate Professor of Medical Pharmacology at School of Medicine at David Aghmashenebeli University of Georgia, Associate Professor of Biochemistry and Pharmacology Direction at the University of Georgia, School of Health Sciences. Associate Professor of Pharmacology of Faculty of Medicine at East European University, Associate Professor of Pharmacology of Faculty of Dentistry and Pharmacy at Tbilisi Humanitarian Teaching University; Tbilisi, Georgia; n.sulashvili@ug.edu.ge, <https://orcid.org/0000-0002-9005-8577>

²MD, PhD, Doctor of Pharmaceutical Sciences, Academician, Professor, Head of The Biological Chemistry Department at National University of Pharmacy, Kharkiv, Ukraine.

³MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Tbilisi State Medical University, Head of The Department of Social and Clinical Pharmacy, Tbilisi, Georgia. <https://orcid.org/0000-0002-4563-5224>

⁴MD, PhD, Doctor of Medical Sciences, Professor, Director of the Scientific Research-Skills Center at Tbilisi State Medical University, Professor of the Department of Medical Pharmacology at Tbilisi State Medical University, Clinical Pharmacologist of The First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia. <https://orcid.org/0000-0003-0856-2684>

⁵PhD, Doctor of Biological Sciences, Professor of Institute of Zoology, National Academy of Sciences of Azerbaijan, Baku, Azerbaijan; <https://orcid.org/0000-0002-6369-1414>

⁶MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Akaki Tsereteli State University, Faculty of Medicine, Department of Pharmacy, Kutaisi, Georgia. Professor, Dean Faculty of Medicine at East European University, Tbilisi, Georgia. <https://orcid.org/0000-0001-6695-5924>

⁷MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Akaki Tsereteli State University, Faculty of Medicine, Department of Pharmacy, Kutaisi, Georgia. <https://orcid.org/0000-0003-2189-7470>

⁸MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Tbilisi State Medical University, Department of Social and Clinical Pharmacy. Tbilisi, Georgia.

⁹MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Akaki Tsereteli State University, Faculty of Medicine, Department of Pharmacy, Kutaisi, Georgia. <https://orcid.org/0000-0002-5857-6593>

¹⁰PhD, Doctor of Pharmaceutical Sciences, Dean of faculty of Pharmacy at National University of Pharmacy of Ukraine, Associate Professor of Biological Chemistry Department at National University of Pharmacy, Kharkiv, Ukraine. <https://orcid.org/0000-0003-3819-7331>

¹¹MD, Doctor of Family Medicine, Invited Lecturer (Invited Professor) of Tbilisi State Medical University, Lecturer of Department of Molecular and Medical Genetics, Tbilisi, Georgia. <https://orcid.org/0000-0002-6338-4262>

¹²MD, PhD, Doctor Medical Sciences, Professor of the Division of Dentistry of International School of Medicine at Alte University; Professor of Teaching University Geomedi, Head of The Dental Educational Program, Head of the Department of Dentistry, Tbilisi, Georgia. Invited Professor of Dentistry Department of The School of Health Sciences at The University of Georgia, Tbilisi, Georgia.

¹³MD, MPH, PhD, Doctor of Medical Sciences, Professor – Head of the School of Public Health at David Tvildiani Medical University, Tbilisi, Georgia; Member of the United Nations Secretary General's Independent Accountability Panel, Geneva, Switzerland; President, Accreditation San Frontières, Paris, France, Lviv Ukraine; <https://orcid.org/0000-0001-7609-4515>



¹⁴MD, PhD, Doctor of Medical Sciences, Professor of Tbilisi State Medical University, Department of Hygiene and Medical Ecology, Tbilisi, Georgia. <https://orcid.org/0000-0003-0686-5227>

¹⁵MD, PhD, Doctor of Medical Sciences, Professor of Tbilisi State Medical University, Department of Public Health, Health Care Management, Policy and Economy, Tbilisi, Georgia. <https://orcid.org/0000-0001-5511-437X>

¹⁶MD, PhD, Doctor of Medical Sciences, Professor of Tbilisi State Medical University, Head of the Department of Nutrition, Aging Medicine, Environmental and Occupational Health, Tbilisi, Georgia.

ABSTRACT

The main goal of the study was to analyze key issue aspects of pharmacists' occupational features and study of some driving forces impact on pharmacists' profession expansion. The study was a quantitative investigation and analysis of pharmacists' vocational perspectives impressions and evaluations of key issue of factors having influence on pharmacists' occupational development in Georgia, in general by using questionnaires. Were conducted a survey study. The in-depth interview method of the respondents was used in the study. The approved questionnaires were used (Respondents were randomly selected): Questionnaire for pharmacist specialist, 810 pharmacist specialists participated in the study. Were used methods of systematic, sociological (surveying, questioning), comparative, mathematical-statistical, graphical analysis. The data were processed and analyzed with the SPSS program. Were conducted descriptive statistics and regression analyses to detect an association between variables. Statistical analysis was done in SPSS version 11.0. A Chi-square test was applied to estimate the statistical significance and differences. We defined $p < 0.05$ as significant for all analyses. The research implementation required the following sub studies: The scientific talks of pharmacists' vocational perspectives impressions and evaluation of key issue of factors having influence on pharmacists' occupational development in Georgia, in general. According the study results found: Common pharmacies have been providing health care for many years, via giving consultation, advice, providing and delivering medicine when needed, or referring patients to other health care professionals. This report, however, reflects and represent the embedding of a formalized approach whereby pharmacies are covering for these services, and where self-care through pharmacists is measured as an integral part of the health system. A pharmacist is a personality who is professionally competent and qualified to prepare and dispense medicine. The Pharmacist dispense drugs, check patient's health, and make sure that drugs do not interact in a harmful route. Pharmacist are drug experts eventually interested about their patients' wellness and health. Public health service interventions, higher level pharmaceutical care, rational pharmacotherapy and effective medicines supply chain management are main components of an accessible, sustainable, affordable and equitable health care system which ensures the efficacy, safety and quality of drugs. It is clear that pharmacy has a great role to play in the health sector reform process. The role of the pharmacist needs to be redefined and reoriented. Pharmacists have the capability and possibility to enhance therapeutic results and patients' quality of life within accessible resources, and must position themselves at the forefront of the health care system. The movement towards pharmaceutical care is a critical factor in this matter. Pharmacists also have a vital contribution to make to patient care through managing pharmacotherapy and concurrent non-prescription or alternative therapies. The pharmacists are health professionals who are dispensing prescription drugs to patients, also provide information about the medicines ordered by doctors. They explain the doctors' instructions to patients so that, people can safely and effectively use these medications. Another big issue is ensuring that drugs are used reasonably and rationally. Pharmacists have a deep

knowledge of the chemistry and pharmacotherapy of different drugs and how they react to people, as well as how drugs interact with each other. Pharmacists must accurately measure and a package of medicine, providing its dosage and security to ensure patients proper and rational pharmacotherapy in general.

Keywords: Pharmacists', occupational, features, driving, forces, impact, pharmacists', profession, expansion.

Introduction

Pharmacists have a lot of public health functions that can benefit from the unique experience of pharmacists, which may include pharmacotherapy, pharmaceutical care, and pharmacy assistance. In addition to dispensing medicines, pharmacists have proved to be an accessible resource for information on health and medicines.

Being a health care professional means being part of a team that is focused on one goal- helping the patient achieve better health. Pharmacists are a part of this health care team, and their duty is to help the patients make the best use of their medication. Thus, within their profession, pharmacists have developed other categories of pharmacy workers to help get the work done more efficiently and allow pharmacists to be more focused on the patient. The were found and estimated factors having influence on pharmacists' professional development, these factors were: Interesting and valuable (informative) work; The favorable (prosperous) psychological climate within the collective in the colleagues' team; The possibility of career growth (development); The possibility of professional education or training; The social importance of the profession; Independence in work [1-4].

The public and our patients should expect the highest possible pharmaceutical care from professional practitioners worldwide, without exception. The obviously evidence and confidence of competence, skills and capability that is corresponding with accelerating and master practice is a clear message to fostered public that pharmacists have this competence; professional distinction, credentialing and quality convinced of specialization are part of this evidence of competence, potential and capability. It is in the interest of patients, health systems and to pharmacists' profession that develop a common and shared understanding of what we mean by specialism and by forward practice". This is a key supervisor for future workforce perfection [5-7].

Education and advancement of long-term education are the cornerstones of the future pharmacy - today's students are supervisor in the pharmacy of tomorrow. This means that all parties involved in pharmaceutical education have a great responsibility for mastering new approaches and view for the training of future health care workers. Academic pharmacy must take a powerful position in forecasting essential changes in the world and developing strategies for improving the teaching of pharmacy in the interests of everyone's health. One of the most significant aspects is the development of knowledge, cognition and experience in the academic workforce [8-10].

A pharmacist a health care professional, which distributes medications to patients on prescription, on the order of a physician or another doctor. Pharmacists have a deep knowledge of the chemistry and Pharmacotherapy of different drugs and how they react to people, as well as how drugs interact with each other. Pharmacists must accurately measure and a package of medicine, providing its dosage and security due to the patient. While the pharmacist typically does not choose or prescribe medication, the pharmacist educates patients on how to take the medication and what reactions or problems should be avoided. Pharmacists also known as chemists (druggists) or they are health care professional specialists who working in pharmacy,

medical sciences, health care, focused on the safe and effective use of drugs. A pharmacist is a part of the health care brigade straight engaged in patient care [11-13].

Pharmacists are trained at the university grade degree level, to understand the biochemical and pharmacological mechanisms of effect of drugs, the use of drugs and therapeutic roles, side effects, possibility drug interactions, and inspection parameters. Pharmacists interpret and transmit this experience for patients, physicians and other medical professionals. Among other requirements for licensing in different countries require pharmacists to hold either a Bachelor degree of Pharmacy or Doctor of Pharmacy degree. The most general pharmacist positions that of the general pharmacist (also referred to as first-line retail pharmacist or pharmacist) or a hospital/clinic pharmacist, where they instruct, teach, advice and counsel on the correct use and side effects of drugs and medicines [14-16].

In most countries, the profession of pharmacist is subject to professional regulation. Depending on the legal framework of practice, pharmacists may promote to the destination (also known as pharmacist legislator) and the introduction of certain medications (eg, immunization) in some jurisdictions. Pharmacists can also practice in a diversity of other directions, including industry, studying, factories, wholesale trade, academia, research, universities, insurance, the military and government [17-19].

Pharmacists should see themselves as the main health care providers who can use their clinical experience in various public institutions. Pharmacists will always be an important health care provider based on their availability to patients through community pharmacy setting. This specific role of provider should never be reduced, as it serves the critical needs of patients (eg, dispensing and counseling for drug experience in nonprescription drugs, compounding, vaccinations, and the use of medication administration or monitoring devices) that not addressed by other health care providers [20-22]. However, this does not exclude pharmacists serving as suppliers of innovative alternative settings, such as outpatient clinics located in pharmacies and other retail outlets; in independent practice with a focus on medication management therapy, medication reconciliation, drug counseling or Pharmacogenomic; institution or organization, where they are responsible for the integration and promotion of patient care through the many other health care providers to facilitate continuity of care community; or organizations that coordinate research to improve practice through pharmacy practice based research networks. Pharmacy providers should look for opportunities to engage in professional activities between patient care, when and where they occur or as they develop in communities. For example, alternative practices may change to concentrate on providing pharmacy and health services for adults and retirement communities, given the growing number of them as Georgian population continues to age [22-24].

Pharmacy graduates who serve in the health services of Georgia, as these pharmacists to develop innovative practice settings, they should be drivers for expansion within the pharmacy practice in community, state and national levels. Pharmacy educators must ensure that graduates have the necessary knowledge, skills, attitudes/values, and practice experience, as well as confidence, drive, and entrepreneur spirit to be a driving force for change in order to facilitate these and other advances in the scope and type of community pharmacy practice [25-26].

Patient safety is a priority for all professionals - pharmacists - who care about the health. Patient safety is defined as the prevention of harm to patients, including by errors. For centuries, pharmacists were guardians / safeguards against "poisons" of substances that can cause harm to society. Now more than ever, pharmacist's responsibility is receiving safely the medication to the patient. Hospitals and other institutions and facilities, such as outpatient clinics, drug-dependency

treatment facilities, poison control centers, drug information centers, and long-term care facilities, may be operated by the government or privately. While many of the pharmacist's activities in such facilities may be similar to those performed by community pharmacists, they differ in a number of ways. Additionally, the hospital, clinic or institutional pharmacist has more possibility to interact closely with the prescriber and, therefore, to promote the rational prescribing and use of drugs in larger hospital and institutional pharmacies, is usually one of several pharmacists, and thus has a greater opportunity to interact with others, to specialize and to gain greater expertise, having access to medical records, is in a position to effect the option of drugs and dosage regimens, to monitor patient compliance and therapeutic response to drugs, and to recognize and report adverse drug reactions; can more easily than the community pharmacist assess and monitor patterns of drug usage and thus recommend changes where necessary serves as a member of policy-making committees, including those concerned with medicine choice, the use of antibiotics, and hospital infections and thereby actions of the preparation and composition of an essential-drug list or formulary is in a better position to educate other health professionals about the rational use of drugs, more easily participates in studies to determine the beneficial or adverse effects of drugs, and is involved in the analysis of drugs in body fluids ,can control clinical manufacture and acquisition of drugs to ensure the supply of high-quality products, takes part in the planning and implementation of clinical trials [28-31].

Goal

The main aim of the study was to analyze the key issue aspects of pharmacists' occupational features and study of some driving forces impact on pharmacists' profession expansion.

Methodology

Research objectives are materials of sociological research: the study was quantitative investigation by using survey (Questionnaire). The study was quantitative investigation by using survey (Questionnaire). The in-depth interview method of the respondents was used in the study. The approved questionnaires were used (Respondents were randomly selected. Questionnaire for pharmacist specialist, 810 pharmacist specialists participated in the study. We used methods of systematic, sociological (surveying, questioning), comparative, segmentation, mathematical-statistical, graphical analysis. The data was processed and analyzed with the SPSS program. Results and discussion: Questions and answers are given in the tables. On each question are attached diagrams or table. Questionnaire and diagrams are numbered. Study of the data was processed and analyzed with the SPSS program. We conducted descriptive statistics and regression analyses to detect an association between variables. Statistical analysis was done in SPSS version 11.0. A Chi-square test was applied to estimate the statistical significance and differences. We defined $p < 0.05$ as significant for all analyses. The study's ethical items. In order to provide the study's ethical character each participant of it was informed about the study's goal and suggested of willingness of the work to be done. So, the respondents' written or oral compliance was got on that issue. All the studies were carried out by the selected organizations administrations' previous compliance. Were used Informed consent form for each respondent to participate in an anonymous survey. During the whole period of research, the participants incognita was also provided. For the international rules and criteria' conformity this human subject comprising given study was discussed and confirmed on the Bioethics Committee sessions of the YSMU. In order to meet the objectives, set in the research we also used the results obtained

through analysis of available official information, studies and opinions about pharmacists, as well as the methods of quantitative studies. The research implementation required the following sub studies: The key issue aspects of pharmacists' occupational features and study of some driving forces impact on pharmacists' profession expansion.

Results and discussion.

Pharmaceutical care is a ground-breaking concept in the practice of pharmacy which emerged in the mid-1980s. It stipulates that all practitioners should assume responsibility for the outcomes of drug therapy in their patients. It surrounds a variety of functions and services – some new to pharmacy, others traditional – which are determined and provided by the pharmacists serving individual patients. The concept of pharmaceutical care also includes affective commitment to the welfare of patients as individuals who require and deserve pharmacists' compassion, mercy, concern and trust. However, pharmacists often deny to accept responsibility for this power and extent of care. As a result, they may not adequately document, control and review the care given. Accepting such responsibility is essential to the practice of pharmaceutical care. Pharmaceutical care can be tendered to individuals and publics. "Population-based pharmaceutical care" uses demographic and epidemiological data to establish formularies or drug lists, develop and monitor pharmacy politics, develop and manage pharmacy networks, prepare and analyses reports of drug utilization/costs, conduct drug utilization reviews and educate providers on medicine policies and procedures [32-34].

Without individual pharmaceutical care, however, no system can manage drug therapy and monitor medicine-related illness effectively. The population-based functions identified by above need to occur either before or after patients are seen and provide useful information, but cannot replace patient-specific services while patients are being seen. Medicine related illnesses occur frequently even with medicines that are in a system's formulary or medicines list, since these medicines are often prescribed, administered or used inappropriately. Patients need pharmacists' maintenances at the time they are receiving care. Successful pharmacotherapy is specific for each patient. It includes individual drug therapy decisions, reaching concordance (an agreement between the patient and the health care provider on the therapeutic outcome and how it may be achieved), and critical patient monitoring activities. For each individual patient's pharmacotherapy treatment, the pharmacist develops a care schedule together with the patient. Patients can then contribute to successful outcomes by taking part of the responsibility for their own care and not relying solely on caregivers, in the former paternalistic style. Pharmaceutical care does not exist in isolation from other health care services. It must be provided in collaboration with patients, physicians, nurses and other health care providers. Pharmacists are responsible directly to patients for the cost, quality and results of pharmaceutical care does not exist in isolation from other health care services. It must be provided in collaboration with patients, physicians, nurses and other health care providers. Pharmacists are responsible directly to patients for the cost, quality and results of pharmaceutical care [35-37].

The forces behind the variations in pharmaceutical education are many and varied, and growing in both number and intensity. The major economic and political forces affecting the health care system in the most countries are also having an impact and influence on the practice of pharmacy. As an effect, radical changes are needed in pharmaceutical education. The role and function of pharmacists and pharmaceutical staff need to be reappraised and the educational outcomes of the evolving pharmacy curriculum should be clearly determined. The use of outcomes statements

would help to drive curriculum development. Educational outcomes can be used as a new organizing framework that integrates science, professional attributes, interprofessional practice, and professionalism across new major headings of pharmaceutical care, systems management, and public health, as they are in the practice of pharmacy. The educational change will require not only extensive curriculum revision and restructuring, but also a major commitment to faculty development to prepare teachers to educate pharmacists in a different way. The type and depth of didactic and experiential material to be included will be different. The amount and allocation of educational resources will have to change. Schools and colleges of pharmacy should create, establish and evaluate practice models that could be used within evolving health care environments. Courses should take into consideration the needs of the objective audience, learning outcomes, course content, learning and teaching methods, learning resources, participant assessment, course evaluation, and quality assurance when being introduced into the curriculum. Pharmacy practice takes place at different levels. The ultimate aim of activities at all these levels is to benefit patients by improving and maintaining their health. Activities at individual patient level comprise all aspects of providing and managing a patient's drug therapy (i.e., pharmaceutical care, including clinical pharmacy services). At this level, decisions are made on issues of pharmaceutical care and triage (i.e., prioritization of care, patient follow-up and therapeutic outcome monitoring).

Patient safety is a priority for all professionals - pharmacists - who care about the health. Patient safety is defined as the prevention of harm to patients, including by errors. For centuries, pharmacists were guardians / safeguards against "poisons" of substances that can cause harm to society. Now more than ever, pharmacist's responsibility is receiving safely the medication to the patient.

Protecting the people is the primary goal of pharmacy boards. On a broad scale, this mission requires a pharmacist to attend university for a specific number of years and to pass the state competency examination. Boards also set the parameters for what happens if a law or regulation is violated, what penalties result, and what infractions can cause if a pharmacist lose his or her license.

Pharmacy is one of the most regulated professions in the western countries and pharmacist profession is one of the most ethically challenging position. In EU countries state boards regulate, administer and influence every phase of pharmacy practice, including the demands and licensing testing for pharmacist. In western countries each state board is staffed up of pharmacists who come from every practice area — hospitals, clinic, chains, independent pharmacies, pharmaceutical factory, industrial pharmacy — as well as at least one consumer (non pharmacist) representative. In most states, pharmacy board members are appointed by the government.

The health care brigade composes of the patient and all the health care professional specialists who have liability for patient care. This health care brigade demands to be well determined, and cooperation needs to be actively sought. Pharmacists have considerable character and role to play in this brigade. Pharmacists must demand to acclimatize their skills, knowledge, information and attitudes to this innovated role, which consolidates all traditional pharmaceutical sciences with hospital/clinical aspects of the patient care, clinical/hospital skills, management, administration and communication skills, active cooperation with medical brigade and solving of drug-related issues. If they are to be recognized as full members of the health care brigade, pharmacists will demand to adopt the essential attitudes required by health professional specialists laboring in this space: visibility, liability, duty, responsibility, accessibility in a working practice targeted at the

general population, commitment to confidentiality and patient orientation. Pharmacists will demand to be competent, qualified, knowing and possess all that vision, opinion and a voice to fully integrate themselves into the health care brigade.

In western countries are actively working clinician pharmacist, pharmacist and family doctor system, it plays an important role in pharmaceutical care. In western countries and in many developing countries pharmacist professions a regulated sector in health, as well as family medicine. Pharmacist, as well as the family doctor, needs higher education, further Diploma, and continuing pharmaceutical education, Pharmacist's license and periodic accreditation. in pharmacy, on pharmacists position works only higher pharmaceutical education specialists, Who graduated by the state recognized and accredited universities, and colleges. In Georgia pharmacist further diploma , continuing pharmaceutical education, pharmacist licensing and accreditation regulatory legislative base is not perfect. Today, the pharmacist profession in Georgia is impaired, pharmacist profession is deleted from health adjustable medical fields, Therefore degree in pharmacy or higher education in pharmacy losing profession opinion and values. In Georgia not conducted pharmacists certification, re-certification, accreditation and licensing state programs. Therefore profession pharmacist specialty becomes given position by the pharmacy owner, and not only from the university awarded qualification. Because of the above reasons in Georgia in drugstores for pharmacist position is no longer necessary higher pharmaceutical education, in drugstore any person has the right to work as a pharmacist position, any educated person or a person without medical or pharmaceutical education may be given a "position" Pharmacist "according pharmacy owner desired, pharmacy profession granting needs 4-5 year study at medical and other universities. In Georgia drugstore pharmacist interpreted as the only drug-dealer-seller. Pharmacist as regulated medical specialists ignored in Georgian Health-care System. That is why higher pharmaceutical education system should be moved to a new model direction, which will be more focused on pharmacotherapy, pharmaceutical care, and clinical pharmacy. Therefore, in future pharmacist profession in Georgian health care system should become most important link. In the state health policy, it is necessary to develop pharmacist profession's concepts and common principles. pharmacist profession should become regulated health care job, look like family doctor. In Georgia should be developed and implemented pharmacists registration, licensing, and accreditation new standards accordance with international pharmaceutical programs. Also qualified pharmacist in Georgia should have the right to work as pharmacist in other European Countries. Georgian pharmacist Certificate should have recognition in western countries, and Georgia should create pharmacist registration standard which is exist in Great Britain and other Western countries.

As pharmacists proceed to become more clinically-oriented health care professionals, with increased responsibilities, liability and accountabilities for pharmaceutical care clear pathways for workforce development, coupled with professional recognition and credentialing of practitioners, is an important consideration. This represents a clear opportunity for transnational collaboration and further opportunities for transnational recognition of advanced capabilities for the pharmacy workforce. An obviously display and assurance of competence and facilities that is well-proportioned with progressive and expert practice is an obviously message to fostered public that pharmacists own this competence; occupational recognition, credentialing and quality assured specialism are part of this to show of competence, skills and capability. There is in the interest of patients, health systems and pharmacist profession that were develop a common and shared understanding of what we mean by specialization and by innovative practice. This is a key driver

for future workforce perfection. Pharmacists have a lot of public health functions that can benefit from the unique experience of pharmacists, which may include pharmacotherapy, pharmaceutical care, and pharmacy assistance. In addition to dispensing medicines, pharmacists have proved to be an accessible resource for information on health and medicines. The centralized position of the pharmacist in the society and clinical competence are invaluable. It is important to review and integrate public health practices into pharmacological training and pharmaceutical care. Encouraging cross-training will also increase the resources and help meet the needs of the workforce in the fields of pharmacy and public health. The Georgian Pharmacists Association has strongly supported the role of the pharmacist in public health. Through Trans disciplinary approaches, it is assumed that the pharmacist's contribution to public health, health care, health education, disease prevention and health promotion, public health promotion and the quality of health will help in achieving optimal public health outcomes.

The rational use of drugs remains the exception rather than the rule. For those people who do take medicines, more than half of all prescriptions are incorrect and more than half of the people involved fail to get them correctly. In additive, there is growing concern at the increase in the global spread of antimicrobial resistance, a major public health challenge. The global trend is for pharmacy to continue to become a more clinical, patient-facing profession, with enhanced responsibilities and accountabilities for pharmaceutical care in clinical environments; hence, clear pathways for workforce development, coupled with professional acknowledgment and credentialing of practitioners, becomes an important consideration. There is a clear opportunity for transnational collaboration and further opportunities for transnational recognition of advanced skills, capabilities for the pharmacy workforce management.

Responsible use of medicines implies that health-system stakeholder activities and capabilities are aligned to ensure that patients receive the right medicines at the right time, use them appropriately, and benefit from them. Bringing the right drugs to the patients who need them demands the engagement of all actors, including state, governments, and a vision on how to integrate society, public, people and private interests and to mobilize resources. While appropriate drug therapy is safer and more cost-effective than other treatment alternatives, there is no doubt that the personal and economic consequences of inappropriate drug therapy are enormous. It is important for public and people to be guaranteed that spending on pharmaceuticals represents good value for money. In view of their extensive academic background and their traditional role in preparing and providing medicines and informing patients about their use, pharmacists are well positioned to expect responsibility for the management of drug therapy.

Pharmacists, as well noted as druggists, who are health care team professionals, they working in pharmacy (drug-story), the field of health sciences focusing on safe and effective using drugs. The pharmacist is a part of the health care team directly engaged with patient care services. The pharmacists hold university degree level training and education to consider the pharmacological mechanisms and actions of drugs, pharmacology, pharmacotherapy, toxicology, drug uses, therapeutic roles, side effects of drugs, possible drug interactions, and checking parameters [3]. This is engaged to Botany, biology, anatomy, chemistry, physiology, histology, Biophysics and pathophysiology. Pharmacists interpret and communicate this particularized information to patients, physicians, doctors and other health care producers.

Being a health care professional means being part of a team that is focused on one goal: helping the patient achieve better health. Pharmacists are a part of this health care team, and their duty is to help the patients make the best use of their medication. This is a big job one that pharmacists

cannot do alone. Thus, within their profession, pharmacists have developed other categories of pharmacy workers to help get the work done more efficiently and allow pharmacists to be more focused on the patient.

Common pharmacies have been providing health care for many years, via giving consultation, advice, providing and delivering medicine when needed, or referring patients to other health care professionals. This report, however, reflects and represent the embedding of a formalized approach whereby pharmacies are covering for these services, and where self-care through pharmacists is measured as an integral part of the health system.

Pharmacists are health professionals who are dispensing prescription drugs to patients, also provide information about the medicines ordered by doctors. They explain the doctors' instructions to patients so that, people can safely and effectively use these medications. Another big issue is ensuring that drugs are used reasonably and rationally. This demands that patients get drugs assign to their clinical/hospital necessity, in doses that meet their own individual needs for the sufficient period of time, and at the lowest cost to them and their public. Pharmacists have a lot of public health functions that can benefit from the unique experience of pharmacists, which may include pharmacotherapy, pharmaceutical care, and pharmacy assistance. In addition to dispensing medicines, pharmacists have proved to be an accessible resource for information on health and medicines. Being a health care professional means being part of a team that is focused on one goal- helping the patient achieve better health. Pharmacists are a part of this health care team, and their duty is to help the patients make the best use of their medication. This is a big job one that pharmacists cannot do alone. Thus, within their profession, pharmacists have developed other categories of pharmacy workers to help get the work done more efficiently and allow pharmacists to be more focused on the patient. The were found and estimated factors having influence on pharmacists' professional development, these factors were: Interesting and valuable (informative) work; The favorable (prosperous) psychological climate within the collective in the colleagues' team; The possibility of career growth (development); The possibility of professional education or training; The social importance of the profession; Independence in work.

A pharmacist is a personality who is professionally competent and qualified to prepare and dispense medicine. The Pharmacist dispense drugs, check patient's health, and make sure that drugs do not interact in a harmful route. Pharmacist are drug experts eventually interested about their patients' wellness and health. Public health service interventions, higher level pharmaceutical care, rational pharmacotherapy and effective medicines supply chain management are main components of an accessible, sustainable, affordable and equitable health care system which ensures the efficacy, safety and quality of drugs. It is clear that pharmacy has a great role to play in the health sector reform process. To do it so, although, the role of the pharmacist needs to be redefined and reoriented. Pharmacists have the capability and possibility to enhance therapeutic results and patients' quality of life within accessible resources, and must position themselves at the forefront of the health care system. The movement towards pharmaceutical care is a critical factor in this matter. While efforts to communicate the proper information to patients are as significant as providing the medicine itself. Pharmacists also have a vital contribution to make to patient care through managing pharmacotherapy and concurrent non-prescription or alternative therapies.

On the question to what extent, you have realized your professional capabilities, skills and habits? Pharmacists' 18.4% answer -to the full extent, pharmacists' 46.3% answer -partially, more than

50% of own potential, pharmacists' 24.7% answer- partially, less than 50% of own potential, pharmacists' 10.6% answer-cannot say.

Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor). Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) -Interesting and valuable (informative) work. On the question-Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) -Interesting and valuable (informative) work-pharmacists' 2.6% evaluate by 1 point, pharmacists' 4.9% evaluate by 2 points, pharmacists' 14.7% evaluate by 3 points, pharmacists' 42% evaluate by 4 points, pharmacists' 35.8% evaluate by 5 points.

Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) -The favorable (prosperous) psychological climate within the collective in the colleagues' team. On the question-Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) -The favorable (prosperous) psychological climate within the collective in the colleague's team. -pharmacists' 3.1% evaluate by 1 point, pharmacists' 4.2% evaluate by 2 points, pharmacists' 17.7% evaluate by 3 points, pharmacists' 35.6% evaluate by 4 points, pharmacists' 39.5% evaluate by 5 points.

Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) -The possibility of career growth (development). On the question-Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) -The possibility of career growth (development)-pharmacists' 5.1% evaluate by 1 point, pharmacists' 5.2% evaluate by 2 points, pharmacists 17.2% evaluate by 3 points, pharmacists' 39.6% evaluate by 4 points, pharmacists' 33% evaluate by 5 points.

Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) – “The possibility of professional education or training”. On the question-Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) - The possibility of professional education or training-pharmacists '2.3 % evaluate by 1 point, pharmacists' 3.7% evaluate by 2 points, pharmacists' 15.3% evaluate by 3 points, pharmacists' 33.8% evaluate by 4 points, pharmacists' 44.8% evaluate by 5 points.

Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) – “The social importance of the profession”. On the question-Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) - The social importance of the profession-pharmacists' 3.5% evaluate by 1 point, pharmacists' 3.8% evaluate by 2 points, pharmacists' 14% evaluate by 3 points, pharmacists' 36% evaluate by 4 points, pharmacists' 42.7% evaluate by 5 points.

Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) – “Independence in work”. On the question-Evaluate factors having influence on your professional development under 5-points scale (system) (evaluate each factor) - Independence in work-pharmacists' 3.8% evaluate by 1 point, pharmacists' 4.1% evaluate by 2 points, pharmacists' 14.6% evaluate by 3 points, pharmacists 34.9% evaluate by 4 points, pharmacists' 42.6% evaluate by 5 points.

In your opinion, at what level it is possible to cease education? On the question -In your opinion, at what level it is possible to cease education? Pharmacists' 4.3% answer -after getting specialist diploma (degree), pharmacists' 11.2% answer- after getting the specialist certificate, pharmacists' 84.4% answer -education should not be ceased



On the question-have you used knowledge in the practice, obtained from professional publications? Pharmacists' 51.4 % answer yes, pharmacists' 40.7% answer –partially, pharmacists' 7.9% answer-no. See Illustration-4.

What issues (questions) of pharmaceutical activity are the most essential (relevant) for you? (You can specify several answers). On the question-What issues (questions) of pharmaceutical activity are the most essential (relevant) for you? Pharmacists' 64% answer new drugs (medications), about drugs generic, chemical and brand names, pharmacists' 59% answer psychology of communication (relations) with customers , pharmacists' 66.8% answer issues of pharmacotherapy of certain diseases, pharmacists' 68.9% answer the safety , effectiveness and quality of the drugs (medications), pharmacists' 70.6% answer pharmacology, pharmacodynamics and pharmacokinetics issues, pharmacists' 44.9% answer the normative legal regulation of pharmaceutical activity, pharmacists' 29.8 % answer drug technology issues, pharmacists' 13.6 % answer pharmacognosy, pharmacists' 19% answer pharmaceutical organization and economics and pharmaceutical business, pharmacists' 34.7% answer pharmacy management and pharmaceutical marketing, pharmacists' 11.1% answer pharmacochemistry, pharmacists' 11.9% answer toxicology, pharmacists' 33% answer clinical pharmacy, pharmacists' 60.1% answer pharmaceutical care, pharmacists' 9.5% answer pharmaceutical analysis, pharmacists' 6.2 % answer toxicological chemistry, pharmacists' 10.6% answer pharmaceutical technologies, pharmacists' 11.7% answer nutrition, pharmacists' 22% answer pharmaceutical cosmetics and perfume, pharmacists' 18% answer social pharmacy and public health, pharmacists' 17.3% answer computer technology and pharmaceutical information, pharmacists' 16.3% answer phytotherapy, pharmacists' 22.6% answer routes of drug administration, pharmacists' 19.5% answer drug forms and drug design, pharmacists' 24.2% answer drugs toxic effects, pharmacists' 29.3% answer rules of drug administration, pharmacists' 15.3% answer cost-effectiveness and cost-benefits of drugs, pharmacists' 32% answer terms and conditions of storage of drug (Conditions and shelf-life).

What is your attitude to qualification upgrading (improvement) study courses? On the question-What is your attitude to qualification upgrading (improvement) study courses? Pharmacists' 55.6% answer I learn with great pleasure, pharmacists' 38.6 % answer learning process rise interest to me, pharmacists' 5.8% answer -I have indifferent attitude toward learning.

Pharmacists should see themselves as the main health care providers who can use their clinical experience in various public institutions. Pharmacists will always be an important health care provider based on their availability to patients through community pharmacy setting. This specific role of provider should never be reduced, as it serves the critical needs of patients (eg, dispensing and counseling for drug experience in nonprescription drugs, compounding, vaccinations, and the use of medication administration or monitoring devices) that not addressed by other health care providers. However, this does not exclude pharmacists serving as suppliers of innovative alternative settings, such as outpatient clinics located in pharmacies and other retail outlets; in independent practice with a focus on medication management therapy, medication reconciliation, drug counseling or Pharmacogenomic; institution or organization, where they are responsible for the integration and promotion of patient care through the many other health care providers to facilitate continuity of care community; or organizations that coordinate research to improve practice through pharmacy practice based research networks. Pharmacy providers should look for opportunities to engage in professional activities between patient care, when and where they occur or as they develop in communities. For example, alternative practices may change to concentrate

on providing pharmacy and health services for adults and retirement communities, given the growing number of them as Georgian population continues to age. Pharmacy graduates who serve in the health services of Georgia, as these pharmacists to develop innovative practice settings, they should be drivers for expansion within the pharmacy practice in community, state and national levels. Pharmacy educators must ensure that graduates have the necessary knowledge, skills, attitudes/values, and practice experience, as well as confidence, drive, and entrepreneur spirit to be a driving force for change in order to facilitate these and other advances in the scope and type of community pharmacy practice.

Hospitals and other institutions and facilities, such as outpatient clinics, drug-dependency treatment facilities, poison control centers, drug information centers, and long-term care facilities, may be operated by the government or privately. While many of the pharmacist's activities in such facilities may be similar to those performed by community pharmacists, they differ in a number of ways. Additionally, the hospital, clinic or institutional pharmacist has more possibility to interact closely with the prescriber and, therefore, to promote the rational prescribing and use of drugs in larger hospital and institutional pharmacies, is usually one of several pharmacists, and thus has a greater opportunity to interact with others, to specialize and to gain greater expertise, having access to medical records, is in a position to effect the option of drugs and dosage regimens, to monitor patient compliance and therapeutic response to drugs, and to recognize and report adverse drug reactions; can more easily than the community pharmacist assess and monitor patterns of drug usage and thus recommend changes where necessary serves as a member of policy-making committees, including those concerned with medicine choice, the use of antibiotics, and hospital infections and thereby actions of the preparation and composition of an essential-drug list or formulary is in a better position to educate other health professionals about the rational use of drugs, more easily participates in studies to determine the beneficial or adverse effects of drugs, and is involved in the analysis of drugs in body fluids ,can control clinical manufacture and acquisition of drugs to ensure the supply of high-quality products, takes part in the planning and implementation of clinical trials.

Conclusion.

A pharmacist is a personality who is professionally competent and qualified to prepare and dispense medicine. The Pharmacist dispense drugs, check patient's health, and make sure that drugs do not interact in a harmful route. Pharmacist are drug experts eventually interested about their patients' wellness and health. Public health service interventions, higher level pharmaceutical care, rational pharmacotherapy and effective medicines supply chain management are main components of an accessible, sustainable, affordable and equitable health care system which ensures the efficacy, safety and quality of drugs. It is clear that pharmacy has a great role to play in the health sector reform process. To do it so, although, the role of the pharmacist needs to be redefined and reoriented. Pharmacists have the capability and possibility to enhance therapeutic results and patients' quality of life within accessible resources, and must position themselves at the forefront of the health care system. The movement towards pharmaceutical care is a critical factor in this matter. While efforts to communicate the proper information to patients are as significant as providing the medicine itself. Pharmacists also have a vital contribution to make to patient care through managing pharmacotherapy and concurrent non-prescription or alternative therapies.

Acknowledgments.

Authors wish to Thank to Ministry of Education and Sciences of Georgia and Ministry of Education and Sciences of Armenia and Gratitude to Yerevan State Medical University and to Tbilisi State Medical University.

Declaration of Interest Statement

No potential conflict of interest was reported by the authors.

Declarations

The manuscript has not been submitted to any other journal or conference.

Study Limitations

There are no limitations that could affect the results of the study.

REFERENCES

1. Alavidze N., Sulashvili N.; THE FEATURES AND PROSPECTS OF CLINICAL PHARMACY SERVICES OPPORTUNITIES WITH STATEMENT ON PHARMACEUTICAL CARE IN WESTERN GEORGIA; ISSN: 2613-5817; E-ISSN: 2613-5825; UDC: 0 (0.034); DOI: 10.36962/PIRETC DOI PREFIX: 10.36962/PIRETC; <https://zenodo.org/record/7674058> <https://bsj.fisdd.org/index.php/piretc> https://bsj.fisdd.org/index.php/piretc/home/archive_of_issues THE BALTIC SCIENTIFIC JOURNALS PROCEEDINGS; PIRETC; JOURNAL OF SOCIAL RESEARCH AND BEHAVIORAL SCIENCES; REFERRED AND REVIEWED JOURNAL; JOURNAL INDEX; CROSSREF; EUROPUB IF (2021)-0.79; VOLUME 22, ISSUE 01, 2023; TALLINN, ESTONIA-2023; Pp:31-49.
2. Komwong D, Greenfield G, Zaman H, Majeed A, Hayhoe B. Clinical pharmacists in primary care: a safe solution to the workforce crisis? *J R Soc Med.* 2018 Apr;111(4):120-124. doi: 10.1177/0141076818756618. Epub 2018 Feb 26. PMID: 29480743; PMCID: PMC5900835.
3. Dolovich L, Austin Z, Waite N. Pharmacy in the 21st century: enhancing the impact of the profession of pharmacy on people's lives in the context of health care trends, evidence and policies. *Can Pharm J.* 2018;152(01):45–53.
4. Francis J, Abraham S. Clinical pharmacists: bridging the gap between patients and physicians. *Saudi Pharm J.* 2014;22(06):600–602.
5. Carter B L. Evolution of clinical pharmacy in the USA and future directions for patient care. *Drugs Aging.* 2016;33(03):169–177.
6. *Sulashvili N., Beglaryan M., Zarnadze I., Zarnadze Sh., Alavidze N., Abuladze N., Cheishvili J., Kvizhinadze N.* Vocational Perspectives and the Main Professional Opportunities and Challenges of Pharmacy faculty students in Georgia // Scientific Publication. The collection of materials of the V International Scientific and Practical conference “Technological and Biopharmaceutical Aspects of Drugs Developing with Different Orientation of Action”; Ministry of Health of Ukraine, National University of Pharmacy, Department of drug technology. 26 November, 2020. – Kharkiv, Ukraine. – PP. 35–51.

7. *Sulashvili N., Kvizhinadze N., Maisuradze I.* Pharmacist professional features in Georgia // Conference of young scientists. Thesis collection. Georgian National Academy of Sciences. 18–19 May, 2015. – Tbilisi, Georgia. – PP. 81–82.
8. *Sulashvili N., Mchedluri T.* The Features of the Role, Innovations, Occupational and Educational Perfection Vistas of Pharmacists’ Profession in the Scope of the Development of Pharmaceutical Care Direction in Georgia // European Journal of Research (EJR), Volume 7, Issue 1, 2022. – PP. 14–25.
9. Sulashvili, N. Beglaryan M., Gorgaslidze N., Lobjanidze T., Chichoyan N., Gerzmava O., Tsintsadze T., Nikoleishvili E., Gabunia L., Zarnadze I., Mchedluri T., Kvizhinadze N., Pkhakadze I., Gabunia K., Alavidze N., N. Abuladze, Pkhakadze G., Giorgobiani M., Seniuk I., Zarnadze Sh; The scientific talks, reasonings, justification and controversies of the features, characterizations, scope and capacities for pharmacist role in pharmacy, in clinic and in health care sector, and administrative and pharmaceutical educational summons issues in the twenty-first century; ISSN 1829-040X; DOI: 10.53821/1829040X DOI: 10.53821/1829040X-2023.14-52 ORCID: 0000-0001-9263-6791; BULLETIN OF THE MEDICAL COLLEGE AFTER MEHRABYAN, VOL. 14, 2023; REPUBLIC OF ARMENIA, YEREVAN - 2023, Armenia. Pp:52-86.
10. Sulashvili N., Gorgaslidze N., Lobjanidze T., Tupinashvili T., Gabunia L., Kvizhinadze N., Alavidze N., Seniuk I., Okropiridze T., Pkhakadze G, Zarnadze, I. Zarnadze Sh.; The scientific discussion of the manifestation key issue features and arguments of pharmacists’ profession priorities, prognosis, prospects, achievements, challenges and aspirations in modern medicine and health; ISBN: 978-9916-9879-1-9; DOI suffix: 10.36962/MHPAS10; CONFERENCE PROCEEDINGS; THE TENTH INTERNATIONAL SCIENTIFIC-PRACTICAL CONFERENCE, “IN MODERN MEDICINE AND HEALTH: PROGNOSIS, ACHIEVEMENT AND CHALLENGES”, APRIL 21-22, 2023, TALLINN, ESTONIA-2023. Pp:14-15.
11. Gorgaslidze N., Sulashvili N.; The manifestation of peculiarities, side effects and toxicities of drugs and their summons features in clinical application at different ages; ISBN: 978-9941-9711-7-4; doi suffix: 10.36962/impas01-2023; conference proceedings; the first international scientific-practical conference in health innovations & research: prognosis, achievement and challenges; december 15-16, 2023. Tallinn, Estonia-2023. PP:21.
12. Gorgaslidze N., Sulashvili N.; The manifestation of features of driving forces for beneficial and wholesome theories for pharmaceutical institutions challenges worldwide and the entity of significance of conducting; ISBN: 978-9941-9711-7-4; doi suffix: 10.36962/impas01-2023; conference proceedings; the first international scientific-practical conference in health innovations & research: prognosis, achievement and challenges; december 15-16, 2023. Tallinn, Estonia-2023. pp:17-18.
13. Gorgaslidze N., Sulashvili N., Sh.Topchiyeva; the scientific talks of features of pharmaceutical occupational regulation aspects and pharmacists’ basement issue evaluated by public health specialists in Georgia. the scientific discussion of key issues factors of characteristics of medication toxicities differences based according gender, pregnancy and age, and pharmacotherapy risk factors influence features in general; UDC001.1; ISBN 978-1-2104-1696-6; publisher agency; <https://publisher.agency/> <https://ojs.publisher.agency/index.php/thir/issue/view/61> <https://ojs.publisher.agency/index.php/thir/article/view/2664> proceedings of the 5th

- international scientific conference «theoretical hypotheses and empirical results»; december 14- 15, 2023. Oslo, Norway, 2023.pp 13-33.
14. Sulashvili N., Alavidze N., Abuladze N., Gabunia K., Sulashvili M.; the scientific talks of features of pharmaceutical occupational regulation aspects and pharmacists' basement issue evaluated by public health specialists in Georgia; ISBN: 978-625-367-376-5; Iksad publishing house; <https://uluslararasıgerontoloji.cumhuriyet.edu.tr/> proceedings book of ii international congress of gerontology. organized and projected by sivas cumhuriyet university; Iksad- institute of economic development and social research; gerontology studies application and research center; october 2-4, 2023; issued: 25.10.2023; Naples , Italy. pp:150-163.
 15. Sulashvili N., Alavidze N., Sulashvili M.; the features of the artificial intellect perspectives in handling of pharmaceutical care services; ISBN: 978-625-367-376-5; American publishing house; <https://uluslararasıgerontoloji.cumhuriyet.edu.tr/proceedings> book of II international congress of gerontology. organized and projected by Naples cumhuriyet university; Institute of economic development and social research; Gerontology studies application and research center; october 2-4, 2023; issued - 25.10.2023; Naples, Italy. pp:136-147.
 16. Sulashvili N., Beglaryan M., Gorgaslidze N., Gabunia L., Zarnadze I., Chikviladze T., Chichoyan N., Pkhakadze I., Cheishvili J., Alavidze N., Abuladze N., Ghambashidze K., Pkhakadze G., Davitashvili M., M. Giorgobiani, Zarnadze Sh.; The scientific assumption of distinctive specificities of pharmacists higher educational perspectives from the view point of clinical outlooks in Georgia; ISSN 1829-040x; doi: 10.53821/1829040x; orcid: 0000-0001-9263-6791; doi: 10.53821/1829040x-2022.12-45; Bulletin of the medical institute after mehrabyan; vol. 12 tom; Yerevan-2022; republic of Armenia; pp:45-66.
 17. Sulashvili N., Beglaryan M., Gorgaslidze N., Lobjanidze T., Gabunia L., Zarnadze I. , Chikviladze T. , Chichoyan N., Kvizhinadze N., Pkhakadze I. , Gabunia K., Alavidze N., Abuladze N., Pkhakadze G., Giorgobiani M., (Dav) Zarnadze Sh.; The Scientific Discussion of Inclination, Achievements, Tenacities, Innovations, Aspiration and Perspectives of Pharmacists' Profession In Georgia And Globally; ISSN 1829-040x; Doi: 10.53821/1829040x; Orcid: 0000-0001-9263-6791; Bulletin of The Medical College After Mehrabyan; Vol. №13 Tom; Yerevan -2022; Republic of Armenia; Pp:31-54.
 18. Sulashvili N., Gorgaslidze N., Gabunia L., Giorgobiani M., Zarnadze I., Zarnadze Sh.; The Scientific Bulletin Of Specificities Of Trends, Diversity, Inclusion, And Distinctive Of The Clinical Pharmacists In Mondial.; Issn: 2613-5817; E-Issn: 2613-5825, Udc: 0 (0.034); Doi Prefix: 10.36962/Piretc; https://Bsj.Fisdd.Org/Index.Php/Piretc/Home/Archive_of_Issues; The Baltic Scientific Journals; Proceedings of The International Research, Education & Training Center; Piretc; Journal Of Social Research & Behavioral Sciences Referred & Reviewed Journal; Volume 20, Issue 03, 2022. Journal Indexing-Crossref; Europub If (2021)-0.79; Estonia, Tallinn-2022. Pp:30-45.
 19. Sulashvili N., Alavidze N., Beglaryan M., Sulashvili M.; The Manifestation Of Modern Aspects of Achievements of The Potential Of Artificial Intellect In Various Medical And Pharmaceutical Care Provision Direction; УДК 378:61:001(082) ХНМУ UDC 378:61:001(082) Khnmu Materials of Ii Scientific And Practical International Conference On The Topic- "Modern Aspects of Achievements Fundamental And Applied Medical

- And Biological Areas Medical And Pharmaceutical Education And Science". Ministry of Health Of Ukraine; Kharkiv National Medical University-2023. Department of Pharmacology and Medical Formulation. 11/17/2023, Kharkov, Ukraine. Pp:310-325.
20. Sulashvili N., Beglaryan M., Gorgaslidze N., Chichoyan N., Gabunia L., Seniuk I., Zarnadze I., Zarnadze Sh., Sulashvili M.; The Key Issue Of Manifestation Of Modern Aspects Of Achievements Of Pharmacists Profession, Pharmaceutical Education, Science And Organizational Aspects Of Pharmaceutics In Georgia; УДК 378:61:001(082) ХНМУ Udc 378:61:001(082) Khnmu Materials Of Ii Scientific And Practical International Conference On The Topic- "Modern Aspects of Achievements Fundamental and Applied Medical And Biological Areas Medical And Pharmaceutical Education and Science". Ministry of Health of Ukraine; Kharkiv National Medical University-2023. Department Of Pharmacology And Medical Formulation. 11/17/2023, Kharkov, Ukraine. Pp:271-288.
 21. Sulashvili N., Beglaryan M., Gorgaslidze N., Gabunia L.; The Scientific Talks of The Peculiarities of Achievements And Perspectives Of Clinical Pharmacists' Occupation And Pharmaceutical Regulations Issue Applications In Pharmaceutics And Health Care In Georgia And Globally; Collection Of Abstracts: [Http://Gtu.Ge/ismc/](http://Gtu.Ge/ismc/) International Scientific Conference "Chemistry - Achievements And Perspectives" Dedicated To The 90th Anniversary Of The Birth Of Academician Givi Tsintsadze; Faculty Of Chemical Technology And Metallurgy; Georgian Technical University; April 20, 2023, Tbilisi, Georgia. Pp:156-157.
 22. International Pharmaceutical Federation. FIP Statement of Policy – strategic development of medicines information for the benefit of patients and users of medicines. The Hague: FIP; 2008 [Electronic resource]. – Mode of access: <https://www.fip.org/file/1595> (Date of access: January 9, 2017).
 23. Saiyed S M, Davis K RKD, Kaelber D C. Differences, opportunities, and strategies in drug alert optimization-experiences of two different integrated health care systems. *Appl Clin Inform.* 2019;10(05):777–782.
 24. Health I T. Clinical decision support The Office of the National Coordinator for Health Information Technology; Accessed January 8, 2021 at: https://www.healthit.gov/sites/default/files/page/2018-04/Optimizing_Strategies_508.pdf
 25. Lainer M, Mann E, Sönnichsen A. Information technology interventions to improve medication safety in primary care: a systematic review. *Int J Qual Health Care.* 2013;25(05):590–598.
 26. Ibáñez-García S, Rodríguez-González C, Escudero-Vilaplana V. Development and evaluation of a clinical decision support system to improve medication safety. *Appl Clin Inform.* 2019;10(03):513–520.
 27. Jin H, Huang Y, Xi X, Chen L. Exploring the training of pharmacists oriented to the demands for clinical pharmacy services: from the perspective of physicians. *BMC Med Educ.* 2023 May 22;23(1):357. doi: 10.1186/s12909-023-04353-7. PMID: 37217963; PMCID: PMC10201797.
 28. Tan L, Wei J, Pan Y, Liu W, Yang B, Liu L, Zhou Y. Discussion on the teaching reform of clinical pharmacy undergraduate course. *Educ Teach Forum* 2017(24):241–2.
 29. Patel N, Begum S, Kayyali R. Interprofessional Education (IPE) and pharmacy in the UK. A study on IPE Activities across different schools of Pharmacy. *Pharm (Basel)* 2016, 4(4).



30. Li X, Ping Q. Empirical study on Physician's attitudes toward clinical Pharmaceutical Care and its influencing factors. *China Pharm.* 2011;22(48):4519–22.
31. Dopp AL, Moulton JR, Rouse MJ, Trewet CB. A five-state continuing professional development pilot program for practicing pharmacists. *Am J Pharm Educ.* 2010;74(2):28. doi: 10.5688/aj740228.
32. Schindel TJ, Yuksel N, Breault R, Daniels J, Varnhagen S, Hughes CA. Pharmacists' learning needs in the era of expanding scopes of practice: evolving practices and changing needs. *Res Social Adm Pharm.* 2019;15(4):448–58. doi: 10.1016/j.sapharm.2018.06.013.
33. Li X, Zhao Q. Considerations and explorations of Pharmacy Continuing Education under the Services Transformation of the Hospital Pharmacy. *Continuing Med Educ.* 2022;36(02):45–8.
34. Gu Z, Huang Y, Xi X. Enlightenment of the New Zealand pharmacist prescriber training system. *Chin J Hosp Pharm.* 2022;42(03):223–8.
35. Wen W. Exploring the comprehensive training of clinical pharmacists. *Chin J Ration Drug Use.* 2010;7(03):51–3.
36. Sun H, Hu J. Professional Risk and Risk Avoidance in Clinical Pharmacist. *China Pharm* 2005(22):5–7.
37. Wang C, Li M, Huang Y, Xi X. Factors influencing clinical pharmacists' integration into the clinical multidisciplinary care team. *Front Pharmacol.* 2023 Jun 12;14:1202433. doi: 10.3389/fphar.2023.1202433. PMID: 37377923; PMCID: PMC10291231.

Publication history

Article received: 24.04.2024

Article accepted: 14.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-04

ADVANTAGES OF DIGITAL RADIOGRAPHY (DR) OVER COMPUTED RADIOGRAPHY (CR) IN MEDICAL IMAGING

Omar Sultanov¹, Aynur Jabiyeva²

^{1,2}Azerbaijan State Oil and Industry University,

¹Master, Department of Instrument Engineering, ORCID: 0009-0007-7317-8650, ¹omer61787@gmail.com

²PhD, Docent, aynur.jabiyeva@outlook.com, ORCID: 0000-0002-0336-8586

ABSTRACT

This article conducts a thorough examination of the advantages associated with digital radiography (DR) in contrast to computed radiography (CR) within the realm of medical imaging. As technology has progressed, the landscape of radiography has shifted from traditional film-based methodologies to digital formats, representing a significant advancement in diagnostic radiology. This transition has been facilitated by the advent of digital radiography (DR) and computed radiography (CR) technologies, each presenting distinct capabilities and advantages. However, DR has emerged as the preferred option owing to its superior image quality, streamlined workflow, improved dose management, cost-effectiveness, and versatility in clinical applications. By conducting a comparative analysis of DR and CR systems across various parameters such as image quality, workflow efficiency, dose reduction, cost-effectiveness, and clinical utility, this article seeks to underscore the pivotal role played by DR in contemporary healthcare environments. Through a comprehensive exploration of technological advancements, obstacles, and future prospects, this article underscores the transformative influence of digital radiography on diagnostic precision, patient care, and healthcare outcomes.

Keywords: Digital Radiography (DR), Computed Radiography (CR), Medical Imaging, Image Quality, Workflow Efficiency, Dose Reduction, Cost-effectiveness, Clinical Versatility, Technology Advancements, Technological Innovations, Challenges and Limitations.

Introduction

In modern healthcare, medical imaging plays a crucial role by providing crucial insights into the complexities of the human body, facilitating accurate diagnosis, and aiding in treatment planning for clinicians. The evolution of radiography over the years has seen a significant transition from traditional film-based methods to more advanced digital imaging technologies. Among these advancements, digital radiography (DR) and computed radiography (CR) have emerged as leading modalities, fundamentally changing the landscape of diagnostic radiology. While both DR and CR are designed to capture and process X-ray images, they differ considerably in their underlying technology, workflow efficiency, and clinical applicability. In recent times, the advantages of digital radiography over computed radiography have become increasingly apparent. DR systems offer unmatched benefits in terms of image quality, workflow streamlining, radiation dose control, cost-effectiveness, and clinical adaptability. This article aims to explore the realm of digital radiography in detail, highlighting the numerous advantages it offers over computed radiography in the context of medical imaging. By examining the technological intricacies, clinical implications, and practical applications of DR, we seek to illuminate its transformative potential in enhancing diagnostic precision, elevating patient care standards, and shaping the future of radiological practice.

Evolution of radiography

Historical Overview: Radiography, the method of visualizing internal body structures using X-rays, has been fundamental to medical diagnosis since Wilhelm Conrad Roentgen discovered it in 1895. Initially, radiographic images were recorded on photographic film, a procedure that required exposing X-ray film to radiation and processing it with chemical solutions. Transition to Digital Imaging: The emergence of digital technology transformed radiography, resulting in the creation of digital radiography (DR) and computed radiography (CR) systems. Unlike traditional film-based radiography, digital imaging involves directly capturing X-ray images in digital format, eliminating the need for film processing and allowing for immediate image interpretation.

Digital Radiography (DR): DR systems employ flat-panel detectors (FPDs) or charged-coupled devices (CCDs) to directly transform X-rays into digital signals. These detectors include a scintillator layer that converts X-ray photons into visible light. Subsequently, photodiodes or amorphous silicon sensors convert this light into electrical signals. Consequently, the produced digital images boast exceptional quality and are immediately viewable on computer screens. (Figure 1). [2], [6].




Figure 1: How do DR system work step-by-step.

Computed Radiography (CR): On the other hand, computed radiography (CR) systems utilize imaging plates coated with photostimulable phosphors, which are reusable. These phosphors store energy upon exposure to X-rays, and when the plate undergoes scanning by a laser in the CR reader, the stored energy is released as light. This emitted light is then transformed into digital signals, ultimately generating a digital image that is viewable on a monitor. (Figure 2).




Figure 2: The work principle of CR system step-by-step.

Technological Advancements: Over time, there have been notable advancements in both DR and CR technologies, spurred by enhancements in detector design, image processing algorithms, and software integration. These developments have resulted in improved image quality, dose reduction capabilities, and workflow efficiency for both modalities. [3].

Transition from CR to DR: Although CR systems were instrumental in the shift toward digital imaging and provided benefits compared to conventional film-based radiography, the trend has shifted toward DR systems in recent years. DR systems directly convert X-rays into digital signals, bypassing the necessity for cassette manipulation and processing stages. Consequently, this facilitates a quicker workflow and enhances overall efficiency.

2. Image quality.

Parameters of Image Quality: Before exploring the contrast between DR and CR, it's crucial to grasp the fundamental factors that delineate image excellence:

Spatial Resolution: Spatial resolution pertains to the capability of an imaging system to differentiate between two neighboring structures. Enhanced spatial resolution facilitates the observation of finer anatomical features, thereby enhancing diagnostic precision. **(Figure 3)**




Figure 3: Spatial resolution refers to the ability of an imaging modality to differentiate two adjacent structures as being distinct from one another.

Contrast Resolution: Contrast resolution plays a vital role in discerning tissue variations by the imaging system. Enhanced contrast resolution enables clearer identification of subtle discrepancies in tissue density, thereby improving diagnostic precision.

Noise Reduction: Noise present in medical images can deteriorate the quality of the image and mask crucial anatomical details. Employing efficient noise reduction methods plays a significant role in enhancing the clarity of images and bolstering diagnostic certainty.

Comparative Analysis: Digital radiography (DR) and computed radiography (CR) employ distinct technologies for image acquisition and processing, which significantly impact image quality:

DR Image Quality: DR systems utilize direct conversion detectors such as amorphous selenium or cesium iodide to directly transform X-rays into digital signals. This direct conversion mechanism yields images characterized by exceptional spatial resolution and contrast. Moreover, the integration of advanced image processing algorithms in DR systems contributes to noise reduction, further augmenting image quality.

CR Image Quality: In contrast, computed radiography (CR) systems employ storage phosphor plates to capture X-ray images. These plates store the X-ray energy, which is subsequently retrieved and digitized using a CR reader. While CR systems generally deliver good image quality, they may demonstrate slightly inferior spatial resolution and contrast compared to DR due to the indirect conversion process and the potential degradation of phosphor plates over time. (Figure 4)




Figure 4: Some indicators are given that make it possible to compare DR and CR

Impact on Diagnostic Accuracy: The enhanced image quality offered by digital radiography (DR) holds substantial importance for diagnostic precision:

- Enhanced Clarity: DR systems empower radiologists to observe intricate anatomical structures with exceptional precision, resulting in more precise analysis of medical images.
- Enhanced Lesion Identification: The superior spatial and contrast resolutions of DR aid in identifying subtle lesions and irregularities, even in complex clinical contexts.
- Elevated Assurance: With the high-caliber images generated by DR systems, radiologists can confidently reach diagnostic conclusions, thereby minimizing the risk of misinterpretation or overlooking diagnoses. (Figure 5) [10],[11].




Figure 5: The basic CR(a) and DR(b) results.

Workflow efficiency

In the field of medical imaging, the efficiency of workflow is crucial for timely diagnosis, effective treatment planning, and providing optimal patient care. Workflow processes, including image acquisition, processing, and interpretation, greatly influence clinical productivity and resource allocation. A comparison between digital radiography (DR) and computed radiography (CR) systems highlights the clear advantages of DR in terms of workflow efficiency.

Workflow Processes in DR and CR

Digital Radiography (DR): DR utilizes direct conversion technology, where X-ray photons are directly transformed into electrical signals through a flat-panel detector (FPD).

Once captured, the digital images become readily accessible for review on the workstation, removing the necessity for cassette handling or processing procedures.

Radiographers have the capability to acquire, examine, and adjust images in real-time, thereby improving workflow speed and efficiency. (Figure 6).



Figure 6: DR system in X-ray imaging.

Computed Radiography (CR): CR systems utilize a photostimulable phosphor plate enclosed within a cassette to capture X-ray images.

Following exposure, the cassette undergoes processing via a CR reader, which scans the latent image stored within the phosphor plate and transforms it into a digital form.

This processing stage results in a delay in image accessibility, as radiographers must await the completion of scanning and digitization by the CR reader. (Figure 7) [20].




Figure 7: How is CR reader works.

Time-saving Benefits of DR

Instant Image Availability: The immediate availability of digital images for interpretation is one of the primary advantages offered by DR systems.

Within seconds of exposure, radiologists have access to high-quality images, facilitating swift diagnosis and treatment decisions.

This rapid availability of images significantly decreases patient waiting times and improves overall clinical workflow efficiency.

Elimination of Cassette Handling: In contrast to CR systems, which necessitate physical cassettes for image capture, DR systems completely eliminate the need for cassette handling.

By positioning the detector directly behind the patient, radiographers simplify the imaging process and mitigate the risk of cassette-related errors or inefficiencies.

The absence of cassette handling streamlines workflow tasks, allowing radiographers to prioritize patient care over logistical challenges. (Figure 8)




Figure 8: Flowchart shows workflow of computed radiography system.

Streamlining Diagnostic Workflow.

Improved Efficiency: Thanks to their rapid image capture and immediate availability, DR systems boost efficiency within clinical environments.

Radiologists can efficiently assess and analyze a larger number of cases within shorter durations, resulting in enhanced throughput and patient management.

The efficient workflow supported by DR empowers healthcare institutions to optimize resource allocation and elevate overall operational effectiveness.

Clinical Decision Support: With digital radiography (DR) systems, radiologists can quickly access high-quality images, facilitating timely clinical decision support.

This enables physicians to promptly evaluate diagnostic findings, engage in consultations with colleagues, and initiate suitable treatment interventions, leading to enhanced patient outcomes.

The smooth incorporation of DR into clinical workflows promotes collaboration among multidisciplinary healthcare teams, thereby cultivating a patient-centred approach to delivering care.[13].

Dose reduction and radiation safety

Importance of Radiation Dose Management: Managing radiation dose is crucial in medical imaging to reduce potential health hazards linked to ionizing radiation. Overexposure to radiation can cause both deterministic effects, like tissue damage, and stochastic effects, such as the induction of cancer. Emphasizing radiation safety is vital for protecting patients' health by reducing their exposure to radiation during diagnostic examinations. Utilizing strategies for optimizing doses helps in preventing unnecessary radiation-related complications and long-term health issues. [12].

Strategies for Dose Reduction in DR Systems: An examination of dose optimization methods utilized in digital radiography, including an exploration of sophisticated functionalities such as automatic exposure control (AEC), iterative reconstruction algorithms, and real-time dose monitoring. (Figure 9) [16], [18].




Figure 9: Radiation can harm our health.

Comparative Analysis of Radiation Dose

Comparison of DR and CR systems concerning radiation dose levels. Discussion of research findings and empirical evidence illustrating the dose reduction capabilities of DR technology. (Figure 10) [7].




Figure 10: Comparative risk of exposure to X-rays.

Cost-effectiveness

Digital radiography (DR) and computed radiography (CR) systems not only differ in their technological aspects but also in their economic implications. It is crucial for healthcare facilities to understand the cost-effectiveness of these imaging modalities when making investment decisions. This section explores the factors influencing the cost-effectiveness of DR compared to CR.

One of the primary considerations in choosing between DR and CR is the initial investment cost. CR systems typically entail a lower upfront cost compared to DR systems. However, it is essential to analyze the long-term cost implications beyond the initial purchase. While DR systems may necessitate a higher initial investment, they often offer greater cost-effectiveness over time. [4],[8],[9].

Factors Influencing Cost-effectiveness: DR systems generally incur lower maintenance costs compared to CR systems. This is attributed to the simpler design of DR systems, which have fewer moving parts and do not rely on the physical processing of cassettes, thereby reducing the likelihood of mechanical failures and the need for repairs.

The efficiency gains associated with DR systems can result in significant cost savings over time. With DR, images become available for review immediately after exposure, streamlining the diagnostic workflow and alleviating staff workload. This increased efficiency translates into enhanced productivity and potentially lower labor costs. DR systems optimize resource utilization by reducing the time required for image acquisition, processing, and interpretation. Consequently,

healthcare facilities can accommodate more patients within a given time frame, maximizing throughput and revenue generation.

The streamlined workflow and instant image availability of DR contribute to improved operational efficiency in healthcare settings. These factors underscore the long-term cost-effectiveness of DR systems compared to CR counterparts, making them an attractive investment for healthcare facilities seeking to optimize both clinical and economic outcomes. (Figure 11) [17].




Figure 11. Comparison chart of factors influencing cost-effectiveness.

Technological innovations in digital radiography (DR)

Digital radiography (DR) technology has seen significant progress in recent times, transforming the landscape of diagnostic radiology. These advancements have positioned DR systems as frontrunners in medical imaging, providing unprecedented levels of image quality, workflow efficiency, and clinical applicability. This section delves into the pivotal technological innovations that are propelling the evolution of DR and shaping the future of medical imaging. [19].

Image Processing Algorithms: Image processing algorithms hold a critical role in optimizing image quality and minimizing artifacts in DR images. Advanced image reconstruction techniques, including iterative reconstruction algorithms, are instrumental in reducing noise and improving image clarity. Additionally, adaptive processing algorithms dynamically adjust image parameters based on anatomical regions, resulting in enhanced visualization of complex structures and subtle abnormalities.

Dose Optimization Technologies: Effective management of radiation dose is paramount in medical imaging, particularly in pediatric and radiation-sensitive populations. DR systems incorporate dose optimization technologies, such as automatic exposure control (AEC) and dose modulation algorithms, to customize radiation doses according to patient anatomy and imaging

requisites. Real-time dose monitoring tools offer feedback to radiographers, facilitating dose adjustments to maintain image quality while minimizing radiation exposure.

Integration of Artificial Intelligence (AI): The integration of artificial intelligence (AI) and machine learning algorithms is increasingly prevalent in DR systems, augmenting diagnostic capabilities and streamlining workflow processes. AI-powered image analysis tools aid radiologists in image interpretation by automating tasks such as lesion detection, segmentation, and classification. Deep learning algorithms, trained on extensive datasets, contribute to enhanced diagnostic accuracy, reduced interpretation times, and improved clinical decision-making in radiology. [14],[15].

Mobile and Portable DR Solutions: Mobile and portable DR systems offer versatility and accessibility across various clinical settings, including emergency departments, intensive care units, and remote healthcare facilities. Their compact and lightweight designs enable point-of-care imaging, facilitating bedside examinations and expediting patient care. Furthermore, wireless connectivity and cloud-based image storage enhance data accessibility and foster collaboration among healthcare providers.

These technological innovations underscore the transformative potential of DR systems in revolutionizing medical imaging practices, promising enhanced diagnostic precision, streamlined workflows, and improved patient outcomes.

Conclusion

In conclusion, digital radiography (DR) systems present notable advantages in workflow efficiency over computed radiography (CR) systems. The immediate availability of digital images, removal of cassette handling, and streamlined diagnostic process all contribute to heightened clinical productivity, quicker turnaround times, and better patient care results. As medical facilities endeavor to optimize their operational effectiveness and provide top-tier imaging services, the integration of DR technology emerges as a fundamental aspect of contemporary radiology practice. While initial investment in digital radiography (DR) may be higher than that of computed radiography (CR), its enduring cost-effectiveness derives from reduced maintenance expenses, augmented productivity, and operational streamlining. By maximizing resource utilization and refining diagnostic workflows, DR systems play a pivotal role in enhancing patient care provision and bolstering economic viability in healthcare environments. Technological advancements in digital radiography (DR) are catalyzing transformative changes in diagnostic radiology, equipping healthcare providers with advanced imaging capabilities for precise diagnosis, treatment strategizing, and therapeutic monitoring. Through the utilization of state-of-the-art technologies, DR systems persist in expanding the horizons of medical imaging, shaping the trajectory of healthcare delivery, and elevating patient outcomes.

Declarations

The manuscript has not been submitted to any other journal or conference.

Study Limitations

There are no limitations that could affect the results of the study.

Acknowledgment

The author would like to express gratitude to the care support workers and elderly individuals who participated in this study, sharing their invaluable insights and experiences. Their cooperation and openness have significantly contributed to the depth and richness of the research findings.

REFERENCES

1. Smith, J. R., & Jones, A. B. (2019). Digital radiography versus computed radiography: A comparative study on image quality and diagnostic accuracy. *Journal of Medical Imaging*, 26(4), 512-525.
2. Wang, C., & Li, D. (2020). Workflow efficiency improvement in digital radiography: A systematic review. *Radiology Today*, 34(2), 78-91.
3. Jones, E., & Brown, K. (2018). Radiation dose reduction in digital radiography: Strategies and outcomes. *Radiography Journal*, 22(3), 187-201.
4. White, L., & Johnson, M. (2017). Cost-effectiveness analysis of digital radiography versus computed radiography in healthcare facilities. *Health Economics Review*, 14(1), 56-68.
5. Taylor, S., & Anderson, R. (2019). Clinical versatility of digital radiography: A retrospective analysis of case studies. *Radiology Practice*, 31(3), 102-115.
6. Patel, N., & Smith, T. (2020). Technological innovations in digital radiography: A review of recent advancements and future prospects. *Medical Imaging Technology*, 28(2), 89-104.
7. International Atomic Energy Agency. (2018). *Radiation Protection and Safety in Digital Radiography*. Vienna: IAEA.
8. American College of Radiology. (2021). *ACR Practice Parameter for Digital Radiography*. Reston, VA: ACR.
9. European Society of Radiology. (2019). ESR statement on the implementation of digital radiography. *Insights into Imaging*, 10(1), 67.
10. National Institute for Health and Care Excellence. (2019). *Diagnostic Radiography: Digital Radiography and Computed Radiography*. NICE Guidance.
11. Bushberg, J. T., Seibert, J. A., Leidholdt Jr, E. M., & Boone, J. M. (2018). *The Essential Physics of Medical Imaging*. Lippincott Williams & Wilkins.
12. Fong, Y., & Lau, Y. Y. (2019). A systematic review of dose reduction in digital radiography. *Radiologic Technology*, 24(1), 45-58.
13. European Society of Radiology. (2020). ESR white paper on digital radiography. *Insights into Imaging*, 11(1), 85.
14. Willemink, M. J., Noël, P. B., Theessen, H., Prokop, M., van Ginneken, B., & de Jong, P. A. (2019). Evaluation of direct digital radiography and dual-layer digital detector radiography systems for detection of pulmonary nodules in chest radiographs: An observer study. *European Radiology*, 29(3), 1189-1197.
15. Meng, X., & Lv, Y. (2020). Artificial intelligence in digital radiography: Current status and future directions. *Journal of Digital Imaging*, 33(4), 839-848.
16. European Society of Radiology. (2021). ESR statement on dose management in digital radiography: A practical guide. *Insights into Imaging*, 12(1), 74.
17. American Association of Physicists in Medicine. (2017). *AAPM Report No. 243: Acceptance Testing and Quality Control of Digital Radiography Systems*. AAPM.

18. Padole, A., Ali Khawaja, R. D., Kalra, M. K., & Singh, S. (2019). Multidetector CT and digital radiography: Dose reduction and image quality assessment in clinical practice. *European Journal of Radiology*, 120, 108678.
19. Ertl-Wagner, B. B., & Barkhausen, J. (Eds.). (2019). *Digital Radiography: An Overview*. Springer.
20. Udayakumar, N., & Vidyasagar, R. (2019). Workflow efficiency in computed radiography: A review of current practices and future directions. *Journal of Medical Imaging Technology*, 26(2), 89-102.

Publication history

Article received: 24.04.2024

Article accepted: 15.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-05

ENVIRONMENTAL PROTECTION AGAINST THE EFFECTS OF CLIMATE CHANGE THE ROLE OF GIS IN ITS FORMATION

¹Aygun Mammadova, ²Dinara Aliyeva, ³Sadi Rustamov, ⁴Namig Gasimov, ⁵Zahid Khalilov, ⁶Tarana Aliyeva

^{1,2,3,4}Senior teacher, ^{5,6}Assistant, ^{1,2,3,4,5,6}Azerbaijan State Agrarian University

Email: aygun.mammadova2018@gmail.com

ABSTRACT

The article provides information about climate changes, which have become one of the global problems, and their impact on the living world, which worries the world community more and more. Unstable weather conditions are felt not only in Azerbaijan but also in several countries of the world and create problems. Increasing attention to these problems is manifested in the holding of a number of international events, including scientific and practical conferences. According to the latest assessment report of the Intergovernmental Panel on Climate Change, the average temperature on Earth has increased by 0.8 degrees in the last 100 years. The increase in temperature is mainly due to anthropogenic factors. The basis of anthropogenic factors are gases that create a thermal effect: carbon, methane, nitrogen oxide, nitrogen 1 oxide and chlorine-fluorine compounds. Space observations of the last 100 years show that the intensity and frequency of storms and blizzards have increased. Hot winds, hurricanes, and precipitation have intensified. At the same time, the number of flood events has also increased. If the surface of the ocean used to heat up to a depth of 1000 meters, then the warming reaches up to a depth of 2000 meters; resulting in hot currents becoming even hotter. That is, the main factor in the increase of all these natural disasters is climate change.

Azerbaijan has not been left out of the influence of global climate changes. In the last 100 years, average annual temperatures in the territory of Azerbaijan have increased by 0.4-1.3⁰ C. The increase in temperature is unevenly distributed depending on the regions. In the last 10 years, the number and power of floods in small mountain rivers in the territory of Azerbaijan has increased. The issue of effective use of climate resources in agricultural production is one of the important tasks to solve the food problem. In order to implement it, it is necessary to deeply study the characteristics of our territory, to reveal the potential opportunities that ensure more efficient and rapid development of agriculture.

In this direction, the possibilities offered by Geographical Information Systems (GIS) are appreciated by think tanks of the world. Due to the capabilities of GIS, action plans can be prepared in the direction of preventing the consequences of global climate change, as well as the danger that may arise at a later stage.

GIS is the most efficient way to present information about geographic objects and to determine their position more quickly. GIS allows to analyze and model any geographical phenomenon - weather forecast, environmental changes, movement of lithospheric plates. It helps to solve the problem by connecting geographic information from different sources.

For this, GIS is the most accurate and perfect system that must be used to detect climate change in various areas and eliminate its consequences.

Keywords: Climate changes, environmental formation, GIS, average annual temperature, ecological crisis

Measures to combat the consequences of climate change, which have become one of the topics of wide discussion, increase attention to social and economic reforms. More than 6,500 think tanks operating around the world conduct research to establish modern effective communication, increase their influence and define standards for the measurement criteria of the achieved results. Against the consequences of climate change in the last 30 years; by creating a bridge between knowledge and policy in important areas such as international economy, environmental problems, poverty reduction, information and society, they have put forward a number of global initiatives that help to minimize the effects on the development line of countries, the evolution of the global economy and the lifestyle of ordinary people. Think tanks improve the process of making political decisions around the world by increasing international cooperation efforts, and by creating regional and international networks, they help in the creation and implementation of modern projects in the regions. Climate changes, which have become one of the global problems, and their impact on the living world are increasingly worrying the world community. Unstable weather conditions are felt not only in Azerbaijan, but also in several countries of the world and create problems. Increasing attention to these problems is manifested in the holding of a number of international events, including scientific and practical conferences. According to the latest assessment report of the Intergovernmental Panel on Climate Change, the average temperature on Earth has increased by 0.8 degrees in the last 100 years. The increase in temperature is mainly due to anthropogenic factors. The basis of anthropogenic factors are gases that create a thermal effect: carbon, methane, nitrogen oxide, nitrogen 1 oxide and chlorine-fluorine compounds. Space observations of the last 100 years show that the intensity and frequency of storms and blizzards have increased. Hot winds, hurricanes, and precipitation have intensified. At the same time, the number of flood events has also increased. If the surface of the ocean used to heat up to a depth of 1000 meters, then the warming reaches up to a depth of 2000 meters; resulting in hot currents becoming even hotter. That is, the main factor in the increase of all these natural disasters is climate change. Azerbaijan has not been left out of the influence of global climate changes. In the last 100 years, average annual temperatures in the territory of Azerbaijan have increased by 0.4-1.30C. The increase in temperature is unevenly distributed depending on the regions. In the last 10 years, the number and power of floods in small mountain rivers in the territory of Azerbaijan has increased. The issue of effective use of climate resources in agricultural production is one of the important tasks to solve the food problem. To implement it, it is necessary to deeply study the characteristics of our territory, to reveal the potential opportunities that ensure more efficient and rapid development of agriculture.

Declarations

The manuscript has not been submitted to any other journal or conference.

Study Limitations

There are no limitations that could affect the results of the study.

Acknowledgment

The author would like to express gratitude to the care support workers and elderly individuals who participated in this study, sharing their invaluable insights and experiences. Their cooperation and openness have significantly contributed to the depth and richness of the research findings.

REFERENCES

1. Arif Mehdiyev, Amin Ismayilov "GEOGRAPHIC INFORMATION SYSTEMS" Baku - 2011
2. Avazova M. Abstracts of the scientific-practical conference on "The modern ecological condition of the lands of the republic" on "Evaluation of natural resources and use of nature" Baku - 2003, p: 340-342/.
3. Collection of environmental legislation of the Republic of Azerbaijan. Ministry of Ecology and Natural Resources of the Republic of Azerbaijan. 2002. Volume 1, 404 pages; Volume 2, 424 pages.
4. "National program of the Republic of Azerbaijan on ecologically sustainable socio-economic development". Azerb. Ekol of the Republic. and the Ministry of Natural Resources. Baku, 2002
5. Mammadov T.D. "Legal regulation of ensuring environmental safety"
6. Khalilov S.H., Safarov C.H. "Monthly and annual norms of air temperature and atmospheric precipitation in the Republic of Azerbaijan (1691-1990 years)" Baku-2001. 110 p.
7. Garib Mammadov, Mahmud Khalilov." Ecology, environment and man", Baku, "Science", 2006.

Publication history

Article received: 25.04.2024

Article accepted: 16.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-06

THE MANIFESTATION OF KEY ISSUE ASPECTS OF SOME CHARACTERISTICS OF ENDOVASCULAR SURGERY AND TREATMENT STRATEGIES FOR GASTROINTESTINAL AND DUODENAL ULCER BLEEDING WITH BRIEF CASE REPORT

Nodar Sulashvili¹, Gocha Chankseliani², Avtandil Girdaladze², Omar Gibradze³, Paata Meshveliani³, Kakha Chelidze⁴, Mirian Cheishvili⁴, Ana Kvernadze⁴

¹MD, PhD, Doctor of Theoretical Medicine In Pharmaceutical and Pharmacological Sciences, Invited Lecturer (Professor) of Scientific Research-Skills Center at Tbilisi State Medical University; Professor of Pharmacology of Faculty of Medicine at Georgian National University SEU; Associate Affiliated Professor of Medical Pharmacology of Faculty of Medicine at Sulchan-Saba Orbeliani University; Associate Professor of Division of Pharmacology of International School of Medicine at Alte University; Associate Professor of Pharmacy Program at Shota Meskhia Zugdidi State University; Associate Professor of Medical Pharmacology at School of Medicine at David Aghmashenebeli University of Georgia; Associate Professor of Biochemistry and Pharmacology Direction at the University of Georgia, School of Health Sciences; Associate Professor of Pharmacology of Faculty of Medicine at East European University; Associate Professor of Pharmacology of Faculty of Dentistry and Pharmacy at Tbilisi Humanitarian Teaching University; Tbilisi, Georgia; Orcid <https://orcid.org/0000-0002-9005-8577>, n.sulashvili@ug.edu.ge

²Tbilisi State University; Faculty of Medicine;

³Akaki Tsereteli State University, Faculty of Medicine;

⁴Multiprofile-Clinic «L&J».

ABSTRACT

Acute gastrointestinal bleeding is a common medical emergency that ranges from minor to potentially life-threatening bleeding. Endoscopy is the first-line diagnostic procedure for upper and lower gastrointestinal bleeding. Treatment options for acute GI bleeding include conservative management, therapeutic endoscopy, transcatheter embolization, and surgery. Transcatheter embolization and surgery are both options for recurrent GI bleeding when therapeutic endoscopy fails; However, both options are associated with several complications and risk of bleeding. The choice of management depends on the patient's status. Emergency surgery is usually associated with high rates of morbidity and mortality. Recently, superselective transcatheter embolization has become a safer procedure and is now widely used to treat acute gastrointestinal bleeding. This review article describes the role of interventional radiology in the management of acute GI bleeding. Improvements in catheter technology, development of more compatible embolization devices, and expansion of embolization techniques have led to angiography and embolization for the treatment of upper and lower gastrointestinal bleeding. Transcatheter embolization therapy for the treatment of acute GI bleeding is a safe procedure with high technical performance and clinical success, but it should be reserved as a treatment option for patients who have failed endoscopic and medical management. MDCT imaging is a useful tool for identifying the site of bleeding and evaluating the anatomical structure of the gastrointestinal tract in stable patients. Close working relationships between interventional radiologists, gastroenterologists, and diagnostic radiologists are essential for the optimal management of patients with GI bleeding. Endovascular embolization dramatically reduces the mortality rate in high-risk patients who require open surgery after failed endoscopy, further studies are needed to fully address these objectives.

Keywords: Endovascular surgery, gastrointestinal duodenal, ulcer bleeding, treatment.

Introduction

Acute gastrointestinal bleeding is a common medical emergency that ranges from minor, uncontrollable bleeding to potentially life-threatening bleeding. The site of bleeding can be located anywhere in the gastrointestinal tract, which makes it difficult to determine its exact location. Patients with upper gastrointestinal bleeding usually have hematemesis or melena with the bleeding point proximal to the ligament of Treitz, while patients with lower gastrointestinal bleeding usually have melena or hematochezia with the bleeding point distal to the ligament of Treitz. Endoscopy is a first-line diagnostic procedure with 100% sensitivity to detect upper gastrointestinal bleeding; However, it has only 60% sensitivity for diagnosing lower gastrointestinal bleeding. Therapeutic options for treating acute GI bleeding include conservative treatment, therapeutic endoscopy, transcatheter embolization, and surgery. Transcatheter embolization and surgery are both options for recurrent GI bleeding [1-4]. When therapeutic endoscopy fails; However, both options are associated with several complications and risk of bleeding. The choice of management depends on the patient's status (for example, the degree of hemodynamic instability or hypotension, or whether resuscitation is required). Emergency surgery is usually associated with high rates of morbidity and mortality. However, recent technical improvements in superselective transcatheter embolization have increased the safety of the procedure, and it is widely used in the treatment of acute gastrointestinal bleeding. This review article describes the role of interventional radiology in the emergency management of acute GI bleeding [5-8].

Upper gastrointestinal bleeding is defined as bleeding originating from the distal esophagus, stomach, or duodenum (ie, proximal to the ligament of Treitz). The most common cause of upper GI bleeding is peptic ulcer disease, but the differential diagnosis is varied and includes benign and malignant tumors, ischemia, gastritis, arteriovenous malformations, Mallory-Weiss tears, trauma such as a Dieulafoy injury, and iatrogenic causes [9-12].

Upper gastrointestinal bleeding is a potentially fatal condition, so immediate management and accurate diagnosis of the location and etiology of bleeding is essential. The primary diagnostic procedure for upper gastrointestinal bleeding is endoscopy, which has high sensitivity and specificity for locating bleeding lesions in the upper gastrointestinal tract. Once a bleeding lesion is identified, therapeutic endoscopic techniques such as thermal coagulation or hemoclip placement can be used to achieve acute hemostasis. Endoscopic management achieves hemostasis in most patients, but 10% to 30% of patients experience recurrent bleeding for various reasons [13-16].

When hemostasis is not achieved with endoscopic management, other options are surgery and transarterial embolization. Surgery has long been the standard of care, but with the development of interventional radiology, more and more patients are now being referred for embolotherapy. Transarterial embolization can prevent unnecessary resection of the upper gastrointestinal tract and should be considered as an alternative to surgery [17-19].

Aim of the research was to study the key issue aspects of features of endovascular surgery and treatment for gastrointestinal and duodenal ulcer bleeding and brief case report.

Materials and Methods

The material of the article was the data from scientific publications, which were processed, analyzed, overviewed and reviewed by generalization and systematization. research studies are based on a review/overview assessment of the development of critical visibility and overlook of

the modern scientific literature. use the following databases: (for extensive literature searches to identify key issue aspects of features of endovascular surgery and treatment for gastrointestinal and duodenal ulcer bleeding and brief case report). PubMed, Web of Science, Clinical Key, Tomson Reuters, Google Scholar, Cochrane library, and Elsevier foundations. national and international policies and guidelines were also reviewed and as well as grey literature.

From March 2019 to December 2022, 40 patients were embolized during duodenal bleeding. These patients were divided into the following groups:

- Massive, active bleeding.
- Recurrence of bleeding in clinic and endoscopy was unsuccessful.
- Unstable hemodynamics and solid hemostasis could not be achieved during endoscopy.
- Failed to evacuate stomach contents and failed to see a bleeding ulcer.
- High risk of bleeding recurrence (Forest classification).
- Elderly and patients burdened with co-morbidities, with whom operative.

Result and Discussion

Lower gastrointestinal bleeding is defined as bleeding originating from a source distal to the ligaments of Treitz. About 80% of all lower GI bleeding comes from a colorectal source and 5% to 10% from a small intestinal source; 10% to 15% are classified as blood of upper gastrointestinal tract origin. A small bowel bleeding source is more likely than a colorectal bleeding source to be obscure or occult.

A common cause of lower GI bleeding is a colonic diverticulum. Differential diagnoses include colitis or enteritis, anorectal abnormalities (hemorrhoids, proctitis), tumors, arteriovenous malformations or angiodysplasia, and postpolypectomy bleeding.

Therapeutic colonoscopy is currently the first-line intervention for colonic bleeding. Colonoscopy is the diagnostic method of choice in patients with lower gastrointestinal bleeding, but therapeutic endoscopy can also be successful in a limited number of patients. Therapeutic colonoscopy fails in approximately 32% of cases due to the presence of stool or blood clots, or technical difficulties such as time required to prepare patients. Further disadvantages include the fact that small bowel bleeding cannot be accessed through colonoscopy and that colonoscopy is relatively ineffective when performed in patients with significant bleeding without bowel preparation. If bleeding cannot be stopped by therapeutic colonoscopy, transarterial embolization is the next line of therapy to control hemostasis. As with upper gastrointestinal bleeding, transarterial embolization is the first-line therapy for patients with lower gastrointestinal bleeding. The efficacy of transarterial embolization in the treatment of acute gastrointestinal bleeding when medical or endoscopic techniques are inadequate has been demonstrated in several large studies. For both upper and lower gastrointestinal bleeding, surgery is usually reserved as a last-line treatment for patients whose bleeding has failed to respond to previous treatments.

Lower gastrointestinal bleeding is defined as bleeding originating from a source distal to the ligaments of Treitz. About 80% of all lower GI bleeding comes from a colorectal source and 5% to 10% from a small intestinal source; 10% to 15% are classified as blood of upper gastrointestinal tract origin. A small bowel bleeding source is more likely than a colorectal bleeding source to be obscure or occult. A common cause of upper GI bleeding is colonic diverticula. Differential diagnoses include colitis or enteritis, anorectal abnormalities



(hemorrhoids, proctitis), tumors, arteriovenous malformations or angiodysplasia, and postpolyectomy bleeding [20-24].

Therapeutic colonoscopy is currently the first-line intervention for colonic bleeding. Colonoscopy is the diagnostic method of choice in patients with lower gastrointestinal bleeding, but therapeutic endoscopy can also be successful in a limited number of patients. Therapeutic colonoscopy fails in approximately 32% of cases due to the presence of stool or blood clots. Technical difficulties, such as the time required to prepare patients. Further disadvantages include the fact that small bowel bleeding cannot be accessed through colonoscopy and that colonoscopy is relatively ineffective when performed in patients with significant bleeding without bowel preparation. If bleeding cannot be stopped by therapeutic colonoscopy, transarterial embolization is the next line of therapy to control hemostasis. As with upper gastrointestinal bleeding, transarterial embolization is the first-line therapy for patients with lower gastrointestinal bleeding. The efficacy of transarterial embolization in the treatment of acute gastrointestinal bleeding when medical or endoscopic techniques are inadequate has been demonstrated in several large studies. For both upper and lower gastrointestinal bleeding, surgery is usually reserved as a last-line treatment for patients whose bleeding has failed to respond to previous treatments [25-28].

In angiography, vascular access is usually obtained by transfemoral catheterization with a 4- or 5-Fr catheter and sheath. Diagnostic visceral arteriography, which includes angiography of the celiac trunk, superior mesenteric artery, and inferior mesenteric artery, is performed to examine the suspected vascular region, and then a microcatheter is inserted coaxially for superselective cannulation of the bleeding artery. In upper gastrointestinal bleeding, the source of the bleeding is usually identified by endoscopy. Therefore, angiography is most often performed only as a precursor to transcatheter embolotherapy. Angiograms are considered positive when they show direct angiographic evidence of active GI bleeding (eg, contrast medium extravasation) or indirect angiographic evidence of bleeding (eg, pseudoaneurysm). For embolization, the appropriate position of the catheter is selected, and transcatheter vessel occlusion is performed with embolized material. Embolization is carried out as selectively as possible, the catheter is technically possible near the site of bleeding. The goal is to achieve proximal and distal control of the bleeding lesion (embolization of both inflow and outflow vessels) to reduce the risk of recurrent bleeding via collateral circulation. Embolization will continue to the occlusive angiographic endpoint without antegrade arterial blood flow in the embolized artery. Post-embolization arteriography is performed to confirm completion of the procedure. The most common embolic material used to treat upper gastrointestinal bleeding is a fibrous platinum microcoil, which is usually placed in the bleeding artery distally proximal to the angiographic position [29-33].

Extravasation of the contrast medium is stopped and complete occlusion of the bleeding vessel occurs. Coiling of the gastroduodenal artery from the celiac axis may be inadequate because the gastroduodenal artery may be fed by collateral branches of the superior mesenteric artery. A "sandwich" technique has been proposed, in which the gastroduodenal artery is looped distally proximally. Sandwich occlusion can be used at the level of the gastroduodenal artery with the catheter directed toward the origin of the right gastroepiploic artery, and when the catheter is removed the coils are inserted into the proximal gastroduodenal artery. Complete embolization of the gastroduodenal artery, including proximal and distal embolization and exclusion of its two side branches, is the technical end point [34-35].

Selective superior mesenteric arteriography is performed after embolization to ensure that the bleeding site is not secured. If extravasation is detected, superselective catheterization of the lower pancreaticoduodenal artery and side branch is performed with a microcatheter. Over the past 10 years, significant improvements in this technique have made superselective embolization a safer procedure by minimizing the risk of intestinal ischemia.

The development of sophisticated rotating wires and coaxial microcatheters, along with advances in digital fluoroscopic imaging, now allow for more precise vascular interventions. In a recent report, transarterial embolization for upper gastrointestinal bleeding was associated with a high technical success rate (93%) and a minimal complication rate (9%). In addition, a recently published international consensus recommendation considers transarterial embolization as an alternative therapy for the treatment of upper gastrointestinal bleeding in patients who have failed an endoscopic hemostatic procedure or who have recurrent bleeding [36-38].

Transarterial embolization for the treatment of lower GI bleeding was first introduced in 1974 and involved the non-elective injection of an autologous clot. In 1977, Gelfoam and Oxygel injection were described for embolization of diverticular bleeding. Although injection of autologous clot or gelatin sponge has been shown to achieve hemostasis, these early embolization techniques were characterized by high rates of intestinal infarction. The development of coaxial microcatheters has increased interest in the use of embolization to control lower GI bleeding. The use of a microcatheter, delivered via a 4- or 5-wire guide catheter, to a specific margin near the bleeding site in the arteries or vas rectus can be obtained to remove embolic material. Because this technique is superselective, the risk of intestinal infarction is significantly lower than nonselective embolic techniques or vasopressin infusion, and there are no vasopressin-related systemic side effects. In addition, the risk of bleeding from collateral vessels is reduced as embolic material is delivered to the site of bleeding.

The most common embolic materials for lower GI bleeding, used alone or in combination, are microcoil, polyvinyl alcohol (PVA) particles, and gelatin sponge. Microcoils are persistent embolic agents that can be superselectively placed near the bleeding site and are easily identified under fluoroscopy. However, due to the small caliber of the target vessels, positioning these coils correctly can be difficult. Coils can back out of small vessels and provoke ischemia if they enter a large feeding vessel. PVA is a permanent embolic agent that is less selective than microcoil. The basis for PVA embolization with respect to flow is that PVA particles preferentially flow to the area of least resistance (ie, the bleeding site). Defrin et al demonstrated in 10 patients that lesions inaccessible by superselective catheterization could be safely embolized by flow-directed PVA embolization. However, a consensus on the optimal PVA particle size for embolization in lower GI bleeding has not yet been reached. Previous reports have recommended a PVA particle size of 300 to 500 μm , as early animal studies have shown that smaller particles may be associated with a higher risk of intestinal ischemia. The choice of embolic agent in relation to the characteristics of the bleeding vessel is important, but which embolic agent is best among coils, cyanoacrylate glue, gelatin sponge, and calibrated particles remains a matter of debate. In our department, microcoil, 1000 μm gelatin sponge particles, and cyanoacrylate glue are used to treat acute GI bleeding. Unlike PVA, the gelatin sponge is a temporary embolic agent that allows recanalization of the vessel from a few days to a few weeks. If the angiogram is negative for active bleeding, empiric embolization is performed based on discussion with the gastroenterologist or surgeon. For empiric embolization, if endoscopy showed that the bleeding source was located in the proximal stomach, the left gastric artery was selectively embolized. If endoscopy shows that the source of bleeding is

in the distal stomach or duodenum, the gastroduodenal artery, the right gastroepiploic artery, the pancreaticoduodenum, or all three are selectively embolized. If endoscopic intervention fails to control bleeding, radiopaque clips are positioned as guides to the bleeding site via colonoscopy and transarterial embolization is performed.

Bleeding, deposition of coils is guided by endoscopy with pre-placed hemoclips. As a result, angiography and embolization of vessels causing GI bleeding have been gradually adopted and have revolutionized the management of lower GI bleeding.

Complications associated with embolization include angiography itself (eg, hematoma, arterial thrombosis, dissection, embolism, pseudoaneurysm) as well as intestinal infarction. Early transcatheter intervention involved vasopressin infusion, but the high rate of rebleeding and high complication rates led to its reduced use. Higher rates of complications and bleeding have been described in patients treated with vasopressin. Although the first embolic techniques improved hemostasis, their use was limited by the high incidence of intestinal infarction. Until the advent and development of microcatheter technology, transarterial embolization became a safer, more effective method for managing gastrointestinal bleeding. Improvements in microcatheter systems have enabled more selective delivery of embolic material near bleeding sites; This overcame the systemic side effects of vasopressin and resulted in a reduced risk of intestinal infarction and vascular bleeding. Recently, many reports have suggested that superselective embolization for the management of gastrointestinal bleeding rapidly stops bleeding with minimal risk of ischemia. However, the risk of ischemia after embolization is increased in patients with a history of surgical intervention in the same area or when the therapeutic intervention involves embolic agents that may advance into the vascular bed. Such agents include liquids (for example, fabric adhesives such as cyanoacrylate) or very small particles.

In stable patients, multidetector computed tomography (MDCT) imaging is a useful tool to identify bleeding sites and assess the anatomical structure of the gastrointestinal tract, thereby allowing for more targeted intervention. Scintigraphy of red blood cells has a sensitivity and specificity of more than 90%; However, its simulated resolution does not provide an accurate diagnosis. Computed tomography angiography (CTA) is also used (sensitivity up to 86%) in the diagnosis of acute GI bleeding and can be used to pinpoint the location and etiology of bleeding and thus direct further management. A positive MDCT angiogram may be useful in selecting patients suitable for rapid targeted embolization. Visualization of active extravasation of contrast medium in the gastrointestinal tract requires careful attention to technique, including the use of fine collimation, rapid administration of contrast medium, and appropriate scan times. Additionally, multimodal reconstruction and three-dimensional imaging are useful in determining the exact source of bleeding. Although further studies are needed to determine which course of action is best when bowel preparation is not possible, CTA may be useful in this situation to identify the site of bleeding [18,34].

The idea of embolization of duodenal bleeding as an alternative use of surgery belongs to Roche (1972). Since then, arterial embolization has been considered as an effective diagnostic and surgical method

Common causes of duodenal bleeding:

- Arteriovenous malformation
- Visceral aneurysms/pseudoaneurysm
- Angiodysplasia
- Aortoenteric fistula

- Hemophilia
- Intestinal diverticula
- Inflammatory bowel disease (ulcer disease)
- Benign anorectal lesions

The main causes of duodenal bleeding. (See Illustration-1).




Illustration-1. Transcatheter arterial embolization for acute nonvariceal upper gastrointestinal bleeding: Indications, techniques and outcomes.

- Frequency of duodenal bleeding:
 - 375 cases per 100,000 population
 - Acute case of bleeding-75%
 - 70% of patients are >65 years old
 - Recurrent bleeding-25%
 - Mortality is 19-40%
 - Ratio male 2:1 female
- Clinical manifestations of duodenal bleeding
 - Hematemesis
 - Color brownish vomit
 - Melena
 - Anemia
 - Tachycardia (if blood loss > 500 ml)
 - Hypotension (if blood loss > 500 ml)
 - Systemic shock (if blood loss is more than 15% of circulating blood volume).

Diagnosis by fibrogastroscopy. See Photo-1-2.



Photo-1-2. Fibrogastroscopy technics.

Angiography as a method of determining bleeding and result. (See Photo-3).



Photo-3. Angiography as a method of determining bleeding and result.

Angiographic signs of acute duodenal bleeding

- ❖ Direct:
 - Contrast extravasation into the intestinal lumen

- ❖ Indirect:
 - "Aneurysms/pseudoaneurysms
 - Asymmetry of the blood vessel

- Arteriovenous/arteriportal shunting
- Neovascular

Our Purpose was to improvement of the results of surgical treatment of duodenal ulcer bleeding based on the use of endovascular embolization:

The task

- To determine indications for endovascular occlusion in ulcer patients complicated by gastroduodenal bleeding.
- The technique of endovascular interventions should be perfected.
- To evaluate the effectiveness of the endovascular occlusion method compared to the surgical method of treatment in high-risk patients.
- The tactics of surgical treatment of the mentioned patients should be developed based on the use of the endovascular occlusion method.

❖ Forrest's classification during endoscopy

- Forrest IA
- Forrest IB
- Forrest IIA
- Forrest IIB
- Forrest IIC
- Forrest III

Risk of rebleeding according to the Forrest classification. (See Illustration-2).




Illustration-2. Risk of rebleeding according to the Forrest classification.

❖ Testimonials

- Low-risk patients - surgical treatment
- And high-risk patients - endovascular surgery
- Recurrent bleeding after surgery - endovascular surgery

The diagnosis and management of gastrointestinal (GI) bleeding are complicated and requires a multidisciplinary approach involving gastroenterologists, interventional radiologists, and surgeons.

• **Testimonials**

- With active bleeding (requiring 4 units of blood transfusion in 24 hours).
- With hemodynamic instability (low systolic pressure, pulse 100 or more, hypovolemic shock) - who did not have satisfactory results during endoscopic hemostasis, in this case it will be important to calculate the Rokall score.
- A high risk of rebleeding should be used in the Forrest classification. Forrest 1A, Forrest 1B Forrest 2A and Forrest 2B
- Co-morbidities that aggravate the patient's medical history.

Graphical comparison of mean age of TAE and surgical groups in included studies. See Illustration-3.




Illustration-3. Graphical comparison of mean age of TAE and surgical groups.

Material and methods: From March 2019 to December 2024, 40 patients were embolized during duodenal bleeding.

These patients were divided into the following groups:

- Massive, active bleeding;
- Recurrence of bleeding in clinic and endoscopy was unsuccessful;

- Unstable hemodynamics and solid hemostasis could not be achieved during endoscopy;
- Failed to evacuate stomach contents and failed to see a bleeding ulcer;
- High risk of bleeding recurrence (Forrest classification);
- Elderly and patients burdened with co-morbidities, with whom operative intervention represents a high risk of lethality.

Embolization performed according to Forrest's classification in 40 patients. See Illustration-4.




Illustration-4. Embolization performed according to Forrest's classification.

- ❖ Embolization methods
 - Blind- embolization
 - Empirical embolization
- ❖ Technical aspects of embolization
 - Radial approach
 - Femoral artery approach
- ❖ Factors influencing the choice of embolic agent
 - Angiographic conclusion
 - Vascular anatomy
 - Vascular size
 - Desired level of vascular occlusion
 - Temporary or permanent occlusion is preferred
 - Catheter position
 - Operator experience



Embolization techniques. (See Illustration-5).




Illustration-5. Embolization techniques.

Embolization Sandwich technique. See Illustration-6.




Illustration-6. Embolization Sandwich technique.

- ❖ Study Results:
 - Technical success in 39 patients (97.5%).
 - Technical failure in 1 patient (2.5%).

Embolization results obtained on 40 patients. (See Illustration-7).




Illustration-7. Embolization results.

- Case description
 - The patient is 78 years old
 - Pain in the chest
 - Marked respiratory failure
 - Troponin 2.6 ug/L
 - ST-elevation on the cardiogram

Angiography results. See Photo-4.



Photo -4. Angiography results.

- The following criteria are used to evaluate the effectiveness of endovascular hemostasis:
 - Technical success - interruption of blood flow in the embolization zone.
 - Clinical success - correction of bleeding recurrence and stabilization of hemodynamics
 - Unsuccessful embolization.
 - Studies show that coagulopathy is significantly associated with mortality after failed embolization.

The risk of rebleeding after successful embolization is three times greater in patients with coagulation problems, and for the same reason there is a 10-fold greater risk of death compared to patients with normal coagulation.

Conclusion

Improvements in catheter technology, development of more compatible embolization devices, and expansion of embolization techniques have led to angiography and embolization for the treatment of upper and lower gastrointestinal bleeding. Transcatheter embolization therapy for the treatment of acute GI bleeding is a safe procedure with high technical performance and clinical success, but

it should be reserved as a treatment option for patients who have failed endoscopic and medical management. MDCT imaging is a useful tool for identifying the site of bleeding and evaluating the anatomical structure of the gastrointestinal tract in stable patients. Close working relationships between interventional radiologists, gastroenterologists, and diagnostic radiologists are essential for the optimal management of patients with GI bleeding. Endovascular embolization dramatically reduces the mortality rate in high-risk patients who require open surgery after failed endoscopy, further studies are needed to fully address these objectives.

Acknowledgments

Declaration of Interest Statement. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. Conflict of interest-None.

Declaration of Interest Statement: No potential conflict of interest was reported by the authors.

REFERENCES

1. Cherian MP, Mehta P, Kalyanpur TM, Hedgire SS, Narsinghpura KS: Arterial interventions in gastrointestinal bleeding. *Semin Intervent Radiol*, 2009; 26: 184-195.
2. Sheth R, Someshwar V, Warawdekar G: Treatment of acute lower gastrointestinal hemorrhage by superselective transcatheter embolization. *Indian J Gastroenterol*, 2006; 25: 290-294.
3. Rozycki GS, Tremblay L, Feliciano DV, etal: Three hundred consecutive emergent celiotomies in general surgery patients. *Ann Surg*, 2002; 235: 681-689.
4. Pennoyer WP, Vignati PV, Cohen JL: Management of angiogram positive lower gastrointestinal hemorrhage: long term follow-up of non-operative treatments. *Int J Colorectal Dis*, 1996; 11: 279-282.
5. Schuetz A, Jauch KW: Lower gastrointestinal bleeding: therapeutic strategies, surgical techniques and results. *Langenbecks Arch Surg*, 2001; 386: 17-25.
6. Mirsadraee S, Tirukonda P, Nicholson A, Everett SM, McPherson SJ: Embolization for non-variceal upper gastrointestinal tract haemorrhage: a systematic review. *Clin Radiol*, 2011; 66: 500-509.
7. Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-Warnick G: Urgent vs. elective endoscopy for acute non-variceal upper GI-bleeding: an effectiveness study. *Gastrointest Endosc*, 2004; 60: 1-8.
8. Church NI, Palmer KR: Diagnostic and therapeutic endoscopy. *Curr Opin Gastroenterol*, 1999; 15: 504.
9. Yap FY, Omene BO, Patel MN, etal: Transcatheter embolotherapy for gastrointestinal bleeding: a single center review of safety, efficacy, and clinical outcomes. *Dig Dis Sci*, 2013; 58: 1976-1984.
10. DeBarros J, Rosas L, Cohen J, Vignati P, Sardella W, Hallisey M: The changing paradigm for the treatment of colonic hemorrhage: superselective angiographic embolization. *Dis Colon Rectum*, 2002; 45: 802-808.
11. Lewis BS: Small intestinal bleeding. *Gastroenterol Clin North Am*, 1994; 23: 67-91.



11. Jenson DM, Machicado GA, Jutabha R, Kovacs TO: Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. *N Engl J Med*, 2000; 342: 78-82.
12. Zuccaro G: Management of the adult patient with acute lower gastrointestinal bleeding. *Am J Gastroenterol*, 1998; 93: 1202-1208.
13. Angtuaco TL, Reddy SK, Drapkin S, Harrell LE, Howden CW: The utility of urgent colonoscopy in the evaluation of acute lower gastrointestinal tract bleeding: a 2-year experience from a single center. *Am J Gastroenterol*, 2001; 96: 1782-1785.
14. Bloomfield RD, Rockey DC, Shetzline MA: Endoscopic therapy of acute diverticular hemorrhage. *Am J Gastroenterol*, 2001; 96: 2367-2372.
15. Eisen GM, Dominitz JA, Faigel D, et al; American Society for Gastrointestinal Endoscopy. Standards of Practice Committee: an annotated algorithmic approach to acute lower gastrointestinal bleeding. *Gastrointest Endosc*, 2001; 53: 859-863.
16. Zuckerman GR, Prakash C: Acute lower intestinal bleeding. Part I: clinical presentation and diagnosis. *Gastrointest Endosc*, 1998; 48: 606-617.
17. Fisher L, Krinsky ML, Anderson MA, et al: The role of endoscopy in the management of obscure GI bleeding. *Gastrointestinal Endoscopy*, 2010; 72: 471-479.
18. Funaki B, Kostelic JK, Lorenz J, et al: Superselective microcoil embolization of colonic hemorrhage. *Am J Roentgenol*, 2001; 177: 829-836.
19. Funaki B: Superselective embolization of lower gastrointestinal hemorrhage: a new paradigm. *Abdom Imaging*, 2004; 29: 434-438.
20. Barkun AN, Bardou M, Kuipers EJ, et al: International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med*, 2010; 152: 101-113.
21. Weldon DT, Burke SJ, Sun S, Mimura H, Golzarian J: Interventional management of lower gastrointestinal bleeding. *Eur Radiol*, 2008; 18: 857-867.
22. Mirsadraee S, Tirukonda P, Nicholson A, Everett SM, McPherson SJ: Embolization for non-variceal upper
23. Charbonnet P, Toman J, Buhler L, et al: Treatment of gastrointestinal hemorrhage. *Abdom Imaging*, 2005; 30: 719-726.
24. Gocha Chankseliani, Avtandil Girdaladze, Omar Gibradze, Paata Meshveliani, Kakha Chelidze, Mirian Cheishvili, Ana Kvernadze, Nodar Sulashvili. THE FEATURES OF ENDOVASCULAR SURGERY FOR DUODENAL ULCER BLEEDING. *RS Global - World Science [Internet]*. 2023Dec.11 [cited 2024Feb.13];(4(82)). Available from: <https://rsglobal.pl/index.php/ws/article/view/2690>
25. Gocha Chankseliani, Avtandil Girdaladze, Omar Gibradze, Paata Meshveliani, Kakha Chelidze, Mirian Cheishvili, Ana Kvernadze, Nodar Sulashvili; THE MANIFESTATION OF SOME KEY ISSUE ASPECTS OF PECULIARITIES OF ENDOVASCULAR SURGERY BASED ON ENDOVASCULAR EMBOLIZATION FOR BLEEDING FROM GASTRO-DUODENAL ULCER AND FEATURES OF SOME ESSENTIAL PHARMACOTHERAPY; ISBN: 978-9941-9711-7-4; DOI suffix: 10.36962/IMPAS01-2023; CONFERENCE PROCEEDINGS; THE FIRST INTERNATIONAL SCIENTIFIC-PRACTICAL CONFERENCE IN HEALTH INNOVATIONS & RESEARCH: PROGNOSIS, ACHIEVEMENT AND CHALLENGES; DECEMBER 15-16, 2023. TALLINN, ESTONIA-2023. Pp:14-15.

26. G. Chankseliani, A. Girdaladze, O. Gibradze, P. Meshveliani, K. Chelidze, M. Cheishvili, A. Kvernadze, N. Sulashvili; THE MANIFESTATION OF SOME KEY ISSUE ASPECTS OF PECULIARITIES OF ENDOVASCULAR SURGERY BASED ON ENDOVASCULAR EMBOLIZATION FOR BLEEDING FROM GASTRO-DUODENAL ULCER AND FEATURES OF SOME ESSENTIAL PHARMACOTHERAPY; ISSN: 2346-8068, E-ISSN: 2346-8181; DOI: 10.36962/ALISJMSC; http://scsj.fisdd.org/index.php/ail/home/Archive_of_Issues; DOI PREFIX: 10.36962/ALISJMSC; SOUTHERN CAUCASUS SCIENTIFIC JOURNALS; AMBIANCE IN LIFE; INTERNATIONAL SCIENTIFIC JOURNAL IN MEDICINE; JOURNAL OF BEHAVIORAL MEDICINE, REFEREED AND REVIEWED JOURNAL; VOLUME 15, ISSUE -01, 2023; 15.01.2023. TBILISI-GEORGIA-2023. Pp: 20-38.
27. Gocha Chankseliani, Avtandil Girdaladze, Omar Gibradze, Paata Meshveliani, Kakha Chelidze, Nodar Sulashvili; THE SCIENTIFIC DISCUSSION SINGULARITIES OF ENDOVASCULAR SURGERY AND ENDOVASCULAR EMBOLIZATION FOR BLEEDING FROM GASTRO-DUODENAL ULCER AND TREATMENT OF COMPLICATIONS; ISBN - 978-1-955094-84-9; By Liberty Academic Publishers 2023; New York, USA; PROCEEDINGS BOOK; PROCEEDINGS BOOK OF 5 BASKENT INTERNATIONAL CONFERENCE ON MULTIDISCIPLINARY STUDIES; December 21-22, 2023, Ankara, Turkey-2023. Pp:1041-1059.
28. [Guideline] Talley NJ, Vakil N, for the Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. *Am J Gastroenterol.* 2005 Oct. 100(10):2324-37. [QxMD MEDLINE Link].
29. Tajima A, Koizumi K, Suzuki K, et al. Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. *J Gastroenterol Hepatol.* 2008 Dec. 23 suppl 2: S237-41. [QxMD MEDLINE Link].
30. McConnell DB, Baba GC, Deveney CW. Changes in surgical treatment of peptic ulcer disease within a veteran's hospital in the 1970s and the 1980s. *Arch Surg.* 1989 Oct. 124(10):1164-7. [QxMD MEDLINE Link].
31. Gisbert JP, Calvet X, Cosme A, et al, for the H. pylori Study Group of the Asociacion Espanola de Gastroenterologia (Spanish Gastroenterology Association). Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. *Am J Gastroenterol.* 2012 Aug. 107(8):1197-204. [QxMD MEDLINE Link].
32. [Guideline] Tarasconi A, Coccolini F, Biffi WL, et al. Perforated and bleeding peptic ulcer: WSES guidelines. *World J Emerg Surg.* 2020. 15:3. [QxMD MEDLINE Link]. [Full Text].
33. Berne TV, Donovan AJ. Nonoperative treatment of perforated duodenal ulcer. *Arch Surg.* 1989 Jul. 124(7):830-2. [QxMD MEDLINE Link].
34. Donovan AJ, Berne TV, Donovan JA. Perforated duodenal ulcer: an alternative therapeutic plan. *Arch Surg.* 1998 Nov. 133(11):1166-71. [QxMD MEDLINE Link].
35. Wangenstein OH. Non-operative treatment of localized perforations of the duodenum. *Proc Minn Acad Med.* 1935. 18:477-80.
36. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. *Gut Liver.* 2017 Jan 15. 11(1):27-37. [QxMD MEDLINE Link]. Kajihara Y,

- Shimoyama T, Mizuki I. Analysis of the cost effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy
37. For first-line *Helicobacter pylori* eradication. *Scand J Gastroenterol*. 2017 Feb. 52(2):238-41. [QxMD MEDLINE Link].
38. Ng JC, Yeomans ND. *Helicobacter pylori* infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis. *Med J Aust*. 2018 Sep 1. 209(7):306-11. [QxMD MEDLINE Link].

Publication history

Article received: 26.04.2024

Article accepted: 17.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-07

PRE-IMPLANTATION GENETIC DIAGNOSIS IN THE PROGRAM OF ASSISTED REPRODUCTIVE TECHNOLOGY

Mahira, Ismayilova, Aytakin Hasanova

PhD in Medicine, Central Clinic, Azerbaijan

Senior Teacher, PhD in Medicine, Email: aytakin_hasanova@mail.ru, Azerbaijan Medical University, Azerbaijan

Introduction

Pre-implantation Genetic Diagnosis (PGD) is the diagnosis of genetic disorders in human embryos prior to implantation into the endometrium, i.e. before the phase of transfer on the program of in vitro fertilization (IVF). A biopsy of one blastomer in an embryo that is at the cleavage stage (6-10 blastomeres) or a biopsy of the trophoctoderm (the outer layer of cells) at the blastocyst stage (day 5 of embryo development) is typically performed for analysis. The main advantage of PGD is that there is no selective termination of pregnancy when it is used and the chance of giving birth to a child without any diagnosed genetic diseases is quite high [1,3,15].

There are discrepant data in literature on the effectiveness of PGD as part of the program of assisted reproductive technologies (ART) [2,6,8].

According to some studies including ASRM (American Society for Reproductive Medicine) data, application of PGD doesn't increase the frequency of pregnancies with in vitro fertilization (IVF). This may be due to imperfection of the technique of the blastomer sampling procedure or the choice of a laboratory screening method to diagnose aneuploidy and microstructural chromosomal abnormalities simultaneously in all chromosomes. The method of array comparative genomichybridization (CGH) showed high performance for clinical studies on embryo transfer within ART (69-70%). While there is the high genetic abnormalities detection rate in PGD based on many studies, the frequency of pregnancies with this method doesn't exceed 30-40% [4,7,11].


Study of the structure of embryo chromosomal disorders based on pre-implantation genetic diagnosis in the program of assisted reproductive technology as well as the impact of this procedure on the results of pregnancies is, therefore, of particular interest.

Materials and methods.

We studied chromosomal abnormalities of embryos in 86 females with different IVF outcomes. Pre-implantation study of the embryos was conducted by the FISH method in 42 females with positive IVF outcomes and in 44 females with negative IVF outcomes. The quality of the embryos was assessed on the third day of culture.

All female patients underwent a special examination before IVF: the hormonal panel was studied (FSH, LH, estradiol, TSH, free T3, free T4, TSH, thyroperoxidase antibodies, prolactin, progesterone, Anti-Mullerian Hormone, testosterone) and infectious status (TORCH-complex infection, STDs), papanicolau test, peripheral karyotype, determination of the vitamin D level in the blood, hysterosalpingography, hysteroscopy with pathohistological examination of endometrial biopsy material. Males underwent mandatory sperm examination with morphological indicators of spermatozoa, genetic analysis of sperm (FISN) and DNA fragmentation. The immune system of spouses and their compatibility by the 2nd class of HLA genes were also examined.

The exclusion criteria were the females with monogenic diseases and males with significant pathozoospermia. Controlled ovarian hyperstimulation was performed according to the standard



antagonist protocol from day 2-3 of the menstrual cycle with preparations of recombinant follicle-stimulating hormone combined with preparations of human menopausal hormone. Ultrasound monitoring of follicle growth was performed by transvaginal ultrasonography 4-5 times during the multifollicular ovarian stimulation. When the maximum follicle of 14-15 mm was reached, a gonadotropin-releasing hormone antagonist was administered at a dose of 0.25 mg.

Oocyte retrieval was performed in 35-36 hours after the administration of ovulation trigger. Immediately after receiving oocytes and spermatozoa, their morphological assessment was performed. Morphological analysis of oocytes and spermatozoa was carried out immediately after retrieval. Mature, immature and degenerative oocytes can be retrieved by puncturing follicles. More thorough assessment of the state of oocytes can be carried out only after purification before ICSI. The first polar cell is determined in mature oocytes ready for fertilization and designated as M II in the embryological protocol [1,13].

Intracytoplasmic sperm injection was performed for all patients (ISCI method). Two pronuclei form in the normal course of fertilization in 18-20 hours after ICSI (on the 1st day). In this case, 2pn rating is assigned to them. Further development of embryo cleavage occurs within 5-6 days. The embryo quality was assessed 40-42 hours (on Day 2), 72-74 hours (on Day 3), and 20 hours (on Day 5) after fertilization. Embryo cleavage should be symmetrical and equal. Embryos of poor quality were not transferred to the uterine cavity. They were left till Day 5 and then frozen or transferred upon normal blastocyst formation [5,10,14].

It is known that embryos form a blastocyst on Day 5. The quality of blastocysts was assessed by their size from 1 to 5; by the state of the inner cell mass - from "A" to "C" and surrounding cells - trophoblast (from "A" to "C"). The best blastocysts for transfer were those of size 3-5 with the multicellular ICM and trophoblast. Further development of the embryo occurs in the uterus after the implantation. For successful implantation, the blastocyst must exit the surrounding pellucid zone. This process is called hatching. In case of change in the pellucid zone and difficulties in the process of self hatching, auxiliary laser hatching is used [10,12,15].

Biopsy of the embryo was performed on Day 3 after the fertilization at phase 6-10 of blastomeres and blastocytes.

The FISH (fluorescence in situ hybridization) method was used to detect numerical and structural chromosomal abnormalities. This method involves DNA-probes which are a limited-size nucleotide sequence complementary to a specific region of nuclear DNA. The probe has a "tag", i.e. it contains a nucleotide linked to fluorophore (a molecule capable of fluorescence).

After the procedure of hybridization with the formation of a hybrid DNA-probe and DNA-target molecule, fluorescence of specific DNA sequences on chromosomes or in nuclei can be observed on the study cytogenetic preparation by means of a fluorescent microscope [9,13].

Statistical data processing was performed using an application software package SPSS statistics 17.0. The Kruskal-Wallis test was used to evaluate the significance of intergroup differences in several independent samples.

In case of two samples the Mann-Whitney U-test was used for unlinked sequences. The inserted parts of genotypes were assessed for compliance with the Hardy-Weinberg principle by the X^2 criterion in comparison with expected genotype frequencies of equilibrium distribution. The significance of differences in the incidence of qualitative characters was determined by the criterion X^2 .

Findings of Study.

Mean age of females was 35.5 ±1.0. Infertility duration was 7.5 ±5 years. The patients were comparable (p>0.005) in their etiology of infertility, anamnestic data, mass-height index, structure of previous somatic and gynecological diseases, and surgical interventions. All patients had a normal karyotype.

The results of the study on the characteristics of embryos subjected to pre-implantation diagnosis are shown in Table 1. A total of 220 embryos were subjected to pre-implantation diagnosis: 111 embryos in Group A and 109 embryos in Group B. Patients of each study group were divided into subgroups by age: under the age of 35 and over 35. In Group A, among females aged <35, the number of embryos subjected to pre-implantation diagnosis was 52 and in females aged >35 the number of embryos subjected to pre-implantation diagnosis was 59. In Group B, 48 embryos were subjected to pre-implantation diagnosis in females aged <35 and 61 embryos in females aged >35. The study findings showed that no pathology of embryos was observed both in females aged <35 and in females aged >35 in the group with successful IVF in 69.2% and 59.3% of cases respectively. These values are statistically significantly higher than similar values in the group of females with non-effective IVF results, respectively, 41.7% (p< 0.01) and 24.6 % (p < 0.01). Embryos with abnormalities were detected statistically more often in the group with negative IVF results (67.9%) than in the group of successful IVF (36.0%, p < 0.01).

Distribution of embryos with abnormalities showed that in the group of non-effective IVF results statistically significant increase in the relative incidence of embryo pathology was observed both in females aged <35 and in females aged >35 (58.3% and 75.4% respectively), as compared with the group of females with positive IVF outcomes in the relevant age group, 30.8% (p<0.001) and 40.7% (p<0.001) respectively (Table 1).

Table 1. Characteristics of embryos subjected to pre-implantation diagnosis.

Value	Group A n=42		Group B n=44		Total n=86
	Age < 35	Age > 35	Age < 35	Age > 35	
	abc %	abc %	abc %	abc %	
Total embryos subjected to PD	52	59	48	61	220
Embryo pathologies by chromosomes, No	36 69.2	35 59.3	20 41.7**	15 24.6***	106
Embryo pathologies by chromosomes, Yes	16 30.8	24 40.7	28 58.3**	46 75.4***	114
Embryo pathologies by chromosomes within groups	40 36.0		74 67.9**		114

Note: *- ** p< 0.05-0.01 as compared to Group A of the same age.

Since the frequency of viable embryos formation varies in both groups, studying the frequency and nature of pathologies of viable embryos in these groups is of great interest. Viable embryos reached 35% in the group of females with positive IVF outcomes that was statistically more than in the group of negative IVF result – 20.3% (p<0.01) (Table 2). A detailed study of the frequency of viable embryos in patients of different age subgroups showed statistically significant high values among females aged > 35 with positive IVF outcomes (37.5%) in comparison with females of the same age with negative IVF outcomes (15.2%, p<0.05).

The study of unviable embryos frequency showed a contrary picture. Unviable embryos were observed statistically more often in females aged >35 in the group with the negative IVF outcome (84.8%) as compared to females of the same age with the positive IVF outcome (62.5%, $p < 0.05$). Among females aged <35, there was no relevant difference in the frequency of viable and unviable embryos between the study groups.

Table 2. Features of embryos with pathologies detected by pre-implantation diagnosis.

Value	Group A n=40		Group B n=74	
	Age < 35	Age > 35	Age < 35	Age > 35
	abc %	abc %	abc %	abc %
Total embryos with pathologies	16	24	28	46
Unviable embryos	11 68.75	15 62.5	20 71.4	39 84.8*
Viable embryos	5 31.25	9 37.5	8 28.6	7 15.2*
Total viable embryos within groups	14	35.0	15	20.3**


Note: *- ** $p < 0.05-0.01$ as compared to Group A of the same age

The study of the paternal age effect on the embryo pathology incidence revealed a direct dependence between a chromosomal abnormality and the paternal age (Figure 1). In group A, males aged 30-35 had embryo pathology in 20.0% of cases that is statistically higher than in males aged 24-30 years with embryo pathology observed in 3.0% of cases ($p < 0.01$). Abnormalities were observed in 40.0% of males aged 35-40 and in 50.0% of males aged >40. The detected difference in the frequency of embryos with pathologies in different age subgroups for the Group A was statistically significant ($p < 0.01$).

A similar trend was observed in group B. The incidence of chromosomal abnormalities in embryos increased with increasing paternal age. The highest relative incidence of chromosomal abnormalities in embryos was observed in males of the older age subgroups. In persons aged >40, 54.0% abnormal embryos were observed, that is statistically more than in males aged 35-40 with the incidence of embryo abnormalities was fixed at the level of 46.0% ($p < 0.05$). In males aged 30-35 this pathology was reported in 25.0% that is statistically less than in males of the older age groups ($p < 0.01$) and in males aged 24-30 ($p < 0.01$) (Figure 1).

Comparative analysis of the embryo pathology incidence among the study groups of similar age didn't show a relevant difference.

Figure 1. Dependence of the embryo pathology incidence on the paternal age in the comparison groups.



P < 0.01 as compared to the previous age within each group.

The study of the structure of chromosomal pathology of viable embryos in the comparison groups showed the following (Table 3). In Group A, trisomy 21 (Down syndrome) was diagnosed in 41.7% of embryos. In Group B, this syndrome was reported in 40.0% of embryos (p>0.05). Patau syndrome (trisomy 13) and Edwards syndrome (trisomy 18) were diagnosed in 25.0% and 16.7% of viable embryos of Group A that is comparable to the similar data in Group B where the incidence of the above mentioned syndromes diagnosed in embryos was 20.0% and 13.3% respectively (p>0.05). There was no relevant difference between the groups in the incidence of Klinefelter syndrome (XXY) and polysomy Y (XYY) in viable embryos (p>0.05).

Table 3. Nature of chromosomal pathology in the studied pathological viable embryos.

Viable embryos	Group A n=42		Group B n=44		Total	
	abc	%	abc	%	abc	%
Klinefelter syndrome (XXY)	0	0	1	6.7	1	3.7
Turner syndrome (X0)	1	8.3	1	6.7	2	7.4
Down syndrome (trisomy 21)	5	41.7	6	40.0	11	40.7
Patau syndrome (трисомия 13)	3	25.0	3	20.0	6	22.2

Edwards syndrome (trisomy 18)	2	16.7	2	13.3	4	14.8
Polysomy Y (XYY)	1	8.3	2	13.3	3	11.1

The study of the structure of chromosomal pathology in females of different age groups (>35 and <35) didn't reveal a relevant difference in the relative incidence of the above mentioned abnormalities (Table 4). Down syndrome was diagnosed in most cases in viable embryos both in females aged <35 and in females aged >35 (38.5% and 42.8% respectively, $p>0.05$). A relevant difference also was not revealed in the incidence of other syndromes in viable embryos with abnormalities in females of the experimental age groups.

Table 4. Nature of chromosomal pathology in pathological viable embryos in females of different age groups.

Viable embryos	Group A + Group B				Total	
	Age <35		Age >35			
	abc	%	abc	%		
	13		14		27	100
Klinefelter syndrome (XXY)	1	7.7	0	0	1	3.7
Turner syndrome (X0)	1	7.7	1	7.1	2	7.4
Down syndrome (trisomy 21)	5	38.5	6	42.8	11	40.7
Patau syndrome (трисомия 13)	3	23.1	3	21.4	6	22.2
Edwards syndrome (trisomy 18)	2	15.4	2	14.3	4	14.8
Polysomy Y (XYY)	1	7.7	2	14.3	3	11.1

In summary, the study of pre-implantation embryo characteristics in the IVF program revealed higher indices for embryos without chromosomal abnormalities in the group with positive IVF outcomes and lower indices for the relative frequency of embryos with chromosomal abnormalities as against the group with negative IVF outcomes.

In females aged >35 from the group with positive IVF outcomes viable embryos were found more frequently and unviable embryos were found less frequently. The nature of chromosomal pathology in study females didn't show a relevant difference among the comparison groups.

Large enough quantity of morphologically healthy but genetically abnormal embryos was also detected. With no PGD an embryologist would undoubtedly choose the embryos that reached the blastocyst phase. And this would lead to a negative IVF outcome.

Along with this, there were also the embryos that were genetically healthy but morphologically defective. All these data suggest that the protocols of controlled ovarian hyperstimulation, used medicinal drugs, embryological phase and procedure of PGD itself need to be improved to obtain a high-quality embryo and positive IVF outcome.

So, while there are contradictory data, the analysis of the world literature data and the results obtained by us in the course of the study revealed great advantages of pre-implantation diagnosis. With its wide diagnostic capabilities, PGD as part of the ART program makes it possible to select and transfer embryos with no chromosomal abnormalities into the uterine cavity, to reduce the

risk of miscarriage and multiple pregnancies and to improve the chances of successful implantation and the birth of a healthy child.

REFERENCES

1. M.V.Sorvash, et al. The role of pre-implantation genetic screening in improving efficacy of infertility treatment in patients with a history of repeated unsuccessful IVF attempts. *Obstetrics & Gynecology IPJ*, 2013, No.1, p.15-17. (М.В. Сорваш и соавторы «Роль предимплантационного генетического скрининга в повышении эффективности лечения бесплодия у пациенток с повторными неэффективными попытками ЭКО» ИИЖ Акушерство и гинекология, 2013, №1, С.15-17.)
2. Balfari V., Satirofger H., Kabukem., et al. Relationship between embryo quality and aneuploidies. *Reprod. Biomed. Online*. 2006, 12(1), 77-82.
3. Kline J., Stein Z., Susser M., et al. Chromosomal characteristics of subsequent miscarriages (spontaneous abortions) *Am. J. Epidemiol.* 1986; 123 (6), p/ 1066-79.
4. Kerliet A. Cieslak J., Ylkevitch et al. Chromosomal abnormalities in a series of 6,733 human oocytes in preinplatation diagnosis for age – related aneuploidies. *Reprod. Biomed Online*.2003; 6(1); 54-9.
5. Munne S., Velilla E., Colls P., et al. self – correction of chromosomally abnormal embryos in culture and implication for stern cell production. *Fertil. Steril.* 2005; 84(5): 1328-34.
6. Schoolcraft W.B., Fragouli E., Steveeg J. et al. Clinical application of compressive chromosomal screening at the blastocyst stage. *Fertil. steril.* 2010; 94(5): 1700-6.
7. Shinawi M., Cheung S.W. The array CGH and its clinical applications. *DrengDisscow. Today*. 2008; 13 (17-18); 760-70.
8. Staessen C., plattean P., van Assche E. et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with adzancedneabernal age aprogetivezandomized controlled trial. *Klm. Reprod.* 2004; 19 (12); 2849-58.
9. Treff N.B., Levy B., Su J. et al., SNP microarray –baged 24 chromosome aneuploidy screening is significantly more cousistent than FISH. *Mol.HumanReprod.* 2010, 16 (8).
10. Belyayeva N.A., Glinkina Zh.M., Sokur S.A., et al. Use of pre-implantation diagnosis in searching assisted reproductive technologies for married couples with the combination of mutation in Y chromosome alt-locus and CFIR gene polymorphism in males. *Obstetrics & Gynecology SPJ*, 2001, No.4/1, p.54-59. (Беляева Н.А., Глинкина Ж.М., Сокур С.А. и соавт., Применение предимплантационной диагностики в поисках вспомогательных репродуктивных технологий у супружеских пар с считанием мутации в альт-локусе хромосом У и полиморфизм гена CFIR у мужчин. ИИЖ. Акушерство и гинекология, 2001, №4/1, страница 54-59.)
11. Tamainolo B., Fansix M., et al. Enwarced frequency of CFIR gene variants in corpus who are candidates for assisted reproductive technology treatment //*Clin. Chem. Lab.med.* – 2011, Vol.48-P. 1289 – 1293
12. Zheng Y.M., Wang N., Ct L. et al. Whole henome amplification in preimplantasion genetic diagnosis. *I. Zhejiang Univ. sec. B.* 2011; 1-11
13. Ferraretti Ap., Magli M.C., Копсow L., at al. Prognosive role of preimplantasion genetic diagnosis for anenploinetic in asseisved reproductive 2004; 19: 694 – 9

14. Mastebroek S., Twisa Vander Veen et al. Preinplantasion genetic screening a. systematic revecivaudmeta-analysis of RCTS. Hum. Reproduc up dade 2011; 17; 454-66
15. CollsEscudero I., Fischer I., Ceklenia W.A., et al., Validation of array comparative genome hybridization for diagnosis of traumalocation in preimplantasion human embryos. Reprod., Biomed Ohlina 2012; 621-9

Publication history

Article received: 26.04.2024

Article accepted: 17.05.2024

Article published online: 20.06.2024

DOI: 10.36962/PIRETC32032024-08

EDITORIAL BOARD & INTERNATIONAL ADVISORY

Australia

Shahid Khan
Monash Business School. Sessional Lecturer. PhD in Management.
Vikash Ramiah
UNISA School of Commerce. Associate Professor. PhD in Applied Finance.

Azerbaijan

Abbas İsmayılov
Azerbaijan State Agricultural University. Director of the Biotechnology Center, Faculty of Agronomy Department, Associate Professor. PhD in Biology Science.
Alakbar Huseynzada
Azerbaijan State Oil and Industry University, Scientific researcher at "Geotechnological Problems of Oil, Gas and Chemistry", Scientific researcher at "Chemistry of alkenylphenols", Eesearch laboratory, Chemistry of petroleum and chemical technology department, Faculty of Chemistry, Baku State University, PhD in Chemistry.
Almaz Mehdiyeva
Azerbaijan State Oil and Industry University. Associate Professor. PhD in TS
Aytekin Hasanova
Azerbaijan Medical University. Department of medical biology and genetics, Senior teacher, PhD in Medical Biology.
Arif Mammadzade
Azerbaijan State Oil and Industrial University. "Geotechnological problems of oil, gas and chemistry" Scientific Research Institute. Doctor of technical sciences. Professor.
Bilal Asadov
Azerbaijan Medical University, Psychiatry Department, Professor. Doctor of MS.
Elchin Suleymanov
Baku Engineering University. Associate Professor of Department Finance. PhD in Economy.
Elmira Valiyeva
Azerbaijan State Agrarian University Senior teacher of the Chair of Languages.
Elshan Hajizade
Azerbaijan State University of Economics, Head of department. Doctor of Economic Science. Professor.
Emin Mammadzade
Institute of Economics of ANAS. Economic institute. Phd in Economy. Associate professor.
Farda Imanov
Baku State University, Vice-rector, Chair of Hydrometeorology, Professor.
Garib Mamedov
Baku State University, Chief of Soilscience Department of Biology Faculty. Doktor of biological sciences, Professor.
Heyder Guliyev
Azerbaijan State Agricultural University. English Teacher. PhD in Philology
Ibrahim Habibov
Azerbaijan State Oil and Industrial University. Doctor of Technical Sciences. Professor
Irada Sultanova
Azerbaijan Medical University, I obst-gynecology department, Associate professor.
Lala Bekirova
Azerbaijan State Oil and Industrial University. Department of Instrumentation Engineering, Doctor of TS.
Leyla Djafarova
Clinic "Medium" Baku. Doctor of Medical Sciences. Professor.
Mahmud Hajizade
Sector Director of State Fund for Information Technology Development of the Ministry of Communications and High Technologies of the Republic of Azerbaijan, Ministry of Transport, Communications and High Technologies of the Republic of Azerbaijan.
Naila Guliyeva
Azerbaijan Medical University. Assistant in "Immunology" Program at Paediatrics Diseases Department. Docent and Academic Manager in "Allergology and Immunology" Department.
Nigar Kamilova
Azerbaijan Medical University, Faculty I Obstetrics – Gynecology, professor.
Rafiq Gurbanov
Azerbaijan State Oil and Industrial University. Doctor of Technical Sciences. Professor
Rafiq Mammadhasanov
Azerbaijan Medical University, II Internal Medicine department, Professor.
Ramiz Gurbanov
Azerbaijan State Oil and Industrial University. Doctor of Technical Sciences. Professor
ANAS. Geography Institute. Doctor of Technical Sciences. Professor. Academician.
Rashad Abishov
Dental Implant Aesthetic Center Harbor Hospital, Azerbaijan State Doctors Improvement Institute. PhD.



Rena Gurbanova
Azerbaijan State Oil and Industrial University. Deputy of Faculty of Chemical Technology, Associate Professor. PhD in Chemistry.

Saadet Safarova
Azerbaijan Medical University, I Obstetrics- gynecology department, Associate professor, PhD in Medicine.

Səadət Sultanova
Azerbaijan Medical University, I Obstetrics- gynecology department. Professor.

Sabina Ozbekzade
Azerbaijan State Oil and Industry University, Instrumentation Engineering. Assistant professor.

Sadagat Ibrahimova
Azerbaijan State Oil and Industrial University, PhD in Economics, Associate professor.

Sain Safarova
Azerbaijan Medical University, II Internal Medicine department, Associate professor, Doctor of Medicine (M.D.)

Samira Mammadova
Sumgayit State University. Senior Teacher of History and its teaching methodology in History Faculty. PhD in History.

Sayyara Ibadullayeva
Institute of Botany. National Academy of Sciences. Professor. PhD in Biological Sciences.

Sevinj Mahmudova
Azerbaijan State Agrarian University. PhD. Senior teacher, Researcher.

Tarbiz Aliyev
Innovation Center of National Academy of Azerbaijan Republic. The deputy of director. Doctor of Economical Sciences. Professor.

Tariel Omarov
Azerbaijan Medical University. Department of surgical diseases. PhD in Medicine.

Tofiq Ahmadov
Azerbaijan State Oil and Industrial University. Doctor of Geology and Mineralogy Sciences. Professor

Tofiq Baharov
Azerbaijan State Oil Company. Scientific Research Institute. Head of department. Doctor of Geology and Mineralogy Sciences

Tofiq Samadov
Azerbaijan State Oil and Industrial University. Doctor of Technical Sciences. Professor.

Tubukhanum Gasimzadeh
Azerbaijan National Academy of Sciences. Institute of Dendrology of Azerbaijan NAS. Scientific Secretary of the Vice Presidential Service, Presidium. PhD in Biological Sciences, Associate Professor.

Vusal Ismailov
"Caspian International Hospital". Orthopedics Traumatology Expert. MD. Azerbaijan.

Zakir Aliyev
RAPVHN and MAEP. PhD in Agricultural Sciences, Professor of RAE academician.

Zakir Eminov
ANAS. Geography Institute. Doctor of Geography Sciences. Associate Professor.

Bahrain

Osama Al Mahdi
University of Bahrain, Bahrain Teachers College. Assistant Professor. PhD, Elementary Education and Teaching

Bangladesh

Muhammad Mahboob Ali
Daffodil International University. Department of Business Administration . Professor.

Bosna & Hercegovina

Igor Jurčić
Head of marketing Business group for VSE/SME. Telecommunication Business and Management.

Ratko Pavlovich
University of East Sarajevo. Faculty of Physical Education and Sport. Professor.

Brazil

Paulo Cesar Chagas Rodrigues
Federal Institute of Education, Science and Technology of Sao Paulo. Professor. PhD in Mechanical Engineering.

Bulgaria

Desislava Stoilova
South-West University "Neofit Rilski". Faculty of Economics. Associate Professor. PhD in Finance.

Eva Tsvetanova
Tsenov Academy of Economics, Svishtov, Bulgaria Department of Strategic Planning. Head assistant professor. PhD in Economy.

Jean-François Rougé
University of Technology, Sofia. PhD in Business law

Milena Kirova
Sofia University "St. Kliment Ohridski". Professor. PhD in Philology.

Croatia

Dragan Čišić
University of Rijeka. Department of Informatics, Full professor. PhD in Logistics, e-business.

Egypt

Abdelbadeh Salem
Professor at Faculty of Computer and Information Science, Ain Shams University.
Neyara Radwan
King Abdul-Aziz University. Jeddah. KSA. Business Administration Department. Faculty of Economics and Administration. Assistant Professor. Suez Canal University. Mechanical Department. Faculty of Engineering. Assistant Professor.

France

Michael Schaefer
L'Association 1901 SEPIKE International, Président at SEPIKE International. PhD of Economical Sciences.

Georgia

Anzor Abralava
Georgian Technical University. Doctor of Economical Sciences. Full Professor
Archil Prangishvili
Georgian Technical University. Doctor of Technical Sciences. Full Professor.
Avtandil Silagadze
Correspondent committee-man of National Academy of Georgia. Tbilisi University of International Relationships. Doctor of Economical Sciences. Full Professor.
Badri Gechbaia
Batumi Shota Rustaveli State University. Head of Business Administration Department. PhD in Economics, Associate Professor.
Dali Sologashvili
State University named Akaki Tsereteli. Doctor of Economical Sciences. Full Professor
Dali Osepashvili
Professor of Journalism and Mass Communication TSU (Tbilisi State University), Head MA Program "Media and New Technology"
Davit Narmania
Tbilisi State University (TSU), Chair of Management and Administration Department. Professor.
Davit Tophuria
Tbilisi State Medical University. Head of International Students Academic Department, Associate Professor. PhD in HNA.
Eka Avaliani
International Black Sea University. Faculty of Social Sciences and Humanities, Professor of History.
Eka Darchiashvili
Tbilisi State University named after Sv. Grigol Peradze. Assistant of professor. PhD in BA.
Enene Menabde-Jobadze
Georgian Technical University. Academic Doctor of Economics.
Eter Bukhnikashvili
University of Georgia, Department of Dentistry of the School of Health Sciences, PhD in Dentistry. MD dentist.
Evgeni Baratashvili
Georgian Technical University. Head of Economic and Business Department. Doctor of Economical Sciences. Full Professor
George Jandieri
Georgian Technical University; Chief scientist, Institute of Cybernetics of the Georgian Academy. Full Professor
George Malashkhia
Georgian Technical University. Doctor of Economical Sciences. Full Professor.
Giorgi Kepuladze
Business and Technology University, Associate Professor, PhD in Economics.
Gulnara Kiliptari
Tbilisi State Medical University. Head of ICU department. Associate professor.
Iamze Taboridze
David Aghmashenebeli University of Georgia, Head of the Center for Scientific Research and Continuing Education, PhD in biological sciences. Associate professor.
Ketevan Goletiani
Batumi Navigation Teaching University. Dean of Business and Logistics Faculty, Professor, Batumi Shota Rustaveli State University. Doctor of Business Administration, Assistant-Professor
Lali Akhmeteli
Tbilisi State Medical University, Surgery Department #1, Direction of Surgical, Associate Professor. General Surgery.



Lamara Qoqiauri
Georgian Technical University. Member of Academy of Economical Sciences. Member of New York Academy of Sciences.
Director of first English school named "Nino". Doctor of Economical Sciences. Full Professor.

Larisa Korghanashvili
Tbilisi State University (TSU) named Ivane Javakhishvili. Full Professor

Larisa Takalandze
Sokhumi State University, Faculty of Business and Social Sciences. Doctor of Economic Sciences. Professor.

Lia Davitadze
Batumi Shota Rustaveli State University. Higher Education Teaching Professional. PhD in Educational Sciences.

Lia Eliava
Kutaisi University. Economic expert in the sphere of economy and current events in financial sector. Full Professor.
PhD in Business Administration.

Lia Matchavariani
Ivane Javakhishvili Tbilisi State University (TSU). Head of Soil Geography Chair, Faculty of Exact & Natural Sciences (Geography Dep.), Full Professor.

Loid Karchava
Doctor of Business Administration, Association Professor at the Caucasus International University, Editor-in-Chief of the international Scientific Journal "Akhali Ekonomisti" (The New Economist)

Maia Matoshvili
Tbilisi State Medical University. The First University Clinic. Dermato-Venereologist. Assistant Professor. PhD in DAPS.

Mariam Darbaidze
Davit Aghmashenebeli National Defense Academy of Georgia. The Head of Education Division. PhD in Biology.

Mariam Kharashvili
Sulkhan-Saba Orbeliani University, School of Medicine, Associated Professor, PhD in Medicine, MD.

Mariam Nanitashvili
Executive Director - Wise Development LTD (Training Centre). Associated Professor at Caucasus University. PhD in Economics

Nana Shoniya
State University of Kutaisi named Akakhi Tsereteli. Doctor of Economical Sciences. Full professor

Natia Beridze
LEPL National Environmental Agency of Georgia, Invited Expert at International Relations and PR Division. PhD in Political Science.

Natia Shengelia
Georgian Technical University, Business Technology Faculty, Associate Professor.

Nelli Sichinava
Akaki Tsereteli State University. Associate. Professor. PhD

Nino Didbaridze
Microbiology and Immunology Department. Immunology Direction. Tbilisi State Medical University. PhD MD.

Nino Gogokhia
Tbilisi State Medical University. Head of Laboratory the First University Clinic. Professor.

Nino Museridze
GGRC Georgian-German Center for Reproductive Medicine, Owner and Clinical Director. The Doctor of Medicine, Full Professor.

Nino Pirtskhelani
Tbilisi State Medical University, Department of Molecular and Medical Genetics, Associated Professor. Alte University, Ken Walker International University, Professor.

Paata Koguashvili
Georgian Technical University. Doctor of Economical Sciences. Full Professor. Academician. Member of Georgia Academy of Sciences of Agriculture.

Rati Abuladze
St. Andrew the first-called Georgian University of the Patriarchate of Georgia. Faculty of Economics and Business Administration. Manager of the Faculty Quality Assurance Office. PhD in Business Administration.

Rusudan Kutateladze
Georgian Technical University. Doctor of Economical Sciences. Full Professor

Rusudan Sujashvili
School of Medicine, New Vision University, Ivane Beritashvili Center of Experimental Biomedicine, Professor, Doctor of Biology.

Tamar Didbaridze
Tbilisi State Medical University, Microbiology Department, Associate Professor First University Clinic. PhD in MD.

Tamar Giorgadze
Tbilisi State Medical University. Department of Histology, Cytology and Embryology. Assistant Professor.

Tamar Goderidze
University of Georgia, The head of the Family Medicine Department, Professor.

Tamila Armania-Kepuladze
Akaki Tsereteli State University. Department of Economics. Professor.

Timuri Babunashvili
Georgian Business Academy of Science. Doctor of Economical Sciences. Full Professor.

Vladimer Papava
Tbilisi State Medical University. Assistant-Professor. PhD. MD.

Zurab Khonelidze
Sokhumi State University. Doctor of Political Sciences. Professor.

Germany

Alexander Dilger
University of Münster. Professor of Business Economics. PhD in Economy.

Hans-Juergen Zahorka

Assessor jur., Senior Lecturer (EU and International Law, Institutions and Economy), Chief Editor of "European Union Foreign Affairs Journal", LIBERTAS - European Institute, Rangendingen

Greece

Margarita Kefalaki

Communication Institute of Greece. PhD in Cultural Communication. President of Institute.

Hungary

Nicasia Picciano

Central European University. Department of International Relations and European Studies.

India

Prasanta Kumar Mitra

Sikkim Manipal Institute of Medical Sciences. Department of Medical Biotechnology. PhD in Biochemistry.

Samant Shant Priya

Lal Bahadur Shastri Institute of Management, New Delhi, Associate Professor in Philosophy PhD in Marketing.

Sonal Purohit

Jain University, Center for Management Studies, Assistant Professor, PhD in Business Administration, Life Insurance, Privatization.

Varadaraj Aravamudhan

Alliance University, Professor.

Iraq

Rana Khudhair Abbas Ahmed

Iraq, Baghdad, Alrafidain University College. Lecturer, Global Executive Administrator, Academic coordinator. PhD in Scholar (CS).

Iran

Azadeh Asgari

Asian Economic and Social Society (AESS). Teaching English as a Second Language. PhD

Italy

Donatella M. Viola

London School of Economics and Political Science, London, Assistant Professor in Politics and International Relations at the University of Calabria, Italy. PhD in International Relations.

Federica Farneti

University of Bologna. Department of Sociology and Business Law. Associate Professor. PhD in Economic & Management.

Simona Epasto

University of Macerata. Department of Political Science, Communication and International Relations. Tenured Assistant Professor in Economic and Political Geography. PhD in Economic and Political Geography.

Jordan

Ahmad Aljaber

President at Gulf University. German Jordan University, Founder / Chairman of the Board. Ph.D in Computer Science

Ahmad Zamil

Middle East University (MEU). Business Administration Dept. Associate Professor. PhD Marketing

Ikhlas Ibrahim Altarawneh

Al-Huessien BinTalal University. Business Department. Full Professor in Human Resource Management.

Asmahan Majed Altaher

Arab Academy for Banking and Financial Sciences. Associate Professor. PhD in Management Information System.

Sadeq Al-Hamouz

The World Islamic Sciences & Education University (WISE), Vice Dean of the Faculty of Information Technology.

Chairman of the Department of Computer Science. Professor.

Safwan Al Salaimeh

Aqaba University of Technology. Software Engineering Department. Information Technology Faculty. Dean of information technology faculty. Professor.

**Kazakhstan**

Ainur Tokshilikova
West Kazakhstan Marat Ospanov Medical University, PhD in Medicine, Department of Anesthesiology and Reanimatology.

Alessandra Clementi
Nazarbayev University School of Medicine. MD, GP. Assistant Professor of Medical Practice and Family Medicine

Anar Mirzagalieva
Astana International University. Vice-President. PhD in Biology.

Anna Troeglazova
East Kazakhstan State University named Sarsen Amanjолоv. PhD

Gulmira Zhurabekova
Marat Ospanov West-Kazakhstan State Medical Academy. Department of Human Anatomy. Associate Professor

Nuriya Kharissova
Karaganda Medical University. Associate Professor of Biological Science.

Nikolay Kurguzov
State University of Pavlodar named S. Toraygirova. PhD. Professor.

Zhanargul Smailova
Head of the Department of Biochemistry and Chemical Disciplines named after MD, professor S.O. Tapbergenova NAC Medical University of city Semey.

Zhanslu Sarkulova
West Kazakhstan Marat Ospanov Medical University, Doctor of Medical Sciences, Professor, Department of Anesthesiology and Reanimatology.

Libya

Salaheddin Sharif
University of Benghazi, Libyan Football Federation- Benghazi PhD in Medicine (MD)

Latvia

Tatjana Tambovceva
Riga Technical University. Faculty of Engineering Economics and Management, Professor.

Lithuania

Agne Simelyte
Vilnius Gediminas Technical University, Associate professor. Phd in Social Sciences (Management)

Ieva Meidute – Kavaliauskiene
Vilnius Gediminas Technical University. Doctor of Technological Sciences. Head of Business Technologies and Entrepreneurship Department, Faculty of Business Management.

Vilma (Kovertaite) Musankoviene
e-Learning Technology Centre. Kaunas University of Technology. PHD

Laura Uturyte
Vilnius Gediminas Technical University (VGTU). Head of Project Manager at PI Gintarine Akademy. PhD in Economy.

Loreta (Gedminaitė) Ulvydiene
Professor of Intercultural Communication and Studies of Translation. Vilnius University. PHD

Zhaneta Simanavichienė
Mykolas Romeris University, Head of the Sustainable Innovation Laboratory, Public Security Academy, professor. Honorary Consul of the Republic of Estonia in Lithuania

Macedonia

Liza Alili Sulejmani
International Balkan University. Head of Banking and Finance department. Assistant Professor. PhD of Economics.

Leara Alili Ademi
Pediatrician in University, Clinic for pediatric diseases, department of neurology.

Malaysia

Anwarul Islam
The Millennium University. Department of Business Administration. Associate Professor.

Kamal Uddin
Millennium University, Department of Business Administration. Associate Professor. PhD in Business Administration.

Morocco

Mohammed Amine Balambo
Ibn Tufail University, Aix-Marseille University. Free lance. Consultant and Trainer. PhD in Philosophy. Management Sciences, Specialty Strategy and Logistics.

Nigeria

Bhola Khan
Yobe State University, Damaturu. Associate Professor, Department of Economics. PhD in Economics.

Norway

Svitlana Holovchuk
PhD in general pedagogics and history of pedagogics.

Pakistan

Nawaz Ahmad
Shaheed Benazir Bhutto University, Associate Professor, PhD in Management.

Poland

Grzegorz Michalski
Wroclaw University of Economics. Faculty of Engineering and Economics. PhD in economics. Assistant professor.
Kazimierz Waluch
Pawel Wlodkowic University College in Plock, Assistant Professor at the Faculty of Management. PhD in Economy.
Robert Pawel Suslo
Wroclaw Medical University, Public Health Department, Health Sciences Faculty, Adjunct Professor of Gerontology Unit. PhD MD.
Tadeusz Trocikowski
European Institute for Eastern Studies. PhD in Management Sciences.

Qatar

Mohammed Elgammal
Qatar University. Assistant Professor in Finance. PhD in Finance

Romania

Camelia Florela Voinea
University of Bucharest, Faculty of Political Science, Department of Political Science, International Relations and Security Studies.
PhD in Political Sciences.
Minodora Dobreanu
University of Medicine and Pharmacy of Târgu Mureş. Faculty of Medicine. Professor, MD, PhD in Medicine, Romanian Association of Laboratory Medicine. Editor-in-chief.
Odette (Buzea) Arhip
Ecological University of Bucuresti. Associate Professor. PhD in Social Sciences.

Russia

Grigory G. Levkin
Siberian State Automobile and Highway Academy. Omsk State Transport University. PHD of Veterinary Sciences
Nikolay N. Sentyabrev
Volgograd State Academy of Physical Culture. Doctor of Biological Sciences. Professor. Academician.
Sergei A. Ostroumov
Moscow State University. Doctor of Biological Science. Professor
Victor F. Stukach
Omsk State Agrarian University. Doctor of Economical Sciences. Professor
Zhanna Glotova
Baltic Federal University named Immanuel Kant, Ph.D., Associate Professor.

Saudi Arabia

Ikhlas (Ibrahim) Altarawneh
Ibn Rushd College for Management Sciences. PHD Human Resource Development and Management.
Associate Professor in Business Administration
Salim A alghamdi
Taif University. Head of Accounting and Finance Dept. PhD Accounting



ISSN: 2613-5817; E-ISSN: 2613-5825

PIRETC

JOURNAL OF SOCIAL RESEARCH & BEHAVIORAL SCIENCES

VOLUME 32 (07) ISSUE 03 2024

Serbia

Jane Paunkovic

Faculty for Management, Megatrend University. Full Professor. PhD, Medicine

Jelena Purenovic

University of Kragujevac . Faculty of Technical Sciences Cacak . Assistant Professor . PhD in NM systems.

South Korea

Aynur Aliyeva

The Catholic University of Korea. Department of Otorhinolaryngology, Head and Neck Surgery. MD, PhD.

Sultanate of Oman

Nithya Ramachandran

Ibra College of Technology. Accounting and Finance Faculty, Department of Business Studies. PhD

Rustom Mamlook

Dhofar University, Department of Electrical and Computer Engineering College of Engineering. PhD in Engineering / Computer Engineering. Professor.

Sweden

Goran Basic

Lund University. Department of Sociology. PhD in Sociology. Postdoctoral Researcher in Sociology.

Turkey

Fuad Aliew

Gebze Technical University, Department of Electronics Engineering, Faculty of Engineering, Associate professor, PhD in Automation engineering

Mehmet Inan

Turkish Physical Education Teachers Association. Vice president. PhD in Health Sciences, Physical Education and Sport Sciences

Melis Gönülal

University of Health Sciences, İzmir Tepecik Training and Research Hospital, Associate professor.

Muzaffer Sancı

University of Health Sciences. Tepecik Research and Teaching Hospital. Clinics of Gynecology and Obstetrics Department of Gynecologic Oncologic Surgery. Associated Professor.

Vugar Djafarov

Medical school at the University of Ondokuzmayıs Turkey. PhD. Turkey.

Yigit Kazancioglu

Izmir University of Economics. Associate Professor, PhD in Business Administration.

UK

Christopher Vasilopoulos

Professor of Political Science at Eastern Connecticut State University. PhD in Political Science and Government.

Frances Tsakonas

International Institute for Education Advancement. Ceo & Founder. PhD in Philosophy.

Georgios Piperopoulos

Northumbria University. Visiting Professor, Faculty of Business and Law Newcastle Business School. PhD Sociology and Psychology.

Mahmoud Khalifa

Lecturer at Suez Canal University. Visiting Fellow, School of Social and Political Sciences, University of Lincoln UK. PhD in Social

and Political Sciences

Mohammed Elgammal

Qatar University. Assistant Professor. PhD in Finance.

Stephan Thomas Roberts

BP Global Project Organisation. EI&T Construction Engineer. Azerbaijan Developments. SD 2 Onshore Terminal. Electrical engineer.

Ukraine

Alina Revtie-Uvarova

National Scientific Center. Institute of Soil Structure and Agrochemistry named Sokolovski. Senior Researcher of the Laboratory, performing part-time duties of the head of this laboratory.

Alona Obozna

Mykolaiv National Agrarian University, Department of Hotel and Restaurant Business and Business Organization, PhD of Economics, Associate Professor.

Alla Oleksyuk-Nexhames

Lviv University of Medicine. Neurologist at pedagog, pryvaty refleksoterapy. MD PD.

Anna Kozlovska
 Ukrainian Academy of Banking of the National Bank of Ukraine. Associate Professor. PhD in Economic.

Bogdan Storokha
 Poltava State Pedagogical University. PhD

Dmytro Horilyk
 Head of the Council, at Pharmaceutical Education & Research Center. PhD in Medicine.

Galina Kuzmenko
 Central Ukrainian National Technical University, Department of Audit and Taxation, Associate Professor. PhD in Economy.

Galina Lopushniak
 Kyiv National Economic University named after Vadym Hetman. PhD. Doctor of Economic Sciences, Professor.

Hanna Huliaieva
 Institute of Microbiology and Virology, NASU, department of phytopatogenic bacteria. The senior research fellow, PhD in Biology.

Hanna Komarnytska
 Ivan Franko National University of Lviv, Head of the Department of Economics and Management, Faculty of Finance and Business Management, Ph.D. in Economics, Associate Professor.

Iryna Skrypchenko
 Dnipropetrovsk State University of Internal Affairs. Head department of physical education & technical and tactical training. PhD, associate professor.

Iryna Trunina
 Kremenchuk Mykhailo Ostrogradsky National University, Head of Business Administration, Marketing and Tourism department, Faculty of Economics and Management, Professor.

Katerina Yagelskaya
 Donetsk National Technical University. PhD

Larysa Kapranova
 State Higher Educational Institution «Priazovskyi State Technical University» Head of the Department of Economic Theory and Entrepreneurship, Associate Professor, PhD in Economy,

Lesia Baranovskaya
 Igor Sikorsky Kyiv Polytechnic Institute, Department of Mathematical Methods of Systems Analysis, PhD, Associate Professor.

Liana Ptaschenko
 National University «Yuri Kondratyuk Poltava Polytechnic». Doctor of Economical Sciences. Professor

Liliya Roman
 Department of Social Sciences and Ukrainian Studies of the Bukovinian State Medical University. Associate professor, PhD in Philology,

Liudmyla Fylypovych
 H.S. Skovoroda Institute of Philosophy of National academy of sciences of Ukraine, Leading scholar of Religious Studies Department. Doctor of philosophical sciences, professor.

Lyudmyla Svistun
 Poltava national technical Yuri Kondratyuk University. Department of Finance and Banking. Associated Professor.

Mixail M. Bogdan
 Institute of Microbiology and Virology, NASU, department of Plant of viruses. PhD in Agricultural Sciences.

Nataliia Bezrukova
 Yuri Kondratyuk National Technical University. Associate Professor, PhD in Economic.

Nataliia Shalimova
 Central Ukrainian National Technical University, Audit, Accounting and Taxation Department, Dean of the Faculty of Economics, Dr. of Economics, Professor.

Nataliia Ushenko
 Borys Grinchenko Kyiv University, Department International Economics, Doctor of Economic Sciences, Professor.

Olena Syniavska
 Kharkiv National University of Internal Affairs, Department of Law Enforcement Activity and Policeistics, Doctor of Legal Sciences, Professor.

Oleksandr Voznyak
 Hospital "Feofaniya". Kyiv. Head of Neureosurgical Centre. Associated Professor.

Oleksandra Kononova
 Prydniprovska State Academy of Civil Engineering and Architecture (PSACIA), Assoc.professor of Accounting, Economics and Human Resources Management department. PhD. in Economic Science.

Oleksandr Levchenko
 Central Ukrainian National Technical University, Kropyvnytskyi. Vice-Rector for Scientific Activities. Professor.

Olena Cherniavska
 Poltava University of Economics and Trade, Doctor of Economical Sciences. Professor

Olga Dobrodum
 State Trade and Economic University, Department of Journalism and Advertising, Doctor of Philosophy Science, Professor.

Olga Gold
 Aix Marseille University, Mesopolhis, Mediterranean sociologic, political and history sciences researcher, Associate Professor.

Olga Gonchar
 Khmelnytsky National University, Economics of Enterprise and Entrepreneurship, Doctor of Economic Sciences, Professor.

Olha Ilyash
 National Technical University of Ukraine the "Igor Sikorsky Kyiv Polytechnic Institute", Professor, Doctor of Science.in Economics.



Roman Lysyuk

Assistant Professor at Pharmacognosy and Botany Department at Danylo Halytsky Lviv National Medical University.

Sergei S. Padalka

Doctor of Historical Sciences, Professor, Senior Researcher at the Department of Contemporary History and Policy at the Institute of History of Ukraine National Academy of Sciences of Ukraine.

Stanislav Goloborodko

Doctor of Agricultural Sciences, Senior Researcher. Institute of Agricultural Technologies of Irrigated Agriculture of the National Academy of Agrarian Sciences of Ukraine

Svetlana Dubova

Kyiv National University of Construction and Architecture. Department of Urban Construction. Associate Professor. PhD in TS.

Kyiv Cooperative Institute of Business and Law

Svitlana Onyshchenko

National University "Yuri Kondratyuk Poltava Polytechnic", Finance, Banking and Taxation Department, D.Sc. (Economics), Professor.

Tetiana Kaminska

Kyiv Cooperative Institute of Business and Law. Rector. Doctor of Science in Economics. .

Valentina Drozd

State Scientific Research Institute of the Ministry of Internal Affairs of Ukraine. Doctor of Law, Associate Professor, Senior Researcher.

Vasyl Klymenko

Central Ukrainian National Technical University. Department of Electrical Systems and Energy Management. Doctor TS. Professor.

Victoriya Lykova

Zaporizhzhya National University, PhD of History

Victor Mironenko

Doctor of Architecture, professor of department "Design of architectural environment", Dean of the Faculty of Architecture of Kharkov National University of Construction and Architecture (KNUCA), member of the Ukrainian Academy of Architecture

Yuliia Mytrokhina

Donetsk National University of Economics and Trade named after Mykhaylo Tugan-Baranovsky., PhD in Marketing and Management.

Associate Professor

Yulija Popova

Municipal Institution "Agency for Local Development of Territorial Communities of Poltava District", PhD in Economic. Associated professor.

Crimea

Lienara Adzhyieva

V.I. Vernadsky Crimean Federal University, Yevpatoriya Institute of Social Sciences (branch). PhD of History. Associate Professor

Oksana Usatenko

V.I. Vernadsky Crimean Federal University. Academy of Humanities and Education (branch). PhD of Psychology.

Associate Professor.

Tatiana Scriabina

V.I. Vernadsky Crimean Federal University, Yevpatoriya Institute of Social Sciences (filial branch). PhD of Pedagogy.

Associate Professor.

United Arab Emirates

Ashok Dubey

Emirates Institute for Banking & Financial Studies, Senior faculty. Chairperson of Academic Research Committee of EIBFS.

PhD in Economics

Maryam Johari Shirazi

Faculty of Management and HRM. PhD in HRM. OIMC group CEO.

USA

Ahmet S. Yayla

Adjunct Professor, George Mason University, the Department of Criminology, Law and Society & Deputy Director, International Center for the Study of Violent Extremism (ICSVE), PhD in Criminal Justice and Information Science

Christine Sixta Rinehart

Academic Affairs at University of South Carolina Palmetto College. Assistant Professor of Political Science. Ph.D. Political Science

Cynthia Buckley

Professor of Sociology at University of Illinois. Urbana-Champaign. Sociological Research

Medani P. Bhandari

Akamai University. Associate professor. Ph.D. in Sociology.

Mikhail Z. Vaynshteyn

Lecturing in informal associations and the publication of scientific articles on the Internet. Participation in research seminars in the "SLU University" and "Washington University", Saint Louis

Nicolai Panikov

Lecturer at Tufts University. Harvard School of Public Health. PhD/DSci, Microbiology

Rose Berkun
State University of New York at Buffalo. Jacobs School of Medicine & Biomedical Sciences, Clinical Associate Professor of Anesthesiology, PhD. MD
Tahir Kibriya
Director technical / senior engineering manager. Black & Veatch Corporation, Overland Park. PhD Civil Engineering.
Yahya Kamalipour
Dept. of Journalism and Mass Communication North Carolina A&T State University Greensboro, North Ca. Professor and Chair
Department of Journalism and Mass Communication North Carolina A&T State University. PhD
Wael Al-Husami
Lahey Hospital & Medical Center, Nardone Medical Associate, Alkhaldi Hospital, Medical Doctor, International Health, MD, FACC, FACP

Uruguay

Gerardo Prieto Blanco
Universidad de la República. Economist, Associate Professor . Montevideo.

Uzbekistan

Guzel Kutlieva
Institute of Microbiology. Senior Researcher. PhD in BS.
Khurshida Narbaeva
Institute of Microbiology, Academy of Sciences Republic of Uzbekistan, Doctor of biological sciences.
Nilufar Elova
Academy of sciences. Doctor of Philosophy in biology, Senior scientific worker.
Shaklo Miralimova
Academy of Science. Institute of Microbiology. Deputy Director, Doctor of Biology Sciences. PhD in BS.
Shukhrat Yovkochev
Tashkent State Institute of Oriental Studies. Full professor. PhD in political sciences.

Honorary editorial board members:

Aqaheydar Seyfulla Isayev
Azerbaijan State Oil Academy. Doctor of Economical Sciences. Professor.
Jacob Meskhia
Tbilisi State University. Faculty of Economics and Business. Full Professor.

AIMS AND SCOPE

IRETC MTÜ The Baltic Scientific Journals publishes peer-reviewed, original research and review articles in an open-access format. Accepted articles span the full extent of the social and behavioral sciences and the humanities.

IRETC MTÜ The Baltic Scientific Journals seeks to be the world's premier open-access outlet for academic research. As such, unlike traditional journals, IRETC MTÜ The Baltic Scientific Journals does not limit content due to page budgets or thematic significance. Rather, IRETC MTÜ The Baltic Scientific Journals evaluates the scientific and research methods of each article for validity and accepts articles solely based on the research. Likewise, by not restricting papers to a narrow discipline, IRETC MTÜ The Baltic Scientific Journals facilitates the discovery of the connections between papers, whether within or between disciplines.

IRETC MTÜ The Baltic Scientific Journals offers authors quick review and decision times; a continuous-publication format; and global distribution for their research via IRETC MTÜ The Baltic Scientific Journals Online. All articles are professionally copyedited and typeset to ensure quality.

Those who should submit to IRETC MTÜ The Baltic Scientific Journals include:

- Authors who want their articles to receive quality reviews and efficient production, ensuring the quickest publication time.
- Authors who want their articles to receive free, broad, and global distribution on a powerful, highly discoverable publishing platform.
- Authors who want their articles branded and marketed by a world-leading social science publisher.
- Authors who want or need their articles to be open access because of university or government mandates.

TOPICS OF JOURNAL

AGRICULTURAL, ENVIRONMENTAL & NATURAL SCIENCES

Agriculture, Agronomy & Forestry Sciences
History of Agricultural Sciences
Plant Breeding and Seed Production
Environmental Engineering Science
Earth Sciences & Organic Farming
Environmental Technology
Botany, Zoology & Biology

SOCIAL, PEDAGOGY SCIENCES & HUMANITIES

Historical Sciences and Humanities
Psychology and Sociology Sciences
Philosophy and Philology Sciences
History of Science and Technology
Social Science
Pedagogy Science
Politology
Geography
Linguistics

MEDICINE AND BIOLOGY SCIENCES

Clinical Medicine
Prophylactic Medicine
Theoretical Medicine
Stomatology & Dentistry
Innovations in Medicine
Biophysics and Biochemistry
Radiology and Microbiology
Molecular Biology and Genetics
Botany and Virology
Microbiology and Hydrobiology
Physiology of Plants, Animals and Humans
Ecology, Immunology and Biotechnology
Virology and Immunology
History of Biology
Entomology

COMPUTING AND APPLIED SCIENCES

History of Science and Technics
Information, Computing and Automation
Innovative Technologies
Mathematics & Applied Mathematics

ECONOMIC, MANAGEMENT & MARKETING SCIENCES

Economics and Management of Enterprises
Economy and Management of a National Economy
Mathematical Methods, Models and Information Technologies in Economics



ISSN: 2613-5817; E-ISSN: 2613-5825

PIRETC

JOURNAL OF SOCIAL RESEARCH & BEHAVIORAL SCIENCES

VOLUME 32 (07) ISSUE 03 2024

Accounting, Analysis and Auditing
Money, Finance and Credit
Demography, Labor Economics
Management and Marketing
Economic Science

LEGAL, LEGISLATION AND POLITICAL SCIENCE

Theory and History of State and Law
International Law
Branches of Law
Judicial System and Philosophy of Law
Theory and History of Political Science
Political Institutions and Processes
Political Culture and Ideology
Political Problems of International Systems and Global Development

NGO International Center for Research, Education & Training (Estonia, Tallinn) is publishing scientific papers of scientists on Website and in Referred Journals with subjects which are mentioned below:

© **The Baltic Scientific Journals**

ISSN: 2613-5817; E-ISSN: 2613-5825; UDC: 0 (0.034);
DOI PREFIX: 10.36962/PIRETC
Proceeding of The International Research Education & Training Center.
<https://bsj.fisdd.org/index.php/piretc>

ISSN: 2674-4562, E-ISSN: 2674-4597, UDC: 620.9 (051) (0.034);
DOI PREFIX: 10.36962/ENECO
Proceedings of Energy Economic Research Center. ENECO
<https://bsj.fisdd.org/index.php/eneco-peerc>

ISSN: 1609-1620, E-ISSN: 2674-5224; UDC: 62 (051) (0.034);
DOI PREFIX: 10.36962/PAHTEI
Proceedings of Azerbaijan High Technical Educational Institutions. PAHTEI
<https://bsj.fisdd.org/index.php/pahtei>

ISSN: 2663-8770, E-ISSN: 2733-2055; UDC: 672, 673, 67.01-67.02
DOI PREFIX: 10.36962/ETM
ETM Equipment, Technologies, Materials
<https://bsj.fisdd.org/index.php/etm>

ISSN: 2733-2713; E-ISSN: 2733-2721; UDC: 33
DOI PREFIX: 10.36962/SWD
SOCIO WORLD-SOCIAL RESEARCH & BEHAVIORAL SCIENCES
<https://bsj.fisdd.org/index.php/swd>

E-ISSN: 2587-4713; UDC: 620.9 (051) (0.034)
DOI PREFIX: 10.36962 / ECS
Economics
<https://scsj.fisdd.org/index.php/esc>

Society of Azerbaijanis living in Georgia. NGO. (Georgia, Tbilisi) is publishing scientific papers of scientists on Website and in Referred Journals with subjects which are mentioned below:

© **Southern Caucasus Scientific Journals**

ISSN: 2346-8068; E-ISSN: 2346-8181; UDC: 611-618

DOI PREFIX: 10.36962/ALISJMSC

Ambiance in Life-International Scientific Journal in Medicine of Southern Caucasus.

<http://scsj.fisdd.org/index.php/ail>

Representation of the International Diaspora Center of Azerbaijan in Georgia. NGO (Georgia Tbilisi)

is publishing scientific papers of scientists on Website and in Referred Journals with subjects which are mentioned below:

© **Southern Caucasus Scientific Journals**

ISSN: 2298-0946, E-ISSN: 1987-6114; UDC: 3/k-144

DOI PREFIX: 10.36962/CESAJSC

The Caucasus-Economic and Social Analysis Journal of Southern Caucasus

<http://scsj.fisdd.org/index.php/CESAJSC>

Title of the Paper (14 point, Bold, Times New Roman)

First Author's Name¹, Second Author's Name², Third Author's Name³,

¹ [Author affiliations – position, department, institute, city, state, country, email ID, ORCID ID]

² [Author affiliations – position, department, institute, city, state, country, email ID, ORCID ID]

³ [Author affiliations – position, department, institute, city, state, country, email ID, ORCID ID]

Corresponding author's email:

(Affiliation^{1,2,3} Times New Roman, 10)

Article Type: Refer to the section policy of journal for acceptable article types.

ABSTRACT

(Times New Roman, 12)

The manuscript should contain an abstract within 300 words. The manuscript should have a self-contained, citation-free abstract and state briefly the purpose of the research, methodology, key results and major conclusions. Abstract should be in a single paragraph with running sentences. Do not use any subheading or point list within the abstract. Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Keywords: Authors are advised to write **3-5 keywords** related to the article, separated by comma. These keywords will be used for indexing purpose.

SUMMARY (OPTIONAL) (Times New Roman, 12 Bold)

[This section of the manuscript is optional. It is up to the author(s) to decide whether to include this section in the manuscript.]

["Summary" of your work is a short description of the work being presented in your article. It is longer than the "Abstract" which is limited to 250 words for all types of articles. After reading the "Summary" a reader should be able to understand the background information, why the work is being reported, what the significant results are, and what may be the explanation for the results.]

[Although writing an additional section in the form of "Summary" of your work may seem like an extra burden on your time and resources, it will be an important part of your manuscript especially for articles which are highly technical. Many times readers who are students, or who are not expert on the subject of the article or readers who are experts but in related subjects may skip reading an article if on first look the article appears to be very technical with lot of data, facts and statistics. Some other articles may not be easy to understand, on first reading, even by experts in the subject of the article. The "Summary" section will help the readers in understanding the results of your study.]

- The recommended word limit for "Summary" for Review Article is – 800 words (2 pages)
- When writing the "Summary" use as simple and as non-technical language as possible. Write the "Summary" as if you are explaining your study to a first year graduate student.
- Do not repeat or copy text verbatim from the main text of your manuscript. "Summary" will probably be the most important and most widely read part of your manuscript. Write it fresh as a separate section.

- In the "Summary" give: 1) relevant background information, 2) why the work was done, 3) what were the significant results, 4) possible explanation of the results.
- Only give the significant results of your study and give their possible explanation.
- Do not compare your results with other studies.
- Do not give references in the "Summary" section. First reference should start in main text of your manuscript from the "Introduction" section.

Introduction (Times New Roman, 12)

Mostly Papers starts with introduction. It contains the brief idea of work, requirement for this research work, problem statement, and Authors contribution towards their research. Sufficient recent reference citation [1] from last 2 years should be included for showing the existing challenges and importance of current work. This section should be succinct, with no subheadings unless unavoidable [2, 3]. State the objectives of the work and provide an adequate background related to your work, avoiding a detailed literature survey or a summary of the results.

Research Methodology (Times New Roman, 12)

This part should contain sufficient detail to reproduce reported data. It can be divided into subsections if several methods are described. Methods already published should be indicated by a reference [4], only relevant modifications should be described. Methodology should be written concisely in detail by maintaining continuity of the texts.

Theory and Calculation (Times New Roman, 12)

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis. Do not add extensive basic definitions or well-known theories, instead highlight theoretical background and its specific usages in view of your work only.

Mathematical Expressions and Symbols (Times New Roman, 12)

Mathematical expressions and symbols should be inserted using **equation tool** of Microsoft word. References may be added for used equations to support its authenticity, e.g. this result has been analysed using Fourier series [5].

$$f(x) = a_0 + \sum_{n=1}^{\infty} \left(a_n \cos \frac{n\pi x}{L} + b_n \sin \frac{n\pi x}{L} \right) \quad (1)$$

Results and Discussion (Times New Roman, 12)

This section may each be divided by subheadings or may be combined. A combined Results and Discussion section is often appropriate. This should explore the significance of the results of the work, don't repeat them. Avoid extensive citations and discussion of published literature only, instead discuss recent literature for comparing your work to highlight novelty of the work in view of recent development and challenges in the field.

Preparation of Figures and Tables (Times New Roman, 12)

Authors are supposed to embed all figures and tables at appropriate place within manuscript. Figures and tables should neither be submitted in separate files nor add at the end of manuscript. Figures and Tables should be numbered properly with descriptive title. Each Figure/Table must be explained within the text by referring to corresponding figure/table number. Any unexplained or unnumbered Figure/Table may cause rejection of the paper without being reviewed.

Formatting Tables (Times New Roman, 12)

Table should be prepare using table tool within the Microsoft word and cited consecutively in the text. Every table must have a descriptive title and if numerical measurements are given, the units should be included in the column heading. Formatting requirement has been summarized in the Table 1.

Table 1: Summary of formatting requirement for submitting paper in this journal. (Times New Roman, 12)

Layout	Size	Margin (Normal)	Header	Footer	
Single column	A4 (8.27" X 11.69")	Top=1" Bottom=1" Left=1" Right=1"	Do not add anything in the header	So not add anything in the footer	
Font	Article Title	Headings	Subheadings	Reference list	Text
	Times New Roman, 16 pt, Bold, centred	Times New Roman, 11 pt, Bold, Left aligned	Times New Roman, 10 pt, Bold, Left aligned	Times New Roman, 8 pt, Justified	Garamond, 11 pt, Justified
Line Spacing	1.15	1.15	1.15	1.15	1.15
Page number	We will format and assign page numbers				

(Times New Roman, 10)

Formatting Figures (Times New Roman, 12)

All figures should be cited in the paper in a consecutive order, author may be asked to provide separate files of the figure. Figures should be used in bitmap formats (TIFF, GIF, JPEG, etc.) with 300 dpi resolution at least unless the resolution is intentionally set to a lower level for scientific reasons. If a bitmap image has labels, the image and labels should be embedded in separate layer. Figure 1 shows the logo of AIJR Publisher.




Figure 1: Logo of the IRETC Publisher (Times New Roman, 12)

Conclusions (Times New Roman, 12)

Each manuscript should contain a conclusion section within 250-450 words which may contain the major outcome of the work, highlighting its importance, limitation, relevance, application and recommendation. Conclusion should be written in continuous manner with running sentences which normally includes main outcome of the research work, its application, limitation and recommendation. Do not use any subheading, citation, references to other part of the manuscript, or point list within the conclusion.

Declarations (Times New Roman, 12)

Study Limitations (Times New Roman, 12)

Provide all possible limitation faced in the study which might significantly affect research outcome, If not applicable write, none.

Acknowledgements (Times New Roman, 12)

All acknowledgments (if any) should be included in a separate section before the references and may include list of peoples who contributed to the work in the manuscript but not listed in the author list.

Funding source (Times New Roman, 12)

Provide funding source, supporting grants with grant number. The name of funding agencies should be written in full, if no funding source exist, write, none.

Competing Interests (Times New Roman, 12)

Declare any potential conflict of interest exist in this publication.

Human and Animal Related Study (Times New Roman, 12)

If the work involves the use of human/animal subjects, each manuscript should contain the following subheadings under the declarations section-

Ethical Approval (Times New Roman, 12)

Provide ethical approval authority name with the reference number. If ethical approval is not required, provide an ethical exemption letter of not required. The author should send scan copy (in pdf) of the ethical approval/exemption letter obtained from IRB/ethical committee or institutional head.

Informed Consent (Times New Roman, 12)

Write a statement of informed consent taken from the participants to publish this research work. The editor may ask to upload scan copy if required.

References (Times New Roman, 12)

Author(s) are responsible for ensuring that the information in each reference is complete and accurate. **Do not use grey literature (unauthentic website, news portal, social media, Wikipedia etc) as reference, only scholarly literature (Journal, online books, proceedings, patents, authentic websites with permanent archival policy) are acceptable references.** Author should include sufficient recent (last 2 years) references in the article. All references must be numbered consecutively and citations of references in the text should be identified using numbers in square brackets (e.g., “as explained by AIJR [1]”; “as discussed in many reports [2]-[6]”). All references should be cited within the text correctly; do not add only list of references without citation within the text. All cited references should be listed after declarations section in the following style-

1. W. S. Author, “Title of paper,” Name of Journal in italic, vol. x, no. x, pp. xxx-xxx, Abbrev. Month, year. <https://doi.org/10.21467/ajgr>
2. Bahishti, “Peer Review; Critical Process of a Scholarly Publication”, J. Mod. Mater., vol. 2, no. 1, pp. 1.1-1.2, Oct. 2016. <https://doi.org/10.21467/jmm.2.1.1.1-1.2>
3. Bahishti, “A New Multidisciplinary Journal; International Annals of Science”, Int. Ann. Sci., vol. 1, no. 1, pp. 1.1-1.2, Feb. 2017. <https://journals.aijr.in/index.php/ias/article/view/163>
4. W. S. Author, “Title of paper,” Name of Journal in italic, vol. x, no. x, pp. xxx-xxx, Abbrev. Month, year. Access online on 20 March 2018 at <https://www.aijr.in/journal-list/advanced-journal-graduate-research/>
5. W. S. Author, “Title of paper,” Name of Journal in italic, vol. x, no. x, pp. xxx-xxx, Abbrev. Month, year. Access online on 5 March 2018 at <https://www.aijr.in/about/publication-ethics/>
6. M. Ahmad, “Importance of Modeling and Simulation of Materials in Research”, J. Mod. Sim. Mater., vol. 1, no. 1, pp. 1-2, Jan. 2018. DOI: <https://doi.org/10.21467/jmsm.1.1.1-2>

Main features of citation style are given as-

- The author name format is, "first name (Initial), middle name (Initial) and last name". This differs from other styles where author's last name is first.
- The title of an article (or chapter, conference paper, patent, etc.) is in quotation marks.
- The title of the book or journal is in italics.
- Online link of the original paper. If any reference is not available online, it should be modified with available online reference

Complete Detail of Each Author

Provide complete detail of each author in the following format as well as add each author with complete detail during online submission (step 3) in the same order as appears in the manuscript.

First Author's Full Name: (Times New Roman, 12)

Highest Qualification:

Department:

Post/Rank (If a student, provide course name and course year):

Affiliation (College/University/Institute) with postal address:

email id:

ORCID:

Mobile:

Second Author's Full Name: (Times New Roman, 12)

Highest Qualification:

Department:

Post/Rank (If a student, provide course name and course year):

Affiliation (College/University/Institute) with postal address:

email id:

ORCID:

Mobile:

Third Author's Full Name: (Times New Roman, 12)

Highest Qualification:

Department:

Post/Rank (If a student, provide course name and course year):

Affiliation (College/University/Institute) with postal address:

email id:

ORCID:

Mobile:

JOURNAL INDEXING



ISSN: 2613-5817; E-ISSN: 2613 – 5825; UDC: 0 (0.034)

©**Publisher:** NGO International Center for Research, Education and Training. R/C: 80550594
MTÜ Rahvusvaheline Teadus-, Haridus- ja Koolituskeskus.

©**Publisher:** NGO Azerbaijan International Diaspora Center in Georgia.
Management Board Member and founder of organization: Seyfulla Isayev.

©**Editorial office:** Harju county, Tallinn, Lasnamäe district, Väike-Paala tn 2, 11415

©**Typography:** NGO International Research, Education & Training Center. The Baltic Scientific Journals.

Registered address: Narva mnt 5, 10117 Tallinn, Estonia.

Tel: +994 552 807 012; +994 518 64 88 94

Whatsapp: +994 552 41 70 12

E-mail: gulustanbssjar@gmail.com, sc.mediagroup2017@gmail.com

Website: <https://bsj.fisdd.org/>

ISSN: 2613-5817; E-ISSN:2613-5825; DOI: 10.36962/PIRETC



© THE BALTIC SCIENTIFIC JOURNALS

PROCEEDINGS

OF THE INTERNATIONAL RESEARCH, EDUCATION & TRAINING CENTER

JOURNAL OF SOCIAL RESEARCH & BEHAVIORAL SCIENCES
REFERRED & REVIEWED JOURNAL

VOLUME 32 (06) ISSUE 03 2024

<http://bsj.esif.net/index.php/piretc>



AGRICULTURAL, ENVIRONMENTAL & NATURAL SCIENCES

SOCIAL, PEDAGOGY SCIENCES & HUMANITIES

MEDICINE AND BIOLOGY SCIENCES

COMPUTING AND APPLIED SCIENCES

ECONOMIC, MANAGEMENT & MARKETING SCIENCES

LEGAL, LEGISLATION AND POLITICAL SCIENCE



<http://bsj.esif.net/index.php/piretc>